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Introduction: Electrosurgery makes dissection with simultaneous haemostasis possible. 
Inadvertently produced heat can cause injury to the surrounding tissue that may result in
wound healing problems and an increased rate of seroma formation. The PEAK
PlasmaBlade™ (PPB) is a new electrosurgery device which may overcome this by having the
ability to operate on a lower temperature, therefore reducing collateral thermal damage.
Method: A double blinded, single centre, randomised controlled trial was conducted, including
a 108 abdominally based free flap breast reconstruction patients who had their flap raise
performed with either the PPB (n=56) or conventional diathermy (n=52). Data were collected
during their in-patient stays and at the 2- and 6-week clinic follow-up appointments. The
primary outcome value for which the study was powered was the number of days the
abdominal drains were required. For statistical analysis the independent t-test, Mann-Whitney
U test, Pearson Chi-Square test and Fisher’s Exact test were used. Uni- and multivariable 
regression were used to identify and correct for predictors and confounders.
Results: Baseline characteristics were similar between the groups, except for a significantly
lower flap weight in the PPB group for which was corrected. The median number of days the
drains were required, was 6.0 (Interquartile Range (IQR) 5.0 – 8.8) days for the diathermy and
5.0 (IQR 4.0 – 8.0) days for PPB, this was not significant (p=0.48). Median amount of drain
fluid was similar with 342.5 mL (IQR 233.8 – 618.8) in the diathermy and 355.0 mL (IQR 228.8
– 532.5) in the PPB group (p=0.68). In recovery, post-operative pain scores were significantly
higher in the PPB group (2/10 vs 4/10, p=0.002). Three pro-inflammatory cytokine in the drain
fluid showed a trend towards lower values in the PPB group on day 0,1 and 2 but did not reach
statistical significance. Complications were similar between the groups (p>0.24). At the 2-
week follow-up appointment there was a tendency towards less abdominal seromas on
abdominal ultrasound in the PPB group (70.6% vs 54.5%, p=0.09) which were significantly 
smaller (62.8cm3 (IQR 22.0 – 110.0) vs 45.6cm3 (IQR 16.8 – 97.9), p=0.04). Due to
spontaneous re-absorption presence and size of the identified seromas did not significantly
differ anymore at the 6-week follow-up appointment. 
Conclusion: Abdominally based free flap harvest performed with the PPB did not result in a
significant reduction of drain requirement time, total output or inflammatory cytokines. Higher
pain scores immediately post-operatively were recorded in the PPB group but could be the
consequence of other factors. The abdominal ultra-sound performed at the 2-week follow-up
appointment showed a tendency towards less seroma collections which were significantly
smaller in the PPB group. Therefore, the PEAK PlasmaBlade™ device could reduce early post-
operative seroma formation.
Key words: Electrosurgery, Conventional diathermy, PEAK PlasmaBlade™, Abdominally 
based free flap, Drain, Seroma. 
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Breast cancer is caused by malignant cells in the breast (Figure 1). It is like all cancers
characterised by uncontrolled division, abnormal growth and the ability to invade normal local
tissue and spread to other sites in the body (metastasis), like lymph nodes (axillary/ internal
mammary), lungs, bones, skin and soft tissue (Davies, 2012).
Figure 1 The breast and associated lymph nodes (Breast Cancer Care, 2016)
The majority of breast cancers (70-80%) originate from the ductal units of the breast (ductal
carcinoma), with several subtypes (medullary, papillary, tubular and mucinous). The
remaining 20% arise from the glandular tissue (lobular carcinoma) (Davies, 2012).




    
              
              
        
            
            
            
              
           
             
     
 
                
          
 
              
         
              
            
           
         
1.1.1 History of breast cancer
The ancient Egyptians were the first to document surgery for breast cancer between 3000 and
2500 before Christ (Champaneria, Wong, Hill, & Gupta, 2012). Due to poor understanding of
the human anatomy surgical treatment was surrounded by great controversy until the
19thCentury (Champaneria et al., 2012). Jean Louis Petit was the first to unify the surgical
eradication of breast cancer by removing parenchymal breast tissue, chest muscle and lymph
nodes (Champaneria et al., 2012). Between 1889 and the 1970s “The Halsted Radical
Mastectomy” was the standard, consisting of an en bloc resection of the breast with underlying
pectoral muscles and ipsilateral axillary lymph nodes (Figure 2). Wounds were closed under
high tension or left to heal by secondary intention, as it was believed to decrease tumour
dissemination (Champaneria et al., 2012).
Figure 2 Drawing of a radical mastectomy, consisting of the surgical removal of all breast tissue with
overlying skin, muscles and lymph nodes. By William Hasted in 1924, (Newmark, 2016).
In the 20th Century radical surgeries for breast cancer were questioned, which led to the
development of breast conserving therapies. Modern prospective randomised controlled trials 
have confirmed that the extent of the mastectomy does not influence survival and also deemed
breast reconstruction as safe, not compromising the cancer treatment (Champaneria et al.,
2012). The introduction of the skin-sparing mastectomy in combination with immediate breast
reconstruction in 1991, have greatly improved aesthetic results (Champaneria et al., 2012).
2
  
     
              
           
              
            
               
             
         
         
              
             
 
    
            
           
             
             
         
              
            
           
         
              
          
          
         
           
1.1.2 Incidence of breast cancer
In the United Kingdom one in seven women develops breast cancer within their lifetime.
Fortunately, the survival rates have almost doubled over the last 40 years. Currently nearly 
eight in ten (78%) woman diagnosed with breast cancer in England and Wales survive their
disease for ten years or more (Cancer research UK, 2017). The incidence increases with age,
with 80% occurring in women over age of 50 years (Davies, 2012). Other risk factors for breast
cancer are early menarche, late menopause, no or late pregnancy, being overweight, lack of
exercise, alcohol consumption and prolonged use of exogenous hormones (hormone
replacement therapy and/ or contraceptive pill) (Cancer research UK, 2017; Davies, 2012). 
Patients with the gene mutation BRCA-1 or BRCA-2 have an increased risk of 40 – 65% to
develop breast cancer by the age of 70 (Cancer research UK, 2017; NHS, 2016). 
1.1.3 Diagnosis of breast cancer
According to National Institute for Health and Care Excellence (NICE) guidelines (2016), all
patients either presenting with symptoms such as a palpable swelling, breast skin changes or
nipple discharge, or picked up through the NHS breast screening programme should be
referred to a specialist breast clinic for triple assessment. This consists of: clinical history and
examination, radiology (ultrasound investigation and/ or a mammogram) and pathology
(biopsy from area of concern). Each component is scored ranging from 1 (benign) to 5
(malignant) (Jeevan et al., 2014; NICE, 2016). Following the assessment, each patient is
discussed at a multidisciplinary team (MDT) meeting to confirm the diagnosis and treatment
plan. This team consists of oncological breast surgeons, medical oncologists, radiologist,
pathologist, psychologist and a specialist breast care nurse. In case of a cancer diagnosis
important factors in the treatment decision-making process are tumour size, lymph node
status, hormone receptor status (oestrogen receptor (OR), progesterone receptor (PR) and
human epidermal growth receptor-2 (HER-2)), general health and wishes of the patient
(Breast Cancer Care, 2016; Davies, 2012; Petit et al., 2012).
3
  
    
         
           
         
             
           
          
              
            
     
 
       
             
             
            
        
          
            
 
  
             
          
             
              
             
           
                
1.1.4 Treatment of breast cancer
Breast cancer can be treated surgically by completely removing the primary tumour and
affected axillary lymph nodes. This can either be by breast conserving wide local excision
(WLE; 70-75% of cases which is usually followed by post-operative radiotherapy) or
mastectomy (25-30% of cases), where the entire breast is removed. To stage the axilla a
sentinel lymph node biopsy (SLNB) can be performed, leading to higher accuracy compared
to previous axillary sampling and less morbidity compared to axillary node clearance (ANC).
The sentinel lymph node is the first node the tumour drains to and would usually be affected
first. The node is identified using blue dye and a radioactive colloid suspension, surgically 
removed and histologically tested (Davies, 2012).
Radiotherapy, hormone therapy, biological therapy and (neoadjuvant-) chemotherapy are all
forms of adjuvant treatment available for breast cancer patients. Their aim is to reduce loco-
regional and distant recurrence to improve overall survival (Davies, 2012). The number of
patients receiving adjuvant treatment has increased over the years, therefore the short- and 
long-term side-effects such as wound healing problems, skin fibrosis, myelo-suppression,
cardiac toxicity and increased risk of thromboembolisms should not be neglected when
planning breast reconstruction (Cancer research UK, 2017; Shapiro & Recht, 2001).
1.1.5 Conclusion
Breast cancer is very common, with currently 1 in 7 woman developing the disease within their
lifetime (Cancer research UK, 2017). Due to improvements in diagnosis and (adjuvant)
treatment of the disease, currently 78% of woman diagnosed with breast cancer in England
and Wales survive their disease for 10 years or more (Cancer research UK, 2017). Despite a
dramatic decrease in radicalism of the surgical treatment, still 25-30% of patients will require
a mastectomy leading to significant asymmetry (Davies, 2012). Breast reconstruction can help
improve quality of life in breast cancer survivors (Zhang et al., 2017; Zhong et al., 2012) and
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is increasingly considered to be an important part of breast cancer management




   
 
           
         
               
             
             
           
             
       
    
 
            
  
 
                
               
           
             
     
        
            
           
       
               
1.2 Breast reconstruction
Even though the radicalism of surgical treatment of breast cancer has dramatically decreased,
both breast conserving surgery and mastectomy can result in significant asymmetry between
the breasts (Figure 3) (Petit et al., 2012). This can have a negative impact on a woman’s self-
image, psychology, relationships/ sexuality and quality of life (Zhang et al., 2017; Zhong et al.,
2012). Due to concerns regarding oncological safety, breast reconstruction did not gain wide
acceptance until the mid 1900s (Champaneria et al., 2012). The aim of breast reconstruction
is to restore shape and symmetry by using the opposite side as a reference point and is
increasingly considered as an important component of breast cancer management
(Champaneria et al., 2012). 
Figure 3 Significant asymmetry after breast conserving therapy (left) and mastectomy (right) (Petit et
al., 2012)
An external prosthesis can be used after a mastectomy, but they are heavy, can slip and often
compromise the patients’ freedom to wear a variety of clothing which can lead to psychological
stress for cancer survivors. Nowadays most patients are offered surgical breast reconstruction
by either using an implant, the patient’s own tissue (autologous) or a combination of both.
Relative contraindications are significant anaesthetic risk factors or metastatic disease.
Usually several operations are needed to complete the reconstruction process (Ahmed,
Snelling, Bains, & Whitworth, 2005). Reconstruction can either be done immediately (at time
of cancer surgery) or delayed (after adjuvant treatment). Immediate reconstruction has got
advantages such as reduced costs, less psychological morbidity and superior cosmetic result
(Ahmed et al., 2005). It has proven to be oncological safe as it does not increase the incidence
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of local recurrence or distant metastases, neither does it affect the delivery of post
reconstruction radiotherapy (Petit et al., 2012; See & Farhadi, 2018; Zhang et al., 2017). 
1.2.1 Implant-based reconstruction
The National Mastectomy and Breast Reconstruction Audit published in 2011 included 16,485
mastectomy patients across England, Wales and Scotland. Twenty-one percent (n=3,389) 
underwent immediate breast reconstruction, which was most commonly with an implant or
tissue expander (n=1,246, 37%). In the United Kingdom implant-based reconstruction is 
performed by both plastic and oncoplastic surgeons (Jeevan et al., 2014).
1.2.1.1 History of implant-based reconstruction
Plastic surgeon Thomas Cronin and his resident Frank Gerow were the first to develop silicone
breast implants for cosmetic surgery with the Dow Corning Corporation in 1961 (Kaya & Serel,
2013). Unfortunately, these devices had a high failure rate, causing silicone leakage leading
to painful deforming capsular contractions (Champaneria et al., 2012). These complications
and public’s concern of silicone implants causing cancer and certain autoimmune diseases
made the American Food and Drug Administration (FDA) in 1992 restrict the use of silicone
implants to breast reconstruction, replacement of previous defective implants and limited
controlled trials (Champaneria et al., 2012). These restrictions were not applied in Europe
(Kaya & Serel, 2013). During the 14-year embargo on silicone devices, saline filled implants
dominated the U.S. market as they were FDA-approved. The ban was reversed in November
2006 after studies had shown silicone implants (Figure 4) to be safe and effective




                
 
          
             
           
             
                 
              
       
 
   
             
            








Figure 4 Silicone breast implant (left), tissue expander with remote port (right) (Ahmed et al., 2005)
Tissue expanders (inflatable implants, Figure 4) play an important role in breast reconstruction
and were first presented in 1982 by Chedomir Radovan (Champaneria et al., 2012). After
surgical implantation, they can gradually be inflated, stretching the overlying skin and muscle
to the desired size. Expansion through an integrated or remotely positioned port can take a 
few months. By over-expansion a degree of ptosis can be created. Depending on the type of
tissue expander, they can either be left or replaced with a permanent implant (Champaneria
et al., 2012; Kaya & Serel, 2013).
1.2.1.2 Types of implants
Currently there are a lot of different types, shapes and sizes of implants available (Table 1.2.1),
from many different manufacturers (Petit et al., 2012). All implants have a silicone envelope
with either a silicone gel- or sterile saline filling (Ahmed et al., 2005; Kaya & Serel, 2013).
8
  
   
     
  
 
    
    




    
  
  





     
    
   
  
    
  
  
   
      
  
   
  
    
   
   
    
    
   
     






      
    
   
   
          
 
   
             
         
              
           
           
               
           
           
           
            
          










Valve to allow filling







Smooth - softer feel














- Firmer to touch
Shapes Round Identical horizontal
and vertical length













BIA-ALCL = Breast Implant Associated – Anaplastic Large Cell Lymphoma
1.2.1.3 Patient selection
Implant based reconstruction is best suited for patients with small (≤500g) and minimally ptotic
breasts. With larger ptotic breasts, reduction mammoplasty and mastopexy to the contra-
lateral side can be used to improve symmetry. Complete coverage of the implant is imperative.
This method of reconstruction has, compared to autologous reconstruction, got the benefit of
a shorter general anaesthetic and hospital stay, without the need for an additional donor site
with the risk of possible complications (Ahmed et al., 2005; Kaya & Serel, 2013). However for
implant based reconstruction, secondary breast procedures and unplanned revisions within 3
years were significantly higher (p<0.001) in a retrospective cohort study including 15,154
woman undergoing immediate breast reconstruction with a tissue expander (70.5%), an
immediate implant (11.3%) or autologous tissue (18.1%) (Fischer, Fox, Nelson, Kovach, &
Serletti, 2015). Lagares-Borrego et al. (2016) published similar significantly higher number of
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procedures (p<0.001) for implant based reconstruction in their prospective cohort study 
including 134 patients (67 expander/implant vs 67 autologous reconstructions) with a minimal
follow-up of 5 years.
1.2.1.4 Reconstruction methods – single and two-stage reconstruction
The two main methods of breast reconstruction with implants are the single-stage
reconstruction with a permanent expander or implant usually with the use of a mesh, or a two-
stage reconstruction where the initial tissue expander is replaced with a permanent implant in
a second surgery (Kaya & Serel, 2013; Lagares-Borrego et al., 2016). The two-stage
procedure is most commonly practiced, due to the significantly higher risk of reconstructive
failure and over-all complications after a single stage procedure. This was supported by the
results of a systematic review and meta-analysis including 18 studies (14,840 cases), showing
both significantly (p<0.05) more complications and implant loss in the one-stage group (Lee &
Mun, 2016). 
The implant breast reconstruction evaluation (iBRA) study was set up to evaluate the
feasibility, design and conduct of a future trial in immediate implant-based breast
reconstruction (Potter et al., 2019). The first part was a national practice questionnaire (NPQ)
to describe the current practice of breast and plastic surgery units with regards to implant-
based breast reconstruction (Mylvaganam et al., 2017). The response rates were 47% (67 of
144) of breast units and 26% (14 of 53) plastic units. The NPQ showed an increase in implant-
based procedures, summarised selection criteria for different techniques and revealed that
biological meshes are predominantly used (Mylvaganam et al., 2017). For the second part a
prospective multi-centre study was performed including 2108 mastectomy patients
undergoing immediate implant-based breast reconstruction, evaluating complications up to 3
months of the initial surgery. The study showed 78% of the reconstructions were single stage, 
using a biological (54%) or synthetic (12%) mesh, non-mesh sub-muscular or sub-fascial
implants (9%), a dermal sling (21%), pre-pectoral implants (2%) or a combination of implants
(4%). Due to the high number of one-stage reconstructions, the complication rates were higher
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than recommended by the national standards, with 9% implant loss, 18% requiring re-
admission, 18% return to theatre and 25% treatment for infection (Potter et al., 2019).
1.2.1.5 Implant-related complications
The most common early complication after implant reconstruction is loss of implant, occurring
in about 6% of cases (Magill, Robertson, Jell, Mosahebi, & Keshtgar, 2017). This can be due
to infection, mastectomy skin flap necrosis or wound healing problems. Capsular contraction
is the most frequent late complication. It results from an immune response to the foreign body
and leads to contraction of the fibroblastic capsule surrounding the implant causing a tight and
painful reconstruction (Figure 5), occurring in about 19-25% of cases. Capsular contraction
after breast reconstruction is classed according to the modified Baker classification (Bachour
et al., 2018; Petit et al., 2012).
Figure 5 Capsular contraction of the right reconstructed breast (Hirsch, Seth, & Fine, 2012)
Other complications associated with implants are malposition, deflation, rupture and breast
implant associated anaplastic large cell lymphoma (BIA-ALCL) (Ahmed et al., 2005; Kaya &
Serel, 2013; Petit et al., 2012).
BIA-ALCL was first reported in 1997 and is a rare T-cell lymphoma associated with breast
implants, in particularly those with a textured outer surface. An accurate risk assessment of
BIA-ALCL has been elusive as both the number of actual cases and the prevalence of women 
with breast implants and implant type have not been registered accurately (Collett et al., 2019). 
The British Association of Aesthetic Plastic Surgery (BAAPS, 2019) estimates the incidence
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between 1:20,000 to 1:60,000. It presents with late onset, rapid swelling of one breast due to
a seroma. Removal of the capsule (capsulectomy) and implant is usually sufficient to treat the
disease, but in more aggressive forms cytotoxic chemotherapy can be necessary (Santanelli
di Pompeo & Sorotos, 2018).
1.2.2 Autologous breast reconstruction
In autologous breast reconstruction, the patient’s own tissue is used to reconstruct the breast.
To achieve this, a flap of tissue is transferred from a donor site to the anterior chest wall. This
can either be as a pedicled flap, still attached to the original blood supply or as a free flap
where the tissue is isolated, detached and anastomosed to a recipient blood vessel using
microsurgery, which is only performed by plastic surgeons (Ahmed et al., 2005). Autologous 
reconstruction is considered the gold standard in breast reconstruction as it replaces like-with-
like resulting in a soft, natural looking ptotic breast shape which is long lasting and does not
require maintenance surgery like implant-based breast reconstruction. The lower abdominal
tissue is most commonly used, due to its availability and low morbidity. Alternative donor sites
are the buttocks, inner thighs, flanks and back (Table 1.2.2) (Kaya & Serel, 2013). 
Table 1.2.2 Common autologous breast reconstruction flaps
(Ahmed et al., 2005; Arnež, Pogorelec, Planinšek, & Ahčan, 2004; Petit et al., 2012)
LD flap
Latissimus Dorsi Flap (pedicled flap) – Figure 7
• Donor side: Back
Skin, fat and latissimus dorsi muscle
• Blood vessel: Thoracodorsal artery/vein (TDA/V)
Flap specific complications: seroma
Often a breast implant is needed to achieve adequate volume reconstruction
Pedicled TRAM
flap
Pedicles Transverse Rectus Abdominus Myocutaneous Flap – Figure 8
• Donor side: Lower abdomen
Skin, fat and rectus abdominis muscle tunnelled
subcutaneously
• Blood vessel: Deep superior epigastric artery/vein (DSAE/V)





     
               
               
              
           
          
          
            
  
  
      
    
      
                             
       
 




     
      
                          
      
 




    
       
                          
      
 




   
     
                          
      
 




        
      
                         
      
 
       
Free
(MS-)TRAM flap
Free (Muscle Sparing-) Transverse Rectus Abdominus Myocutaneous
Flap – Figure 8
• Donor side: lower abdomen
Skin, fat and portion of rectus abdominus
• Blood vessel: deep inferior epigastric artery/vein (DIEA/V)
Flap specific complications: abdominal hernia, seroma
DIEP flap
Deep Inferior Epigastric Perforator Flap – Figure 9
• Donor side: lower abdomen
Only skin and fat
• Blood vessel: deep inferior epigastric artery/vein
Flap specific complications: abdominal hernia, seroma
TUG flap
Transverse Upper Gracilis Flap – Figure 10
• Donor side: upper inner thigh
Skin, fat and gracilis muscle
• Blood vessel: medial circumflex femoral artery/vein
Flap specific complications: wound healing problems, seroma, asymmetry
IGAP flap
Inferior Gluteal Artery Perforator Flap- Figure 11
• Donor side: lower buttock
Skin and fat
• Blood vessel: inferior gluteal artery/vein
Flap specific complications: wound healing problems, seroma, asymmetry
SGAP flap
Superior Gluteal Artery Perforator Flap – Figure 11
• Donor side: mid/ upper buttock 
Skin and fat
• Blood vessel: superior gluteal artery/vein
Flap specific complications: wound healing problems, seroma, asymmetry
1.2.2.1 History of autologous breast reconstruction
Attempts to reconstruct the breast in the early 1900s with the use of the contralateral breast
and tubed flaps from the abdomen (Figure 6) were unsatisfying due to poor design, high donor
site morbidity, the need for multiple stages and poor cancer survival rates. The first pedicled
muscle flaps for breast reconstruction were the latissimus dorsi (described by Tansini in 1896
(Maxwell, 1980)) and pectoralis muscle (described by Ombredanne in 1906 (Teimourian &
Adham, 1983)) (Table 1.2.3) (Champaneria et al., 2012; Rozen, Rajkomar, Anavekar, &
Ashton, 2009). In the second part of 20th Century other donor sides were popularised for
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single-stage procedures. Initially only pedicled flaps were used including the greater omentum
and the lower abdomen (based on the deep superior epigastric artery) (Rozen et al., 2008). 
Figure 6 Stages of tubed pedicled flaps for early breast reconstruction (Gillies, 1959)
Daniel and Taylor (1975) introduced the free microvascular tissue transfer concept, which was
first used for breast reconstruction by Fujino and colleagues (1975) using a free flap from the
buttocks (Champaneria et al., 2012; Rozen et al., 2009). Donor site morbidity associated with
muscle harvest in musculocutaneous flaps has been reduced over recent years following the
advent of muscle-sparing perforator flaps such as the deep inferior epigastric perforator





    
           
               
             
              
                
            
          
        
     
     
      
     
       
        
      
      
        
      
    
     
       
      
        
      
         
        
         
       
          
        
         
         
Table 1.2.3 Important milestones in the evolution of autologous breast reconstruction
(Champaneria et al., 2012; Rozen et al., 2009)
1887 Pedicled contralateral breast (Verneuil)
1896 Pedicled latissimus dorsi myocutaneous flap (Tansini)
1895 Free lipoma transfer to breast (Czerny)
1906 Pectoralis minor muscle flap (Ombredanne)
1950 Composite tube pedicled contralateral breast (Yannilos)
1957 Pedicled racket shaped abdominal flap (Gillies and Millard)
1963 Pedicled greater omentum flap (Kiricuta)
1973 Pedicled, multistage gluteal myocutaneous flap (Orticochea)
1973 Free micro-vascular tissue transfer (Daniel and Taylor)
1975 Free superior gluteal artery myocutaneous flap (Fujino)
1977 Rectus abdominis myocutaneous flap (Mathes and Bostwick)
1979 Pedicled vertical rectus abdominis myocutaneous flap (Robbins)
1979 Rubens flap or deep circumflex iliac artery flap (Taylor)
1979 Free transverse rectus abdominis myocutaneous flap (Holström)
1982 Pedicled transverse rectus abdominis myocutaneous flap (Hartrampf et al)
1983 Extended deep inferior epigastric flap (Taylor)
1989 Free inferior gluteal artery myocutaneous free flap (Paletta et al)
1989 Free transverse rectus abdominis myocutaneous flap (Grotting et al)
1989 Free deep inferior epigastric artery perforator flap (Koshima and Soeda)
1992 Free transverse myocutaneous gracilis flap (Yousif et al)
1994 Muscle sparing deep inferior epigastric perforator flap (Allen and Treece)
1995 Pedicled latissimus dorsi perforator flap (Angrigiani et al)
1995 Free superior gluteal artery perforator flap (Allen and Tucker)
2004 Free inferior gluteal artery perforator flap (Guerra et al)
1.2.2.2 Latissimus dorsi (LD) flap
The latissimus dorsi myocutaneous flap is a pedicled flap based on the thoracodorsal blood
vessels and was first described by Professor Ignio Tansini in 1896 (Champaneria et al., 2012;
Maxwell, 1980). The flap fell out of favour after the Second World War but was re-discovered
in 1976 by Neven Olivari (1979). It can reconstruct both skin and volume although usually a
breast implant is needed to enhance the volume. It is a robust flap raised with a skin paddle,
underlying subcutaneous fat and (part of) the latissimus dorsi muscle and transferred to the
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anterior chest wall (Figure 7). Complications are usually donor site related, with large scars





Figure 7 Latissimus dorsi flap a. Preoperative; b+c. Postoperative LD with implant; d. Donor site scar
on the right side of the back (Petit et al., 2012)
1.2.2.3 Abdominal flaps – Transverse rectus abdominus (TRAM) flap, deep inferior epigastric 
perforator (DIEP) flap and superficial inferior epigastric artery (SIEA) flap
The first vertically pedicled musculocutaneous rectus abdominis flap for breast reconstruction
was performed by Robbins (1979). In the same year, Holmstrom (1979) described the use of
a transverse rectus abdominis myocutaneous (TRAM) flap for free-tissue transfer breast
reconstruction. Hartrampf and colleagues (1982) subsequently published and popularised the 
pedicled TRAM flap, based on the superior epigastric artery. This flap used a vertically 
oriented rectus abdominis muscle but a horizontally oriented cutaneous skin paddle, resulting
in a more cosmetically pleasing abdominal scar (Figure 8A). When it became apparent
sacrificing the rectus abdominis muscle was not required, muscle sparing techniques were
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sought to reduce abdominal wall morbidity. Taylor and colleagues (1983) only used the lower
portion of the rectus muscle for his extended deep inferior epigastric flap (Champaneria et al., 
2012). Koshima and Soeda (1989) first described the deep inferior epigastric perforator (DIEP)
skin flaps without muscle sacrifice for a groin defect and the oral floor reconstruction. Allen
and Treece (1994) used this DIEP flap for the first time in breast reconstruction. It is currently 
widely accepted to spare most of the rectus muscle, only sacrificing a cuff of muscle around
the pedicle. Nahabedian et al. (2002) developed a classification system, ranking the amount
of rectus abdominis muscle that was spared during the TRAM breast reconstruction (Table
1.2.4 and Figure 8) (Rozen et al., 2009).
Table 1.2. 4 Muscle sparing (MS) TRAM classification (Nahabedian et al., 2002)
MS-0 TRAM Sacrifice of the full width (partial length) of the rectus muscle
MS-1 TRAM Preservation of a lateral strip of muscle
MS-2 TRAM Preservation of both lateral and medial strips while sacrificing only a small cuff of
muscle around the perforators















              
   
 
            
             
              
         
        
 
              
            
               
             








Figure 8 A) pedicled TRAM flap; B) MS-0 TRAM; C) MS-1 TRAM; D) MS-2 TRAM (Patricio Andrades 
et al., 2008)
Grotting (1991) first used the superficial inferior epigastric artery (SIEA) flap in 1991, which is 
the least invasive technique because it does not require opening of the anterior rectus sheath
or any muscle dissection, as it is a supra-fascial cutaneous artery branching from the femoral
artery. Disadvantages are the inconsistent, short vascular pedicle anatomy and small arterial 
diameter (Munhoz et al., 2011; Patel & Ramakrishnan, 2017).
The abdomen is the ideal source of tissue for autologous breast reconstruction as it is soft,
easily shapeable and usually excessively available at a later age (Figure 9). Flap harvest also
leads to the added benefit of improving the patients’ abdominal contour, leaving them with a
result similar to an abdominoplasty (tummy tuck) (Granzow, Levine, Chiu, & Allen, 2006;
Rozen et al., 2009). 
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  a. b. c.
Figure 9 Deep inferior epigastric perforator flap. a. Preoperative markings; b. Raised DIEP flap; c. 
Postoperative result of right immediate reconstruction. Drawings by Ms Julia Ruston.
By preserving all or most of the rectus muscle with techniques such as the DIEP and SIEA
flaps, the incidence of abdominal donor site weakness and complications has been greatly 
reduced, compared to the TRAM flap (Egeberg, Rasmussen, & Sorensen, 2012). Donor side
weakness was evaluated by Blondeel at al. (1997) prospectively in 18 DIEP patients (mean
follow-up of 17.8 months), comparing them to a control group (n=20) and a retrospective group
of free TRAM flap breast reconstruction patients (n=20). Despite this only being a small study
population it showed a significantly reduced exercise strength of the TRAM group compared
to both DIEP and control group (p<0.05). Ten of the 12 DIEP patients examined with a CT or
MRI scar had no muscle atrophy. The objective data was correlated to patient questionnaires,
which also subjectively TRAM patients experience a reduced abdominal strength with a
reduced ability to daily activities. Pre-operative mapping of the perforators with computed
tomography angiography (CTA) has reduced the operating time and complication rate
(Ghattaura et al., 2010; Rozen et al., 2008). Disadvantages of the free (MS)-TRAM and DIEP
flap include an average operating time of 4-6 hours, 6-day hospital stay, 6-week recovery
(Ahmed et al., 2005). Possible complications are (partial) flap failure (0.4-5%), haematoma (1-
15%) , infections (1-12%), wound healing problems (12-39%), umbilical necrosis (2-3%) and
an abdominal bulge (2.3-33%) or hernia (0-7.1%) (Lindenblatt, Gruenherz, & Farhadi, 2019;
Schaverien & Butler, 2017). If the abdomen is insufficient in a thin patient or not usable after
previous surgery alternative donor sites can be used for autologous breast reconstruction.
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1.2.2.4 Transverse Upper Gracilis (TUG) flap
The first description of the free myocutaneous gracilis flap by Harii et al. (1976) for soft-tissue 
defect coverage (Rozen et al., 2009). Problems with the perfusion of the vertical skin paddle
led to further anatomic studies. Yousif et al. (1992) published the presence of mainly
transversely oriented perforators, which resulted in the use of the first transverse upper gracilis 
flap (Arnež et al., 2004; Patel & Ramakrishnan, 2017; Rozen et al., 2009). The harvested
melon-slice shaped flap consists of skin, fat and part of the gracilis muscle. This is a true
musculocutaneous flap supplied by the medial femoral circumflex system. Up to 400mg can
be harvested from the medial upper thigh, making it suitable for reconstruction of small to
medium sized breasts (Figure 10). Possible donors side complications are a low non-
concealable scar, wound healing problems, infection, seroma, lymphedema and sensory 






Figure 10 a. Preoperative marking TUG flap; b. Raised free TUG flap; c. Coned TUG flap with nipple
reconstruction; d. Bilateral TUG breast reconstruction; e. Bilateral donor site scars (Buchel, Dalke, &
Hayakawa, 2013; Patel & Ramakrishnan, 2017)
1.2.2.5 Superior/Inferior gluteal artery perforator (S/IGAP) flap
The gluteal region was first used for breast reconstruction by Orticochea (1973), where he
transferred a musculocutaneous gluteal flap in 5 stages, using the volar forearm as a transport
20
  
               
           
            
             
              
              
         
                
   
 
 
              
                 
                                                                                                       
 
    
          
              
         
                 
   
 
    
  
 
medium (Champaneria et al., 2012; Rozen et al., 2009). Fujino et al. (1975) introduced a one
stage free musculocutaneous based on the superior gluteal artery (Champaneria et al., 2012). 
From 1989 the inferior gluteal artery musculocutaneous free flap has been used in breast
reconstruction. The perforator flaps concept in the buttocks area lead to the introduction of the
superior and inferior gluteal artery perforator flaps (S/IGAP) (Figure 11) (Allen, 1998; Allen &
Tucker, 1995; Rozen et al., 2009; Shaw, 1983). The main issues with these flaps are
challenging perforator dissection, short vascular pedicle, recipient vessel discrepancy,
exposure of the sciatic nerve and the need to turn the patient over during the procedure (Patel
& Ramakrishnan, 2017).
a. b. c. d.
e. f.
g.
Figure 11 a. Markings of superior (b) and inferior (e) gluteal artery perforator flaps. Donor site scars
after SGAP (c) and IGAP (f). Results after SGAP (d) and IGAP (g) (Anita T. Mohan & Saint-Cyr, 2015;
Satake et al., 2015)
1.2.3 Combination of implant and autologous reconstruction
Sometimes a small implant is used if autologous tissue flaps are insufficient to achieve
adequate volume reconstruction (Ahmed et al., 2005; Champaneria et al., 2012; Kaya & Serel,
2013). The downside of combining these two techniques is the patient experiences the worse
of both worlds, having the donor side scar and long recovery of the flap combined with the
need for maintenance surgery for the used implant.
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1.2.4 Further procedures
Nipple reconstruction can be done at the initial breast reconstruction procedure but is usually
done at a later stage. It has been shown patients satisfaction with their overall reconstruction
is higher after nipple reconstruction has been completed (Momoh et al., 2012). Nipple
reconstruction can either be achieved by a local flap or nipple sharing, in which a part of the
opposite nipple is grafted to the reconstructed breast. The areola can be reconstructed with
the help of tattooing.
Touch up operations can be done to improve the symmetry and cosmetics after breast
reconstruction. Some examples are scar revisions, lipofilling for contour deformities and
contra-lateral breast procedures such as reduction, mastopexy or augmentation (Rozen et al.,
2009).
1.2.5 Breast reconstruction and radiotherapy
Radiotherapy uses ionizing radiation, which is delivered by external beam radiation to the
target areas (chest wall and/ or lymph nodes). This causes irreversible damage to both
malignant and healthy cells within the treated field, clinically leading to skin fibrosis,
telangiectasia, skin thinning, pigmentation and reduced healing capacity (See & Farhadi,
2018). Due to same tumour control but fewer adverse effects most centres now give 40 Gy in
15 fractions over three weeks (Schaverien, Macmillan, & McCulley, 2013). The published
benefit on overall survival of postmastectomy radiotherapy in patients with node-positive
disease has resulted in an increase in its role as an adjunct in the breast cancer treatment
(Cassidy et al., 2017; Everett, De Los Santos, & Boggs, 2018; Magill et al., 2017; McGale et
al., 2014; Overgaard et al., 1997; Ragaz et al., 1997; Tendulkar et al., 2012). This has led to
an increased number of patients requesting 1) immediate breast reconstruction with the need
for post-mastectomy radiotherapy and 2) delayed reconstruction following previous irradiation
(See & Farhadi, 2018). Despite the therapeutic advantages on overall-/ loco-regional
recurrence and survival, post-reconstruction radiotherapy increases the risk of complications
and can compromise the cosmetic outcome and patient satisfaction after breast reconstruction
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(Ho, Hu, Mehrara, & Wilkins, 2017; Magill et al., 2017). Implant-based reconstruction has got
a much higher risk of failure (18.7 - 32%) compared to autologous reconstruction (1.0 - 4.3%)
(Ho et al., 2017; Jagsi et al., 2018; Schaverien et al., 2013; See & Farhadi, 2018). Also, the
capsular contracture rates increase dramatically in case of pre- or post-operative radiotherapy 
with a systematic review and meta-analysis publishing an odds ratio of 10.21 (95% CI 3.74 to
27.89, p<0.00001) (Magill et al., 2017). Autologous reconstructions are less affected by
radiotherapy and have a higher patient satisfaction and aesthetic outcome. Some degree of
tissue shrinkage has been reported and significantly more patients develop fat necrosis after
radiotherapy (OR 2.82, 95% CI 1.35 – 5.92, p= 0.006) but this usually does not require revision
surgery (Schaverien et al., 2013). Jagsi et al. (2018) published a prospective multicentre
cohort study reporting the impact of radiotherapy on complications and patient reported
outcomes in 2247 breast reconstruction patients. After a two years follow-up, they reported 
33.2% of irradiated patients who had received implant-based reconstruction experienced
major complications (rehospitalisation or re-operation), compared to 17.6% of irradiated
patients receiving autologous breast reconstruction. Failure rates at two years of irradiated
implants were 18.7% compared to 1% of irradiated autologous reconstructions. The BREAST-
Q patient-reported satisfaction in irradiated patients at 2 years was 63.5/100 after autologous
reconstruction and only 47.7/100 after implant-based reconstruction.
1.2.6 Costs of breast reconstruction
The increased survival and public awareness have led to a continuous rise in the demand for
surgical breast reconstruction after mastectomy from 15% in 2000 to 32% in 2011 in the US
(Ho et al., 2017). The costs of breast reconstruction have a significant impact on the already
under stress British National Health System (NHS).
A cost-effectiveness analysis from Grover et al. (2013) including 54 publications (n=7278)
compared health effects, outcomes and complications up to 7 years postoperatively in five
different breast reconstruction techniques. This study concluded autologous tissue
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reconstruction techniques to be the most cost-effective options in both irradiated and non-
irradiated patients.
Lagares-Borrego et al. (2016) compared the 2-year costs of the two-stage expander/ implant
reconstruction with the autologous Deep Inferior Epigastic Perforator (DIEP) flap in 134
delayed breast reconstruction patients. They included costs of the procedure/labour costs,
used materials, length of hospital-stay, number of consulting appointments and costs of
additional interventions due to complications or for aesthetic retouches. Despite the initial
higher costs of the DIEP reconstruction there was no significant difference between the total
costs of both techniques. This can be attributed to the fact autologous reconstruction achieves 
great stability compared to implant reconstruction which tends to develop complications and
other unfavourable outcomes leading to an unsuccessful reconstruction over time.
1.2.7 Conclusion
Due to an increased survival rate (Cancer research UK, 2017), proven oncological safety
(Champaneria et al., 2012) and numerous studies demonstrating positive influence on
emotional and psychological well-being (Jeevan et al., 2014; Rowland, Holland, Chaglassian,
& Kinne, 1993; Zhang et al., 2017; Zhong et al., 2012) the demand for breast reconstruction
has increased over recent years (Grover et al., 2013; Ho et al., 2017). Implant-based
reconstruction is still most commonly performed also in the setting of radiotherapy, despite
higher rates of complications, implant loss and revision surgery (Ho et al., 2017; Magill et al.,
2017). Possible reasons for this are the initial higher costs of autologous breast reconstruction,
the availability of resources (plastic surgeons performing microsurgery and theatre time),
patient factors (age, co-morbidities, unavailable donor-site) and patient preference (more
extensive surgery and recovery time) (Jagsi et al., 2018; See & Farhadi, 2018). 
St. Andrew’s Centre for Plastic Surgery and Burns in Broomfield Hospital, Chelmsford UK is 
one of the biggest regional specialist plastic surgery units in the United Kingdom, covering a
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population of over 3.2 million people. The department performs over 300 autologous free flap
breast reconstructions every year, which are mainly DIEP flaps. The increasing demand on
the service and innovative character of the speciality are driving forces to keep looking for
ways to improve efficiency and outcomes for abdominally based free flap breast reconstruction
patients. The following chapter will go through the stages of wound healing with the aim to




   
             
            
 
   
             
          
   
 
    
             
          
          
             
            
          
          
           
          
        
            
           
             







An injury to the skin compromises its protective integrity and sets in motion a well-orchestrated
response to heal the wound and eliminate the possible outside threats.
1.3.1 The skin
The skin is the largest organ of the human body and has many different functions, but most
importantly provides a protective physical barrier from external factors to keep the internal
systems safe (Gawkrodger, 2003).
1.3.1.1 Contents of the skin
The skin is made out of three layers, an epidermis, dermis and hypodermis (Figure 12). The
avascular epidermis is further divided into five layers (from superficial to deep): stratum
corneum, stratum lucidum, stratum granulosum, stratum spinosum and stratum basale.
Keratinocytes, the main cells of the epidermis replicate in the basal layer, pushing up older
cells while losing their nucleus and flattening off. A complete turnover cycle takes around 48
days. Essential appendages within the epidermis such as pilo-sebaceous units (hair follicle
with associated sebaceous gland) and apocrine glands, contain epithelial stem cells which
can differentiate into basal keratinocytes, making them essential in re-epithelization. The
dermis is a tough supportive connective tissue matrix, containing blood vessels, lymphatics,
nerves, skin appendages and different cells such as fibroblasts, dermal dendrocytes,
macrophages and lymphocytes. There is an upper papillary dermis and a deeper and thicker
reticular dermis. The hypodermis or subcutis is mainly built of loose connective tissue and fat
(Gantwerker & Hom, 2012; Gawkrodger, 2003). The different layers of the skin vary in




          
 
    




     
 
          
     
Figure 12 Sectional view of skin and subcutaneous layers (Gantwerker & Hom, 2012)
1.3.2 Stages of wound healing




• Maturation and remodelling
This division of the actually overlapping (Figure 13) stages of wound healing is arbitrary




             
 
 
            
              
        
            
           
             
             
          
         
 
 
        
        
Figure 13 Time scale of four phases of wound healing (Gantwerker & Hom, 2012)
Haemostasis
This phase initiates within seconds to minutes of the initial injury disrupting the vascular
endothelium. Platelets are key as they not only ensure initial haemostasis by activating the
extrinsic and intrinsic coagulation cascades, but also release cytokines, hormones and
chemokines to attract inflammatory cells and start the other phases of wound healing. Larger
vessels vasoconstrict under the influence of vasoactive substances such as catecholamines
and serotonin. Smaller vessels vasodilate to allow the entrance of red blood cells, leukocytes 
and plasma proteins. The formed clot made of collagen, platelets, thrombin and fibronectin
not only serves as a scaffold for infiltrating cells but also releases and concentrate growth
factors and cytokines to initiate the inflammatory response (Gantwerker & Hom, 2012).
Inflammation
The inflammatory phase is characterised by vasodilatation and increased vascular
permeability, allowing the influx of neutrophils, lymphocytes and macrophages. The
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neutrophils who arrive first onsite, attract the macrophages via by-products of their apoptosis.
These and other phagocytic cells stay present until the end of the inflammatory phase, clearing
debris and bacteria from the area. Macrophages produce numerous enzymes, such as
collagenases to debride the wound, tumour necrosis factor (TNF) and interleukins (ILs) to
stimulate fibroblasts and angiogenesis and transforming growth factor (TGF) which activates
keratinocytes and fibroblasts. These macrophages are also key in the transition into the
proliferative phase (Broughton, Janis, & Attinger, 2006a; Gantwerker & Hom, 2012). 
Proliferation
This repair phase involves re-epithelization, capillary budding and granulation tissue
formation. If the basement membrane has been damaged, re-epithelization occurs from stem
cells in apocrine glands and buds of hair follicles. They differentiate into keratinocytes which
then migrate over the wound edges and lay down a new basement membrane. Contact
between keratinocytes, after the wound defect is filled in, inhibits further migration.
Angiogenesis by endothelial cell migration and the formation of capillaries is essential for a
sufficient nutrient supply and proper wound healing. Fibroblasts are key in granulation tissue
formation as they transform into myofibroblasts which synthesize several extracellular matrix 
proteins (ECMs) such as fibronectin, glycosaminoglycans and collagens. Myofibroblasts also
have the ability to contract, achieving wound contraction (Broughton, Janis, & Attinger, 2006b;
Gantwerker & Hom, 2012). 
Maturation and remodelling
This is the longest phase and results in the final appearance of the wound. The provisional
ECMs and type III collagen is replaced with type I collagen, cells from previous phases go into
apoptosis, granulating tissue involutes and excessive blood vessels retract. This phase
requires more synthesis than lysis (Gantwerker & Hom, 2012).
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1.3.3 Cytokines in wound healing
The initial response to trauma is largely coordinated by endogenous soluble mediators 
referred to as cytokines. They are produced by systemic immune cells and diverse cell types
at the site of injury (Lin, Calvano, & Lowry, 2000). Cytokines can be classified into families
based on their three-dimensional structure and binding receptors. Some of the key cytokines
are interferons (IFNs), chemokines, lymphokines, interleukins (IL), colony-stimulating factors
(CSF) and tumour necrosis factor (TNF) (Holdsworth & Gan, 2015; Tanaka & Kishimoto,
2014). They are made up of polypeptides or glycoproteins of molecular weight of 5 to 30
kilodalton and function predominantly within a short distance of their release by intracrine,
autocrine and paracrine mechanisms. By binding to specific cellular receptors, they influence
immune cell activity, differentiation, proliferation and survival. The activity of these pleiotropic
mediators ultimately results in pro- and anti-inflammatory response at the site of injury aiding
in wound healing (Henry & Garner, 2003; Lin et al., 2000).
The main cytokines related to (surgical) injury and inflammatory response are listed below:
Tumour necrosis factor-α (TNF-α)
TNF-α is one of the earliest and most potent mediators released after an injury or during an
infection. It is primarily produced by T lymphocytes and monocytes/ macrophages. Despite a
half-life of less than 20 minutes, TNF-α is able to elicit a significant metabolic and
haemodynamic changes and activate cytokines further down the cascade. Other actions of
TNF-α involve coagulation activation, stimulating the expression or release of adhesion
molecules, platelet-activating factor (PAF), prostaglandin E2, glucocorticoids and eicosanoids
(Lin et al., 2000).
Interleukin-1 (IL-1)
IL-1 is primarily released by endothelial cells and activated macrophages. Like TNF-α, at high 
dosages IL-1 can elicit a stage of haemodynamic decompensation. Low doses of both
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cytokines can produce the same response, emphasizing the synergistic role in the
inflammatory response. The half-life of IL-1 is only 6 minutes making it even more difficult to
detect than TNF-α. By stimulating local prostaglandin activity in the anterior hypothalamus, it
induces a febrile response after injury (Lin et al., 2000).
Interleukin-2 (IL-2)
IL-2 primarily promotes T lymphocyte proliferation, immunoglobulin production and the
integrity of the gut barrier. Its half-life is less than 10 minutes. A transient immunocompromised
state of the surgical patient can potentially be a consequence of diminished levels of IL-2 after
major injuries or perioperative blood transfusions (Lin et al., 2000).
Interleukin-4 (IL-4)
IL-4 has a diverse influence on haematopoietic cell proliferation and is produced by activated
T helper cells. It is important in antigen presentation, antibody-mediated immunity and induces
B lymphocytes to produce predominantly IgG and IgE. IL-4 has got anti-inflammatory
properties as it can down regulate the effects of IL-1, TNF-α, IL-6 and IL-8 on activated
macrophages and increases their susceptibility to the effects of glucocorticoids (Lin et al.,
2000). 
Interleukin-6 (IL-6)
IL-6 is a multifunctional cytokine (Figure 14) but its key-functions are mediation of the
physiologic acute phase response to injury and haematopoiesis. Production in a wide variety
of non-immune and immune cell types is induced by tissue damage, triggering an alarm signal
which activates the hosts defence mechanisms (Biffl, Moore, Moore, & Peterson, 1996). IL-6 
is an early and sensitive marker of tissue damage and is considered to represent the extend
of stress following surgery (Y. Kumagai et al., 2014). The increase is evident soon after injury 
and usually lasts for 24-48 hours but can persist longer in patients with more severe injuries










       
 
 
           
           
   
 
  
           
        
       
 
  
         
             
       
 
  
          
       
 
Figure 14 Pleotropic activity of IL-6 (Tanaka & Kishimoto, 2014).
Interleukin-8 (IL-8)
IL-8 is produced by phagocytes and mesenchymal cells exposed to tissue injury and is the
main chemoattractant and potent activator of neutrophils (Baggiolini & Clark-Lewis, 1992; Lin
et al., 2000).
Interleukin-10 (IL-10)
IL-10 is a potent anti-inflammatory cytokine which can attenuate the production of other
inflammatory cytokines, thereby limiting the host’s immune response preventing chronic
inflammatory and autoimmune pathologies (Iyer & Cheng, 2012).
Interleukin-12 (IL-12)
IL-12 has a primary role in cell-mediated immunity and encourages the differentiation of T-
helper cells. It also promotes coagulation and neutrophil activation, as well as the expression
of both anti- and pro-inflammatory mediators (Lin et al., 2000).
Interleukin-13 (IL-13)
IL-13 modulates macrophage and selected B lymphocytes function. Along with IL-4 and IL-




        
         
       
 
  
          
         
           
 
 
           
         
 
  
       
         
       
 
  
              
            
        
 
     
            
      
Interleukin-15 (IL-15)
IL-15 is macrophage-derived cytokine with potent autocrine regulatory features. Sharing
receptor signalling components with IL-2, results in similar bioactivity in promoting lymphocyte
activation and proliferation (Lin et al., 2000). 
Interleukin-18 (IL-18)
IL-18 (previously known as interferon-γ-inducing factor) is a member of the IL-1 superfamily.
This pro-inflammatory cytokine produced by activated macrophages is an important regulator
of the innate and acquired immune responses (Gracie, Robertson, & McInnes, 2003).
Interferon-γ (IFN-γ)
IFN-γ is produced by activated human T helper lymphocytes and has an important role in
activating circulating and tissue macrophages (Lin et al., 2000).
Macrophage Inflammatory Protein-1 alpha and beta (MIP-1 alpha and beta)
MIP-1 is produced mainly by macrophages, dendritic cells and lymphocytes. Their primary
effects are chemotaxis and induction and modulation of the inflammatory response. They can
also stimulate homeostasis (Maurer & von Stebut, 2004). 
Monocyte Chemotactic Protein-1 (MCP-1)
MCP-1, also referred to as chemokine C-C motif ligand 2 (CCL2) belongs to the CC chemokine
family. It is one of the important chemokines that regulates migration and infiltration of
monocytes and macrophages (Deshmane, Kremlev, Amini, & Sawaya, 2009).
1.3.4 Growth factors in wound healing
Growth factors are proteins with a weight between 4000 and 60,000 Kilodalton (kDa). They
modulate wound healing by stimulating non-hematopoietic cellular functions through
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endocrine, paracrine, intracrine or autocrine mechanisms. Main effects are stimulation of
protein production, matrix turnover, synthesis of extra cellular matrix and cell death. There are
five superfamilies of growth factors namely, platelet-derived growth factor (PDGF), epidermal
growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF) and
insulin-like growth factor (IGF) (Henry & Garner, 2003).
1.3.5 Levels cytokines in correlation to trauma
Biffl et al. (1996) published a literature review where they concluded IL-6 response to injury is 
uniquely consistent and relates to the magnitude of the insult after trauma, burns and elective
surgery. Taniguchi et al. (1999) found a significant correlation between serum IL-6 and IL-10 
levels and injury severity scores in 20 patients with chest and abdominal trauma. Those results
were repeated by Stenseballe at al. (2009), also showing a significant correlation between
injury severity scores in 265 trauma patients and their serum levels of IL-6 and IL-10 measured
upon arrival and at 6, 12 and 24hours after admission. The same findings have been published
for open vs closed elective procedures such as cholecystectomy, gastrectomy, colonic
resection and aortobifemoral bypass surgery (Delgado et al., 2001; Grande et al., 2002; Haq
et al., 2004; Hildebrandt et al., 2003; Jawa, Anillo, Huntoon, Baumann, & Kulaylat, 2011; Krog
et al., 2016; Y. Kumagai et al., 2014; Reith, Kaman, Mittelkotter, Kilic, & Kozuschek, 1997;
Schietroma et al., 2004; Schwenk, Jacobi, Mansmann, Bohm, & Muller, 2000).
1.3.6 Levels of inflammatory cytokines in drainage fluid
Levels of inflammatory cytokines in wound drainage fluid are higher compared to circulating
levels in serum and are expected to be a better representation of interstitial levels (van der
Heide, van der Kraan, Rijnberg, Buma, & Schreurs, 2010). Di Vita et al. (2005; 2006) published 
two papers measuring levels of several cytokines (IL-1, IL-6, IL-10) and growth factors in 
wound drainage fluid of ten patients after an incisional hernia repair on post-operative days 1
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to 4. This showed the highest levels of all cytokines on day 1, decreasing over the following
days.
Van der Heide et al. (2010) reported a significant increases of levels for almost all cytokines
(IL-1, IL-2, IL,4, IL-5, IL-6, IL-7, IL-8, IL-12, IL-13, IFN-gamma, TNF-alpha and MCP-1) in
drainage fluid samples taken after one and six hours post-operatively in 30 total hip
replacement patients. 
Özdogan et al. (2008) published an important paper for this thesis where they showed
significantly higher levels of TNF-alpha in the drain fluid 24 hours after diathermy (n=18)
dissection compared to the less traumatic scalpel (n=20) dissection in mastectomy patients.
They also showed a significantly higher rate of seroma formation. This non-randomised study
only included a small number of patients in each group. Diathermy settings were not disclosed,
neither was the number of different operating surgeons mentioned. The same group published
another study a few years later (Yilmaz et al., 2011) where they showed significantly higher
levels of pro-inflammatory cytokines TNF-alpha and IL-6 in the drainage fluid after diathermy
(n=26) dissection compared to scalpel (n=27) or ultrasonic dissection (n=29) in mastectomy
patients. Study groups were again small and not randomised, and unfortunately no power
calculation was performed with the data from their previous study. The major issue with this
study was the collection time of the drain fluid, which was reported as within 24 hours post-
operatively. As the inflammatory marker levels will raise significantly within the initial hours
post-surgery (van der Heide et al., 2010), the collection time should have been narrowed down 
to ensure the significant difference is due to the different dissection device and not the different
sample times.
Lucas et al. (2018) analysed levels of cytokines in the drain fluid of twenty autologous
abdominal based breast reconstruction patients at 24-, 48-, 72- and 96-hours post-operatively.
The found a significant decrease over time for cytokines IL-1, IL-2, IL-6, IL-8, IL-9, IL-10, IL-
17 MIP-1 alpha, MIP-1 beta, MCP-1, IFN-gamma and TGF-alpha, stable levels for IL-7, and
only an increase over time for IL-5 levels.
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1.3.7 Patient factors in wound healing
Due to its complexity wound healing can be interrupted at many different levels by intrinsic 
and/or extrinsic factors (Table 1.3.1). Intrinsic factors are those related to the patients’ overall
health and further predisposing factors. Extrinsic factors are conditions affecting the patient
healing capacity (Gantwerker & Hom, 2012).
Table 1.3. 1 Factors affecting wound healing (Gantwerker & Hom, 2012)




• Hereditary healing diseases
• Acquired chronic diseases
• Malnutrition
• Infection





• Foreign material in wound
• Trauma
1.3.8 Conclusion
The initial response to trauma is largely coordinated by inflammatory cytokines (Lin et al.,
2000). A greater degree of tissue injury results in the production of higher levels of
inflammatory cytokines (Biffl et al., 1996; Jawa et al., 2011; Stensballe et al., 2009; Taniguchi
et al., 1999). The levels of inflammatory cytokines can be measured in wound fluid such as
seroma fluid captured in a drain and can be compared between different operating techniques
to identify the one causing the least amount of trauma (Özdogan et al., 2008; Yilmaz et al.,
2011). The next chapter will explain what a seroma is, how to diagnose it and explore methods






            
             
           
  
        
 
             
            
              
             
          
              
         
             





            





A seroma is an accumulation of non-infected subcutaneous fluid (Figure 15). The name comes
from serum (Latin for “whey”) and oma (Latin for “tumour”), meaning “tumour from the
collection of serum” suggesting it originates from the ultrafiltration of blood (P. Andrades &
Prado, 2007).
Figure 15 Collection of subcutaneous seroma fluid. Source: www.fairview.org
It is one of the most frequent donor site complications after DIEP/ MS-TRAM breast
reconstruction. Reported incidence varies from 3% - 58% (P. Andrades & Prado, 2007; Kuroi
et al., 2005; Miranda, Wilson, Amin, & Chana, 2015; Porter, O’Connor, Rimm, & Lopez, 1998). 
Di Martino et al. (2010) showed a significant increase in seroma identification (38.1%) if
ultrasound is used compared to clinical examination (23.8%) because small-volume seromas 
can be missed clinically for example due to local oedema of the subcutaneous tissue. An
ultrasound machine uses high-frequency sound waves to create images ranging from white
to black with different shades of grey in between. Dense tissue like bone is white and fluids
like a seroma collection are black (Figure 16).
* *
*




          
            
             
          
          
 
          
           
              
            
            
         
         
 
              
       
          
              
               
              
             
            
            
 
 
       
          
             
Formation has been positively correlated with body mass index (BMI) and flap weight (P.
Andrades & Prado, 2007). A seroma can cause discomfort, wound breakdown, infection and
if chronic, can turn into a pseudocyst. It is usually self-limiting, but occasionally results in
significant problems requiring multiple percutaneous drainages or even surgery (P. Andrades
& Prado, 2007; Kuroi et al., 2005; Porter et al., 1998).
Andrades and Prado (2007) showed post-abdominoplasty seroma is actually an exudate,
which changes from an early inflammatory exudate into a late exudate with some
characteristics similar to those of lymph. It’s true origin is uncertain but different mechanisms
have been suggested such as skills and operation technique of surgeon, creation of dead
space, shear forces between skin flap and fascia, disruption of lymphatics and vessels, 
surgical dissection tool and the release of inflammatory cytokines following surgery (Nagarkar 
et al., 2016; Sforza et al., 2015; Swanson, 2015).
A prospective clinical trial published by Di Martino et al. (2015) evaluated the beginning and
progression of seroma formation following abdominoplasty by performing abdominal
ultrasounds at 7-day intervals in 21 female patients. Electrosurgery was used on power setting
35 Watt for cut and coagulation to carry out the abdominoplasty. Drains were removed when
the output was less than 40ml/ 24 hours, resulting in a mean drain requirement of 4.4 days.
Abdominal ultrasounds were performed on day 4, 11, 18, 25 and 32. They concluded the
highest incidence of seroma formation was between day 11 (38.1%) and 18 (33.3%) post-
operatively, which fell significantly to 19% on day 32. They also found a significantly increased
incidence of seroma with an increased weight of the resected tissue.
1.4.1 Methods to reducing abdominal seroma formation
Due to the uncertain pathophysiology of seromas there is no consensus on prevention or
treatment of this complication. Different methods to reduce the formation of the abdominal
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seroma in both cosmetic abdominoplasties and DIEP/MS-TRAM breast reconstruction have
been published over recent years (Table 1.4.1).
Table 1.4. 1 Methods to reduce abdominal seroma formation
Principle Method
Reducing dead space • Closed suction drains
• Progressive tension or quilting sutures
• Adhesives or fibrin sealants
• Compression
Reducing shear forces • The Scarpa fascia preservation
• Immobilization
Reducing tissue injury • Surgical dissection tool
1.4.1.1 Drains
Using closed suction drains help obliterate a surgically created dead space and for decades 
has been considered the standard of care to prevent seromas. They are usually kept in place
until the output is lower than 20 to 50 ml/ 24 hours (volume subjected to surgeons’ preference)
(Friedland & Maffi, 2008). Considering the study results of Di Martino et al. (2015) the drains
would have to stay in for a long period of time (up to 18 days) to actually capture the period of
highest seroma incidence. A long indwelling drain period is usually not clinically desirable as
the drain can cause pain/ discomfort, infection, limited patient mobility and potentially increase
inpatient stay which result in an increased financial burden (Thacoor, Kanapathy, Torres-Grau,
& Chana, 2018). In St. Andrews free flap breast reconstruction patients, drains are used and




      
              
            
          
               












              
        
 
 
           
           
                   
           
          
               
             
 
    
            
            
           
           
            
1.4.1.2 Progressive tension or quilting sutures
Baroudi and Ferreira (1998) were the first to describe quilting sutures between the abdominal
flap and abdominal wall fascia for cosmetic abdominoplasty surgery. Pollock and Pollock
(2000), subsequently introduced progressive tension suture which not only closed the dead
space but also helped to distribute tension in the abdominal skin flap as it was advanced
(Figure 17).
Figure 17 Progressive tension sutures closing of the dead space and distributing tension in the
abdominal skin flap (T. A. Pollock & Pollock, 2012)
Multiple interrupted sutures have been criticised for introducing multiple knots which can lead
to increased tissue reaction, they can cause skin dimpling and can significantly increasing
length of the operating time (up to 50 min) (A. T. Mohan et al., 2015). The use of continuous
absorbable barbed progression tension sutures without the use of drains has been published
more recently in both aesthetic abdominoplasty and DIEP/ TRAM breast reconstruction to
reduce the dead space and aid in tension free closure without significant increase of operative
time (Nagarkar et al., 2016; Sforza et al., 2015; Thacoor et al., 2018). 
1.4.1.3 Fibrin sealants and adhesives
Fibrin was first introduced in 1983 as a tissue sealant. It consists mainly of thrombin and
fibrinogen with factor XIII derived from pooled human plasma. They function through the
formation of fibrin clots, which reaches the maximal bonding strength 10 minutes after
application (Mabrouk, Helal, Al Mekkawy, Mahmoud, & Abdel-Salam, 2013; Wattin & Van
Loock, 2011). In theory it reduces seroma formation through three mechanisms: 1) sealing off
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microvascular, lymphatic and connective tissue injuries; 2) binding tissue layers together,
thereby reducing dead space and shear forces between skin flaps; 3) enabling faster
revascularization of damaged tissue across suture lines (J. C. Lee, Teitelbaum, Shajan,
Naram, & Chao, 2012). Different low volume trials and systemic reviews have not been able
to show a statistically significant decrease in post-operative seroma after the application of
fibrin sealants in abdominoplasties (Ardehali & Fiorentino, 2017; Bercial, Sabino Neto, Calil,
Rossetto, & Ferreira, 2012). This could potentially be due to the large wound area and high
traction forces exciding the fibrin adhesions (Gilbert, Badylak, Beckman, Clower, & Rubin,
2013; Nahas, di Martino, & Ferreira, 2012; W. Oliver, A. Hamilton, A. Figle, H. Wood, & B.
Lamberty, 2002).
TissueGlu® Surgical adhesive is a synthetic, lysine-derived urethane adhesive. It is designed
to adhere large tissue flaps and has been shown to be significantly more resilient to shear
forces than fibrin adhesives. In a canine model the application of TissueGlu® in a surgically
created pocket did reduce the seroma formation significantly up to 12 weeks post operatively
(Gilbert et al., 2013). So far only two clinical trials in abdominoplasty patients have been
performed, but due to poor design results are not considered valuable (Hunstad et al., 2015;
Spring, 2018).
1.4.1.4 Compression - Abdominal binders
Most surgeons use some sort of abdominal support after abdominal wall surgery. This does
not seem to have any significant effect on pain or seroma formation. However, subjectively
the majority of patients found wearing the binder beneficial (Christoffersen, Olsen, Rosenberg,
& Bisgaard, 2015). There is also no prospective study on the role of compression on
established seromas, which is interesting as aspiration and compression is usually the initial
treatment (Janis, Khansa, & Khansa, 2016). In St. Andrews free flap breast reconstruction
patients wear an abdominal binder for 6 weeks post-operatively (see materials and methods).
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1.4.1.5 Preservation of the Scarpa fascia
Scarpa fascia preservation with underlying deep fat compartment (Figure 18) was suggested
by Le Louarn (1996) and has shown to reduce drain output, lead to earlier drain removal and
reduces postoperative seroma formation in abdominoplasty operations. Two possible
explanations for the result are: better preservation of lymphatic drainage and blood supply of
the abdominal wall and better adhesion between upper skin flap and the deep fat compartment
resulting in a higher resistance to shear movements (Correia-Goncalves et al., 2017; Costa-
Ferreira, Marco, Vasconez, & Amarante, 2016; Costa-Ferreira, Rebelo, Silva, Vasconez, &
Amarante, 2013; Koller & Hintringer, 2012; Xiao & Ye, 2017). An anatomical study showed
the lymphatics are most prevalent in the superficial and deep dermis, with only approximately
17% of lymphatic vessels in the deep tissue. The clinical significance of this stays unclear but
this could support the first explanation (Friedman, Coon, Kanbour-Shakir, Michaels, & Rubin,
2015). 
Figure 18 Preservation of the Scarpa fascia and deep fat compartment on the abdominal wall (held up
by forceps) (Costa-Ferreira et al., 2016)
It must be noted that in the large RCT published by Cost-Ferreira et al. (2013, 2016) not only
preservation of the Scarpa fascia but also the dissection method (electrosurgery vs blade and
avulsion technique) was different between the two groups, which can also have a significant




             
           
        
              
        
 
     
        
         
            
               
     
        
          
           
         
       
            
          
           
            
            
            
              
            
          
               
1.4.1.6 Immobilisation
One study has shown to decrease the rate of post abdominoplasty seroma’s by immobilising
the patients up to 48 hours. Immobilisation results in a higher chance of thromboembolic 
complications despite prophylaxis making this method not desirable (Beer & Wallner, 2010). 
In St. Andrews free flap breast reconstruction patients are usually immobilised for 24hours as
part of the standard post-operative protocol (see materials and methods).
1.4.1.7 Dissection tool
As described previously, electrosurgery uses electricity to achieve the clinically desired effects
of separating tissue and simultaneously providing haemostasis by sealing off small blood
vessels. The heat produced during electro-dissection can cause collateral tissue damage (see
chapter “Electrosurgery and cautery”). Such an internal burn injury can results in an increased
capillary permeability and fluid leak containing pro-inflammatory cytokines and inflammatory
cells (Swanson, 2013). A greater inflammatory response with higher levels of pro-inflammatory 
cytokines have been shown in the seroma fluid of mastectomy patients treated with
electrocautery compared to scalpel dissection (Özdogan et al., 2008; Yilmaz et al., 2011). 
Different studies have compared electrosurgery to scalpel dissection in abdominoplasty
patients and the effect on seroma formation.
Rousseau et al. (2011) published a retrospective review comparing scalpel (n=327) dissection
to diathermy (cut mode, n=320) in abdominoplasty patients. Four different surgeons in each
group performed the procedures, which could be a confounding factor. Non-infectious
collections, including both haematomas and seromas, were identified with an ultrasound scan,
CT or needle aspiration, between day 7 and 45 post-operatively and were significantly
(p<0.05) more common in the diathermy group (8.8%) than the scalpel group (4.9%). Patients
in the diathermy group also had significantly higher average drain production and required the
drain longer. The follow-up protocol was not discussed and could be a confounding factor if
collection assessment was performed at different post-operative time points for the different
groups. It was unclear if all patients underwent USS, CT or needle aspiration or only if there
43
  
               
           
       
           
           
             
              
            
            
            
            
              
           
               
         
             
         
          
            
             
         
            
           
          
           
               
             
               
was a clinical suspicion of a collection, which could lead to under diagnosis. Due to the
retrospective character and unclarities regarding time and method of seroma diagnosis,
results should be interpreted with caution.
Valença-Filipe et al. (2015) published a paper comparing scalpel (n=39) to diathermy 
dissection (coagulation mode, n=80) in full abdominoplasty patients. The different dissection
methods were performed by one surgeon in the scalpel group and four surgeons in the
diathermy group, which could be a confounding factor. This was a prospective study, without
randomisation which could have resulted in selection bias. Seromas were diagnosed clinically
which could result in under diagnosis and it was not reported when they were diagnosed and 
how long the follow-up was. Both BMI and specimen weight were significantly higher in the
scalpel group, which could be confounding factors. Outcomes showed a significantly lower
drain output with shorter drain requirement and hospital stay in the scalpel group. The scalpel
group also experienced significantly less seromas. The findings of this study are interesting,
but their value should be approached with caution due to study design which could have
resulted in bias and confounding factors, for which was not corrected.
Marsh et al. (2015) published a blinded randomised controlled trial comparing scalpel (n=44)
with diathermy (coagulation setting 35 Watt, n=58) dissection in abdominoplasty patients.
Operations were performed by two different surgeons, but it was not clarified if the use of
scalpel or diathermy was equally divided between them. A difference in experience for either
of the two surgical instruments was not commented on and could be a confounding factor. No
power calculation was performed. Patients were only clinically assed for seroma collections
at 1-, 6-weeks and 3 months, which could result in an underdiagnosis. Seroma rates were
equal between the scalpel (20.1%) and diathermy (17.2%) groups, not showing a statistically 
significant difference (p=0.48). Thirty-nine patients underwent liposuction in addition to their
abdominoplasty. This was equally divided between the two groups but does add another
variable. It was not reported if infiltration was used and at which ratio (dry, wet, super-wet or
tumescent). The authors do not explain the fourteen-patient difference in group size, which is
unexpected in a randomised controlled trial and could be due to patient loss to follow-up which
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would be a source of bias and a possible explanation for the similar seroma rates. Despite this
study supplying level 1 evidence, due to possible bias and confounding factors results should
be interpreted with caution.
Swanson (2013, 2015, 2016, 2017) published one article and a few letters to editor regarding
his experience with scalpel dissection in abdominoplasty reducing seroma rates. He published
his 5-year cases series of abdominoplasty (n=17) and lipo-abdominoplasty (n=150) patients 
after super-wet infusion of up to 1L of normal saline mixed with 0.025% bupivacaine and
1:526,000 epinephrine followed by scalpel dissection and cautery for haemostasis of individual
vessels. On clinical examination nine patients developed a post-operative seroma (5.4%) in
the 12.26 months follow-up period, which were all treated with aspiration. Clinical assessment
alone can result in an underdiagnosis of seroma presence. This large sample prospective
study including patient from one surgeon presents an interesting technique possibly causing
the low seroma incidence, but a future sufficiently powered RCT should supply higher level
evidence. It would not be desirable to apply this infiltration technique for abdominal breast
reconstruction patients as the vasoconstrictive epinephrine could complicate perforator
identification.
1.4.2 Difference in seroma incidence between DIEP/ MS-TRAM and elective abdominoplasty
The elective abdominoplasty is one of the most popular aesthetic operations performed,
removing excessive abdominal skin and fat tissue to improve the contouring of the abdomen















             
 
        
            
        
            
             
            
            
            
                
             
    
 
 
           
           
              
            
       
 
Figure 19 Elective abdominoplasty. Pre- (left) and post-operative (right) (Kurt Yazar & Serin, 2019). 
Despite the identical anatomical area, publications regarding seromas in abdominoplasty
patients, cannot be transferred directly to the DIEP/MS-TRAM abdominal donor site due to
differences in operation technique and patient characteristics (Salgarello, Tambasco, &
Farallo, 2012). Salgarello et al. (2012) published a literature review including 3,937 patients
to compare short-term complication rates between DIEP flap donor site (n=1,997) and elective
abdominoplasties (EA, n=1,940). They found a four-time higher incidence of seroma rates in
the EA (16.1% vs 3.7%), despite intramuscular dissection and longer operating times in DIEP
patients. Possible explanations given by the authors are earlier mobilisation after EA, a higher
BMI in the EA cohort, the use of liposuction as an adjunct to EA, simultaneous hernia repair
or rectus plication in EA and more meticulous and atraumatic dissection technique and
coagulation in DIEP operations.
1.4.3 Conclusion
A seroma is an accumulation of non-infected subcutaneous fluid of uncertain origin. Its
occurrences is reported between 3 and 58% after DIEP/MS-TRAM breast reconstruction (P.
Andrades & Prado, 2007), with the highest incidence between day 11 and 18 (M. Di Martino
et al., 2015). Methods to reduce dead space, shear forces and/ or tissue injury have been 
published to reduce or eliminate seroma formation. 
46
  
           
           
           
            
            
          
          
             
          
           
           
           
















In St. Andrews suction drains, compression garment and 24-hour immobilization are part of
the normal protocol after abdominally based breast reconstruction. In the search of methods 
to reduce drain requirement and seromas formation in the DIEP/MS-TRAM patient population,
publications on the subject were evaluated on evidence and applicability: 1) Progressive
tension or quilting sutures could add operating time to an already long free-flap breast
reconstruction and was therefore less appealing; 2) Currently the use of fibrin sealants and
adhesives in large wounds lacks evidence on its ability to reduce seroma formation; 3)
Preservation of the Scarpa fascia would not be possible in a DIEP/MS-TRAM breast
reconstruction procedure as this would make identification, isolation and preservation of the
perforator very difficult; 4) Reduction of the effects of electrosurgery was the most promising
method to reduce drain requirement and seroma formation and was also the easiest to
implement. Therefore, the next chapter will explain the principle of electrosurgery, possible
side effects and explore alternative modalities trying to overcome these.
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1.5 Electrosurgery and cautery
In prehistoric times, heated stones were used for cautery. Ancient Egyptian writings describe
the use of heated tips to produce tissue coagulation (Jones, Pierre, Nicoud, Stain, & Melvin,
2006). The use of electricity in medicine started at the end of the 18th Century. In 1897, Franz
Nagelschmidt introduced the term diathermy (Massarweh, Cosgriff, & Slakey, 2006). This
comes from the Greek words ‘through heat’, to describe the heating effect caused by a current
passing through the body (Boyd & MacG Palmer, 2013; Massarweh et al., 2006). 
The first use of electricity in surgery was in 1900 by Joseph Riviere who utilised an arching
current from an electrode to treat a carcinomatous ulcer on a patient’s hand (Massarweh et
al., 2006). Around 1910 William Clark made further advancements to the electrosurgical
apparatus by increasing the amperage and decreasing the voltage which resulted in a hotter
and shorter spark that could penetrate deeper into the tissue (Massarweh et al., 2006). 
In the early 1920s biophysicist Dr William T Bovie of Harvard University developed the first
version of the instrument we use today. He constructed a diathermy unit producing high-
frequency current delivered through a loop which could be used for coagulation, cutting and
desiccation (tissue destruction by dehydration) (Jones et al., 2006; Massarweh et al., 2006). 
Dr Harvey Cushing, neurosurgery director in Boston was the first to use this machine in
October 1926 to remove an enlarged vascular myeloma. He had attempted removal of the
mass several days earlier but was unsuccessful due to the vascularity of the tumour
(Massarweh et al., 2006). The Liebel-Flarsheim Co purchased the patent from Bovie for only 
1 dollar and started the production of the unit for other operating theatres (Jones et al., 2006;
Massarweh et al., 2006).
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1.5.1 Conventional radiofrequency diathermy
Electrosurgery is described as high-frequency electrical current creating a clinically desired
effect while passing through tissue. This is different from electrocautery where an electrical
current heats an instrument and application of heated tool to the tissue causes the clinical
effect (Messenger, Carter, & Francis, 2014; Sankaranarayanan, Resapu, Jones,
Schwaitzberg, & De, 2013). Electrons follow Ohm’s Law (Table 1.5.1) when passing through
an electrical circuit (Jones et al., 2006).
Table 1.5. 1 Ohm’s Law
Voltage = Current x Resistance
Voltage (V): Force driving a current against the resistance of the circuit (in Volts)
Current (I): Flow of electrons during given period (in Amperes, Amps)
Resistance (R): Difficulty to pass an electronic current through tissue dependent on water
content (in Ohms)
In electrosurgery the voltage is created by a generator and an electrode tip of the instrument
delivers the current to the human tissue, which has got an inherent resistance. Electrons will
always seek the path of least resistance. If the circuit is incomplete the current will seek the
ground, which can cause burns in patients (Massarweh et al., 2006; Messenger et al., 2014). 
Electrical energy is transformed into heat (in Watts or Joules) according to Joules Law (Table
1.5.2).
Table 1.5. 2 Joules Law
Energy (Heat) = (current/cross-sectional area) x (Resistance x Time)
< 45°C: Reversible thermal damage to tissue
> 45°C: Proteins denaturalize and loss off structural integrity resulting in coagulation
> 90°C: Evaporation of liquid in tissue resulting in desiccation or vaporization
> 200 °C: Fulguration or carbonization where solid tissue components reduce to carbon
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Due to the small surface area of the active electrode a concentrated heating effect is produced
at the point of contact with the patient’s tissue (Figure 20) (Jones et al., 2006; Messenger et
al., 2014).
Figure 20 An electrosurgery circuit. High current density at the active electrode generates heat when
passing through tissue (Arash Taheri et al., 2014).
An alternating current (AC) changes its direction of flow, in contrary to a direct current (DC)
which does not change direction. The rate of change is called frequency, measured in Hertz
(Hz, cycles per second) (Hay, 2008; Jones et al., 2006). It was discovered by Morton in 1881
that an alternating current with frequency of 100 kHz could pass through the human body
without causing spasm, pain or burns. Direct or low frequency (<100 kHz) alternating currents 
cannot be used as they can activate susceptible tissues resulting in neuromuscular
stimulation, muscle contraction, cell membrane depolarisation and even cardiac arrhythmias
(Massarweh et al., 2006; Arash Taheri et al., 2014; A. Taheri et al., 2014). Electrosurgery uses 
high-frequency alternating currents around 500 kHz to achieve the heating effect without killing
or injuring (electrocuting) the patient. (Gallagher, Dhinsa, & Miles, 2011; Hay, 2008; Arash
Taheri et al., 2014).
Electrosurgical generators can modulate the current output (mode) resulting in the delivery of




                
      
             
             
                 
            
              
 
 
               
            
               
        
 
 
              
    
 
     
      
         
Table 1.5. 3 Modes of energy delivery
• Cut mode: continuous sinusoidal waveform
• Coagulation mode: interrupted sinusoidal waveform
• Blend: modification to the degree of current interruptions 
The output voltage can be adjusted to deliver the same amount of power in the continuous
and interrupted modes (Gallagher et al., 2011). In the coagulation mode, current exposure to
the tissue is interrupted and only 6% of the activation time (Figure 21). This allows more
thermal spread within the tissues, which reduces production of heat and results in a slower
rise of tissue temperature leading to a coagulum. The cut mode on the other hand results in a
fast rise in temperature causing rapid expansion of the intracellular contents and explosive
vaporization. This leads to a fine tissue incision with minimal coagulation (Gallagher et al.,
2011).
Besides the output modes and power settings, a number of other factors like size and
geometry of the electrode delivering the energy, exposure time and manipulation of the
electrode influence the depth and the rate at which heat is being produced and its effect on
the tissue (Massarweh et al., 2006). 
Figure 21 Relation of instrument settings to voltage and current interruption (Massarweh et al., 2006)
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Manipulation of the electrode is one of the most important factors in achieving the wanted
surgical effect. By holding the electrode in the cut mode in close proximity to the tissue allows
arcing which results in vaporization of intracellular content, dividing the tissue. Arcing in the
coagulation mode causes a coagulum over a larger area due to higher voltage waveforms.
Direct contact with the active electrode causes the tissue to dry out and form a coagulum
(desiccation). Cutting can be achieved in both the coagulation and cut mode, with the latter
requiring less voltage due to the continuous current. A higher voltage generates a greater
force on the electrons in a circuit which can lead to increased or uncontrolled thermal spread
(Figure 22) (Arash Taheri et al., 2014).
Figure 22 Thermal spread at different generator settings (Massarweh et al., 2006)
Generators can provide energy in a monopolar or bipolar fashion (Figure 23). With the
monopolar a dispersive electrode pad is required to complete the circuit by passing the current
from the body back into the generator (Figure 24a). The much larger surface area of the return
electrode facilitates dissipation of the current returning to the generator, which minimizes local
heat production.
a. b. d.c.




          
            
                
         
             
             
 
              
 
            
               
           
                







               
            
 
   
Bipolar delivery is without a dispersive return electrode pad as the patient’s body is not part of
the circuit (Figure 24b). The target tissue grasped between tips of the forceps completes the
circuit. A much lower voltage can be used, which results in very small chance of unintended
dispersal of current (Messenger et al., 2014). Today’s generators use closed-loop control 
loops so the voltage and current can be adjusted when the monopolar moves through tissues
of varying resistance, leading to a constant output power (Massarweh et al., 2006).
Figure 24 Electro circuits a. Monopolar circuit; b. Bipolar circuit (Messenger et al., 2014)
The published incidence of intra-operative electrosurgical injuries from the 1970s through the
1990s has been 2 to 5 per 1,000 and is often operator dependent (Massarweh et al., 2006). 
In all circumstances, a higher voltage carries a greater risk of perioperative complications
(Table 1.5.4, Figure 25) (Boyd & MacG Palmer, 2013; Gallagher et al., 2011; Hay, 2008; Jones
et al., 2006; Sankaranarayanan et al., 2013).
a. b. c.
Figure 25 a. Capacitive coupling; b. Inadequately applied grounding pad; c. Large off-side burn on left




          
           
              
             
                
               
        
	  
                 
             
      
 
         
              
            
 
 
      
 
  
       
        
     
   
        
          
    
    
     
Table 1.5. 4 Possible perioperative electrosurgical complications
• Inadvertently activation
• Interference with pacemakers or implantable cardioversion devices
• Current concentrations in the tips of the lead wires
• Conductive joint within circuit
• Insulation failure
• Direct coupling and capacitive coupling (Figure 25a)
• Off-site burns due to improper grounding (Figure 25b and 25c)
• Fire and explosion
• Surgical smoke inhalation
• Complications to surgeon
1.5.2 Models to describe thermal injury to the skin and subcutaneous layers
Thermal injury to cells depends on the temperature height and exposure time. The critical
temperature, also called the “break point”, a human cell can withstand is around 43.5 ºC, above
this, irreversible alterations in proteins lead to cellular death (Ye & De, 2017). An Arrhenius
analysis can be used to determine the heat required to inactivate cells, by plotting the rate of
cell killing (1/D0; D0 = number of minutes to reduce survival by 63%) vs 1/temperature (ºK)
(Figure 20). Formula to calculate heat of inactivation:
)*)� = ��(' 
( 
E = heat of inactivation in kcal/mole, A = is a constant over the temperature range studied, R
= molar gas constant (1.987 x 10-3 Kcal/mole-ºK) and T = absolute temperature in ºK (Dewhirst,
Viglianti, Lora-Michiels, Hanson, & Hoopes, 2003).
Arrhenius plots (Figure 26) are typically biphasic around the “break point’, with the slope being
steeper below the break, related to the occurrence of thermos-tolerance of the tissues. Above











            
            
 
            
           
  
	 	  
                   
              
             
     
 
            
              
             
              
             
 
 
            
           
Figure 26 An Arrhenius plot displaying the relationship between a kinetic constant (1/D0) and the
inverse temperature, with a ‘breakpoint’ at 43.5 ºC (Martin & Falder, 2017).
Sapareto and Dewey introduced a formula to convert a time-temperature combination to an
equivalent number of minutes at 43ºC. This is termed ‘thermal iso-effective dose’ and used in 
hyperthermia treatment:
���43 ºC = �� (56'7)
CEM 43 ºC = cumulative number of equivalent minutes at 43 ºC, t = time (minutes), T =
average temperature during time interval t. R = number of minutes needed to compensate for
a 1 ºC temperature change either above or below the breakpoint (threshold temperature for
damage) (Dewhirst et al., 2003).
One well defined time-temperature combination can be extrapolated, but might not be
accurate at temperatures below 39 ºC or above 57 ºC, possibly due to non-linearity’s in the
surface and deeper layer skin temperature relationship and heat transfer (Dewhirst et al.,
2003). A partial or complete reduction in bloods supply to a region of the body increases the
thermal sensitivity of the tissue, making it more susceptible to thermal injury (Dewhirst et al.,
2003).
A second formula to quantify cell injury caused by thermal exposure is the damage or thermal
injury index Ω, which is more commonly used in thermal ablation practice. It gives the ratio
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between the pre-treatment number of undamaged cells C(0) to the remaining number of
undamaged cells after time � , indicated by C(�).










A = frequency factor (1/s); Ea = activation energy (J/mol); R = universal gas constant (8.3143
J/mol-K); T = temperature in Kelvin and t = time (Viglianti, Dewhirst, Abraham, Gorman, &
Sparrow, 2014).
The longest time a constant surface temperature can be endured without resulting in
irreversible trans-epidermal necrosis was established at Ω = 0.53. With Ω = 1 being the
shortest time resulting in complete trans-epidermal necrosis (Martin & Falder, 2017). 
Due to its thinness, the epidermis does not contribute significantly to the response after a
thermal injury (Ye & De, 2017). As collagen is one of the main components of the skin, it is
assumed to be one of the main proteins affected by thermal damage (Viglianti et al., 2014). 
Owing to the tissue’s inherent resistance (impedance) applied electricity will be converted into
heat. Permittivity of skin (�skin=1832.8) is much higher than fat (�fat=27.22), therefore skin
polarises much easier than fat making it less resistive to an electric flux. Electric conductivity
for skin (�skin=0.22) is also much larger than that of fat (�fat=0.025) (Jimenez-Lozano, Vacas-
Jacques, Anderson, & Franco, 2012).
Subcutaneous tissue is made up by a fine fibrous and collagenous septa network, surrounding
clusters of adipocyte fat cells. Current passing through fat and septa form different electric
environments. As electric conductivity of the septa is one magnitude larger than the
conductivity of fat in subcutaneous tissue, it is more favourable for electric currents. Therefore,
the intensity of the electric field is larger in fat, due to higher resistivity. There is great variety
in density and orientation of the fibrous septa networks between individuals, resulting in
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different electric fields and distribution of thermal response within the subcutaneous tissue
(Gonzalez-Suarez, Gutierrez-Herrera, Berjano, Jimenez Lozano, & Franco, 2015).
1.5.3 Concerns regarding electrosurgery
The use of electrosurgery causing collateral heat damage has raised concerns regarding poor
wound healing and increased infection rates resulting in excessive scaring. The support for
these concerns came from different experimental studies in rats which showed significantly 
more extensive tissue necrosis and inflammatory response in abdominal fascia incisions with
diathermy compared to cold scalpel with a reduced tensile strength (S. G. Kumagai et al.,
1991; Ozgun et al., 2007; Rappaport et al., 1990). Soballe et al. (1998) published a study with
the misleading title “Electric cautery lowers the contamination threshold for infection in
laparotomies”. They performed an experimental study including 375 rats where fascia
incisions with either scalpel, diathermy cut setting (30 Watt) or diathermy coagulation (30 Watt)
was performed followed by bacterial inoculation (different levels of bacteria: 0, 103, 105, 107, 
or 109). Histological specimens showed significantly more inflammation and necrosis in the
diathermy coagulation group at all levels of bacterial inoculation, compared to the diathermy
cut and scalpel group. Comparison between the diathermy cut setting and scalpel only showed
a significant difference in inflammation and necrosis at level 105 bacteria, above that threshold
most wounds were infected in all three groups. The National Institute for Health and Clinical
Excellence (NICE) recommended in the 2008 published guidelines against the use of
electrosurgery for skin incisions due to increased concerns regarding surgical site infection
(Leaper et al., 2008). Subsequent large randomised clinical trials comparing scalpel and
electrosurgery for abdominal incisions included in two published Cochrane systemic review
(16 RCTs, 2769 participants) (Charoenkwan, Chotirosniramit, & Rerkasem, 2012;
Charoenkwan, Iheozor-Ejiofor, Rerkasem, & Matovinovic, 2017) contradicted this
recommendation as no significant differences in wound infections or wound dehiscence were
found, but further research is needed to draw a firm conclusion as evidence was low with a
significant risk of bias. 
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Ismail et al. (2017) did not find a significant difference in wound characteristics in their systemic 
review of nine heterogeneous studies, including 2720 participants between cutting diathermy 
and scalpel, neither did they find significant differences in objective scar assessment at 120
days in two studies including 171 participants or subjective scar assessments in two studies
including 185 participants.
Most clinical studies suggest electrosurgical incision of skin significantly reduces bleeding and
operating time compared to the use of scalpel (AbdElaal, Ellakwa, Elhalaby, Shaheen, & Aish,
2019; Kearns, Connolly, McNally, McNamara, & Deasy, 2001; Talpur, Khaskheli, Kella, &
Jamal, 2015). This was also reported by a meta-analysis by Ly at al. (2012) including 14 RCTs
with a total of 2541 patients and by Ismail et al. (2017) in their systemic review and meta-
analysis including 41 studies with a total of 6422 patients. The studies included in the
Cochrane systematic review (Charoenkwan et al., 2017), did not find a significant difference
in blood loss (3 RCTs, 241 patients) or incision time (4 RCTs, 325 patients) between the
diathermy and scalpel.
1.5.4 Alternative modalities
Over the years, different novel energy-based surgical technologies have been introduced,
trying to overcome the potential negative effects of electrosurgery (Table 1.5.5). 
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Table 1.5. 5 Different energy-based surgical technologies (MacDonald, Bowers, Chin, & Burns,
2014; Sankaranarayanan et al., 2013)
Instrument Modality Positives Negatives
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1.5.4.1 Ultrasonic energy
Ultrasonic energy was first used in medicine in 1960 for the treatment of Ménière’s disease
(Sankaranarayanan et al., 2013). In the late 1980s ultrasonic dissection was popularised in
laparoscopic surgery to avoid monopolar associated risks, like thermal injuries
(Sankaranarayanan et al., 2013). Electrical energy from a generator gets converted by the
ultrasonic device into ultra-high frequency mechanical energy (55.5 kHz or vibrations/second).
The generated heat seals blood vessels up to 5 mm in diameter by causing protein
denaturation and coagulum formation (Messenger et al., 2014). Studies have shown that
ultrasonic devices are not as efficient in sealing medium to large sized blood vessels
(Sankaranarayanan et al., 2013). Heat generated with ultrasonic dissection does not exceed
150 °C which minimizes the distance of thermal spread leading to minimal thermal tissue injury
(Chilaka Obonna & Mishra, 2014; Messenger et al., 2014; Sankaranarayanan et al., 2013).
1.5.4.2 LASER (Light Amplification by Stimulated Emission of Radiation)
Lasers were first used in 1979 in laparoscopic surgery but have gained widespread popularity
in different medical field such as cosmetic and dermatological treatments, atrial fibrillation
treatments and gynaecological procedures (Sankaranarayanan et al., 2013). Laser generate
heat by a concentrated beam of light. The high intensity light waves are formed in a laser
system which amplifies electromagnetic or light waves multiple fold in an optical resonator.
The light waves transmit energy when they get absorbed by tissue, leading to heat which cuts
and coagulates (Sankaranarayanan et al., 2013). The power of a laser is measured in terms
of ‘irradiation’ is defined as the ratio of power applied to the spot-size of the laser beam (W/m2).
Time of exposure and wave length (frequency) are two other variables that need to be
considered when using lasers in surgery (Sankaranarayanan et al., 2013). Disadvantages are
higher cost of specialised equipment, the need for advanced training and eye protection, risk
of fire and it is less accessible than electrosurgery (Sankaranarayanan et al., 2013; Arash
Taheri et al., 2014).
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1.5.4.3 Argon beam coagulation (ABC)
The first use of argon beam coagulation was reported by Ward and colleagues (1989). From
the electrode tip a beam of argon gas helps to conduct radiofrequency current to the tissue by
ionization. This results in a non-contact method where the argon gas transports the current to
the tissue (Messenger et al., 2014; Sankaranarayanan et al., 2013). ABC is faster and more
precise than conventional coagulation, provides a shallower and more uniform coagulation
area, leading to faster dispersion and therefore minimizing tissue damage. This also prevents
tissue carbonization and gives a clearer field of vision by reducing smoke production (Hay,
2008; Sankaranarayanan et al., 2013). The greatest risk of ABC systems is the argon gas
embolism, which can be fatal. To reduce this risk a low argon flow rate should be used, direct
contact of the tip with the tissue should be avoided and the tip should be held in an oblique
angle (Sankaranarayanan et al., 2013).
1.5.4.4 Ferromagnetic induction (FMI)
A 4- to 10 µm thick coating of ferromagnetic alloy on a tungsten loop tip creates heat through
a rapidly alternating magnetic field generated by a high frequency electrical current, which is
sufficient enough to incise and seal tissue. No grounding pad is required (MacDonald et al.,
2014). This technique results in a lower tissue temperature (75 °C) at the margin of the
incisions leading to a thermal injury depth of only 10 to 25% of that associated with standard
monopolar electrosurgery (MacDonald et al., 2014; Starr, Gates, Palafox, & Quill, 2016).
1.5.4.5 Radio frequency (RF) energy
Radio frequency is a type of electromagnetic radiation, which ranges from 3 kHz to 300 MHz.




          
               
     
 
     
          
           
              












          
                    
            
         
               
                
         
           
  
 
   
The pulsed-electron avalanche knife (PEAK) PlasmaBlade™ device uses this technology. Due
to the relevance of this device to the research described in this thesis, the following section
will describe its features in more detail.
1.5.5 PEAK PlasmaBlade™ (PPB) device
The PEAK PlasmaBlade™ device (Medtronic Advanced Energy, LLC., Portsmouth, New
Hampshire, Figure 27) uses very brief pulses (40 µsec) of radio frequency energy to create
electrical plasma along the edge of a thin (12.5 µm) 99.5% insulated electrode. This creates
a cutting edge with simultaneous haemostatic properties.
a. b. c.
Figure 27 a. Duty cycle of 1% in cut mode; b. PEAK PlasmaBlade™ hand piece; c. PEAK
PlasmaBlade™ generator. Source: Medtronic.com
Plasma is an electrically conductive cloud comprised of water vapour and charged ions from
the breakdown of tissue (Loh et al., 2009). With a burst rate of less than 1 kHz and a duty
cycle not exceeding 5% in cut mode, this technology uses less total energy and operates at
significantly lower temperatures than traditional electrosurgical devices (40 °C -170 °C vs 200
°C - 350 °C), which leads to less depth of lateral thermal damage (LTD) (Loh et al., 2009). 
Ughratdar et al. (2018) also showed the PEAK PlasmaBladeäused in the cut mode (setting 4
- 5) significantly reduced intraoperative smoke formation compared to traditional
electrosurgery (1.8 vs. 38.7 mg average mass of smoke particulate) in neuromodulation
implant revision.  
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The machine is CE-marked and cleared by the US Food and Drug Administration. Traditional
electrosurgery devices are significantly cheaper (£20 vs £200) (Fine & Vose, 2011). Table
1.5.6 shows different characteristics of both the conventional diathermy and PEAK
PlasmaBlade™.
Table 1.5. 6 Characteristics of the conventional diathermy and the PEAK PlasmaBlade™
Conventional Diathermy PEAK PlasmaBlade™ 
Introduced in (year) 1920s 2008
Type of electromagnetic
radiation
High frequency energy Low radiofrequency energy
Frequency (kHz) 500 kHz 1 kHz
Cut cycle duty (%) 100% Less than 5%
Mode Continuous alternating Pulses
Operating temperature (°C) 200 - 350 °C 40 - 170 °C
Costs (£) 20 200
1.5.5.1 Experimental studies comparing incisions created with the PEAK PlasmaBlade™ to
electrosurgery and scalpel. 
Experimental studies have shown skin incisions with the PEAK PlasmaBlade™ used in the cut
mode have a wound-healing profile comparable to that of scalpel incisions and superior to
those of conventional electrosurgical incisions with respect to inflammation, wound strength
and thermal zone of necrosis (Chang, Carlson, Vose, Huang, & Yang, 2011; Ekin et al., 2018;
Loh et al., 2009; MacDonald et al., 2014; Ruidiaz et al., 2011). In this paragraph the published
experimental studies will be presented in the order of publication date.
The first paper comparing healing of surgical incisions created with a scalpel, conventional
diathermy and the PEAK PlasmaBlade™ was in a porcine skin model, published by Loh et al.
(2009). Parameters examined were instrument operating temperature, blood loss,




               
                 
            
           
             
               
    
            
      
 
            
                  
            
              
    
          
       
         
              
         
           
          
            
On six Yucatan swine 3 cm full-thickness incisions were made on day 0, 21, 28, 35 and 42
using a no. 10 scalpel, the PEAK PlasmaBlade™ on cut setting 3 (6 Watt) and a conventional
diathermy on cut (40 Watt, Blend 2) and coagulation (40 Watt, Spray). Instrument operating
temperatures were captured with a Thermavision SC600 infrared camera while moving the
instrument approximately 0.5 to 1cm/sec. The PPB reached an average temperature of 45 ºC 
compared to the much higher temperatures of the diathermy of 241 ºC in cut and 180 ºC in the
coagulation mode (Figure 28).
Figure 28 Infrared images of operating temperature profiles of the PEAK PlasmaBlade™ (left) and
conventional diathermy (right) (Loh et al., 2009)
Blood loss was evaluated with filter paper-based bleeding analysis (relative area unit = 105 
pixels) measuring 2.50 ± 0.32 for the scalpel, 1.03 ± 0.27 for the PPB, 0.52 ± 0.33 for
electrosurgical cut and 0.29 ± 0.29 for electrosurgical coagulation mode. The difference
between the scalpel and PPB was significant (p=0.002), this was not shown for the PPB and
electrosurgery modes (p=0.23 and p=0.07).
Inflammation was examined under high-power magnification (40x) by counting number of T
lymphocytes (CD3+), macrophages (CD68+) and myofibroblasts by a blinded observer. By
week 3, the PPB incisions contain significantly less T lymphocytes. The number of
macrophages was highest in the 1-week specimens, with the lowest amount seen in the PPB
incision. At six weeks the electrosurgical coagulation setting had significantly more
macrophages than the other modalities. The scalpel and PPB incisions showed similarly low
levels of myofibroblasts, compared to significantly higher prevalence for both electrosurgical
modes throughout the entire 6-week time period. The lower levels of these cells suggest less
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inflammation is induced after the use of the PPB compared to the conventional electrosurgical
cut and coagulation settings.
Formalin fixed, haematoxylin and eosin stained specimens were evaluated by light microscopy
by a single pathologist in a blinded manner. The zone of thermal coagulation necrosis was
significantly (p<0.0001) narrower in PPB incisions (66 ± 5 µm) compared to electrosurgical cut
(456 ± 35 µm) or coagulation mode (615 ± 22 µm) (Figure 29).
Figure 29 Different widths of zone of thermal necrosis (Loh et al., 2009)
Scar width was comparable between the scalpel and PBB. Both were significantly narrower
than the electrosurgical scars and showed superior aesthetic outcomes.
To test the wound strength the incision line was aligned in clamps and a progressive force
(extension rate of two inches per minute) was applied until the scar disruption. The scalpel
and PPB incisions showed greater burst strength compared to electro-surgical incisions at
every time point.
In this study 30 wounds were evaluated for each instrument, created at five different
time points. Optimal power settings were determined by extensive pilot studies. The average
instrument operating temperatures were not measured while performing this study, but on
tissue at room temperature. It was not reported how many measurements were performed or
after how long this temperature was reached and if it was the maximum temperature possible
or if it was the maximum temperature reached within the time of the incision. The significantly
smaller zone of thermal necrosis, reduction in inflammatory markers and increased wound
burst strength after the use of the PEAK PlasmaBlade™ compared to electrosurgery could
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indicate less inflammation due to reduced collateral tissue damage which resulted in improved
wound healing and significantly narrower scars after six weeks, which is a short scar follow-
up time. The significant results in this pig study provide evidence to support the hypothesis
that the use of the PEAK PlasmaBlade™ could reduce collateral tissue injury in breast
reconstruction patients and improve recovery.
The second experimental study published by Chang et al. (2011) compared healing of 90 rat
fascia’s following incision with three surgical instruments, traditional “cold” scalpel (SC),
conventional electrosurgery (CE – cut 40 Watt, Blend 2 and coagulation 40 Watt, Spray
modes) and PEAK PlasmaBlade™ (PPB - cut setting 3 (6 Watt)). Harvested fascia specimens
were examined on burst strength, depth of thermal injury and histologic healing-associated
scores on day 7, 14, 21 and 42.
Burst strength was determined by slow progressive stressing of a segment till disruption at a
speed of 2 inch /min. This only showed a significant difference (p = 0.001) between the 1-
week specimens of the EC-coag vs the PPB, with all four surgical methods regaining
equivalent burst strength of uncut fascia at the end of 6 weeks.
On histological samples the zone of tissue injury was significantly larger in both coagulation
(68% greater p<0.0001) and cut (46% greater p<0.0001) EC-modes and surprisingly for
incision by SC (25% p=0.024) compared to the PPB.
In this study five fascial wounds were evaluated for each instrument at four different
time points. Results of burst strength were compared to a control group. Used settings were
chosen based on a previous pilot study. Histopathologic characters we scored by a blinded
single pathologist, but the objective rating of this and the healing scores makes it less reliable
values. Difference were given in percentages and p values only for comparison with the
scalpel incision. A decreased zone of tissue injury, which appears to be evaluated at all
different time points, after PPB incision even compared to scalpel incision was speculated to
be caused by decreased inflammation. This evaluation of zone of tissue injury does not reflect
the thermal and/ or mechanical injury correctly and can only be done shortly after infliction to
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prevent introduction of other forms of bias such as the inflammatory response. Due to the
critiqued study outcomes and evaluation this study was less valuable.
The third paper comparing the healing of human cutaneous incisions created by PEAK
PlasmaBlade™, Conventional diathermy and scalpel was published by Ruidiaz et al. (2011). In
20 healthy female adult subjects undergoing an abdominoplasty, three 5cm full-thickness skin
incisions were made with a no. 10 scalpel, PPB on Cut setting 3 (6 Watt) and conventional
diathermy in cut mode (30 Watt) at 6- and 3-weeks pre-operative and immediately before the
abdominoplasty (Figure 30).
Figure 30 Arrangement of incisions made by scalpel (SC), PlasmaBlade (PB) and electrosurgery (ES)
at 6- and 3-week pre-operatively and immediately before abdominoplasty (week 0) (Ruidiaz et al., 2011)
Thermal injury depth was significantly lower in the PPB samples, compared to the
conventional diathermy (p<0.001). Burst strength of the PPB scars was equivalent to the
scalpel scars and was significantly better than conventional electrosurgery (p<0.001). Only
the 3-week PPB scar was significantly narrower than the electrosurgery scar (p=0.01).
Inflammatory markers CD3+ and CD68+ were significantly higher after the use of the
conventional diathermy compared to scalpel and PPB for the 3-week scars.
In this study 60 human wounds were evaluated for each instrument at three different
time points. In agreement with the previous studies in porcine skin and rat fascia, it was found
that the PPB resulted in lower thermal injury depth and an increased burst strength, compared
to the conventional electrosurgery. This was the first experimental study in humans in a novel
cutaneous wound healing model. Long-term scars evaluation was not performed and the
significant difference in scar burst strength might have disappeared beyond the 6-week follow-
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up period. The significant results in this human model also provide evidence to support the
hypothesis that the use of the PEAK PlasmaBlade™ could reduce collateral tissue injury in
breast reconstruction patients and improve recovery.
The last experimental study published on the subject by MacDonald et al. (2014) compared
incisions created in rabbit livers using monopolar electrocautery (MPE, settings 40/40 Watt
Blend2), harmonic scalpel (HS, settings 3 - 5), PEAK PlasmaBlade™ (PPB, settings 9 - 1) and
ferromagnetic induction loop device (FMI, settings 60 Watt). In three rabbits, three incisions
were created with each of the four instruments (12 incisions in each liver) by a single surgeon.
Subjective coagulation and cutting qualities (tissue drag, haemostasis, margin uniformity and
collateral tissue damage) were scored (1= optimal, 5 = unsatisfactory) for each device. The
subjective scoring did show some significant differences mainly between the PPB vs MPE and
FMI vs MPE. 
Histological analysis of the tissue specimens for lateral thermal damage was performed by a
single pathologist, resulting in a damage index ratio (damaged tissue area divided by the
incisional depth). This revealed a comparable damage index for incisions created with the
PPB, FMI and HS. The damage index was significantly higher for the incisions created by
MPE.
In this study nine rabbit liver incisions were evaluated for the four different instruments, 
incision for the usual baseline values with a scalpel was not performed. It was not specified if
the PPB was used in the cut or coagulation setting and the 9-1 cannot be identified on the
settings chart (appendix 1). Device settings used were not tested in a pilot study. The
pathologist analysing the histological samples was not blinded which could introduce bias.
The value of significant findings for the subjective scoring of characteristics of the surgical
dissection is questionable due to its subjective character. Due to the unclear used settings for




            
          
        
            
             
              
             
         
            
          
           
            
          
           
         
          
             











Since its introduction in the early 1900s, electrosurgery has become an important tool in
surgical practice (Ly et al., 2012) as it enables surgeons to cut and perform haemostasis 
simultaneously. Experimental studies in animals raised the concern electrosurgery could lead
to poor wound healing and an increased risk of complications such as surgical site infection,
however clinical trials do not seem to support this (Charoenkwan et al., 2012; Charoenkwan
et al., 2017; Ismail et al., 2017; Ly et al., 2012). The PEAK PlasmaBlade™ is a new
electrosurgical device that can operate on a lower temperature due to brief pulses of
radiofrequency energy (Loh et al., 2009). Experimental studies in animal and human models
comparing skin incisions with scalpel, electrosurgery (cut and coagulation mode) and the
PEAK PlasmaBlade™ have shown wound profiles with less inflammation, a higher burst
strength and a smaller zone of thermal necrosis for the PEAK PlasmaBlade™ compared to
conventional electrosurgery (Loh et al., 2009; Ruidiaz et al., 2011). These findings make the
PEAK PlasmaBlade™ an interesting alternative to the conventional diathermy. In DIEP/MS-
TRAM breast reconstruction patients a lower operating temperature could cause less
collateral thermal damage which would reflect in lower pro-inflammatory cytokine
concentrations and possibly less drain fluid production and complications such as seroma
formation. The next chapter will present the conducted literature review on clinical studies
comparing the PEAK PlasmaBlade™ to conventional diathermy for tissue dissection.
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1.6 Literature review: Clinical studies comparing PEAK PlasmaBlade™ to conventional
electrosurgery
For this part of the introduction a literature search was conducted including all papers
published on PubMed comparing the PEAK PlasmaBlade™ to conventional diathermy for
tissue dissection in clinical studies. Search terms used were “PEAK PlasmaBlade”,
“PlasmaBlade”, “Plasmakinetic Cautery” and “Plasma Surgery”. References of included
papers were also reviewed for relevant publications. The search was limited to the English
and German language. Clinical studies where only skin was incised or use for simple excision
(tonsillectomy and wound debridement) were excluded. The search resulted in the inclusion
of eight papers, which are chronologically presented by publication date. Each study will be
briefly summarised and study design, outcomes, flaws and inconsistencies will be discussed.
Tables 1.6.1 and 1.6.2 give an overview of the included papers.

















CE vs PPB - Operating time






















































   
 
   
 
    
   
   
   












        
  
    
   
  
  





   
 
 
     
   
    
    








   





   
   
   
  
 
            
         
 
 
         
 
      
       
   
      
   
       
   
 
     
    
     
      
   
    
   
        
   
      
   
     
   
      
   
    
   
      
    
     
   
   
    
   
   
   
   
   
   
    
     
    
        
    
    
   
     
     
    
   
     
   
 
Sowa, Retrospective 44 LD breast CE vs PPB - Operating time







Kypta, Retrospective 762 cardiac device CE vs PPB - Operating time












Schlosshauer, Retrospective 9 upper arm lifts and CE vs PPB - Drainage amount















CE = conventional electrosurgery, PPB = PEAK PlasmaBlade™ , ITA = Internal thoracic artery,
UHS = Ultracision harmonic scalpel, APC = Argon Plasma Coagulation
Table 1.6. 2 – Clinical studies included: Main findings, strengths and limitations
First author Main findings Strengths Limitations
Ruidiaz - No difference in operating
time (p=0.47)
- No difference in drain
duration
- No difference in course of
healing







Dogan - No difference in operating
time
- No difference in the
amount
of blood loss





- No difference in start arm
exercises 

























       
   
     
    
      
    
      
   
      
    
    
     
    
     
   
 
    
   
   
    
   
   
    
    
    
    
    
   
     
   
       
    
  
    
   
      
     
   
      
      
    
     
   
    
     
     
    
   
   
   
   
   
    
     
      
   
 
   
   
     
      
    
   
      
   
    
      
    
      
   
 
       
   
   
     
  
    
     
    
     
   
 
    
   
   
 
   
   
    
   
   
    
   
    
    
    
    
   
    
    
   
   
     
   
     
       
   
     
       
   
   
     
   
   
   
   
 
   
    
     
    
    
Chiappa - No difference in operating
time (p=0.737)
- No difference intra-OP
blood loss (p=0.095)
- No difference in drainage
amount (p=0.761)
- No difference in mean
draining duration (p=0.061)





















Zientara - Significant quicker harvest
CE (p=0.001)
- Significantly less 
endothelial damage 
(p=0.04)
- No difference in vessel
integrity and adventitial
haemorrhage
- No significant difference in


































- Significantly less 
Drainage (p=0.0358)
- No difference drain
requirement (p=0.16)
















- Power settings 
not disclosed




- Significantly less lead
damage (p<0.001). no 
difference in infection or
haematoma.
- Over-all per patient saving















       
     
     
     
      
     
      
   
 
    
    
      
    
    
    
   
    
   
    
   
    
     
     
      
     
    
   
    
    
    
    
    
     
   
     
      
 
      
   
     
   
      
   
     
     
     
 
   
   
    
      
   
   
   
    
   
 
  
   
   
   
    
   
   
    
     
    
     
    
 
             
 
 
          
          
        
             
           
            
            
             
              
              
            
Schlosshauer - No difference in 1st post-
op drainage day (p=0.106)
- Significant difference in
drainage volume (p=0.041)
- No difference in drainage
duration (p=0.109)










- Clear follow-up 
protocol
- Baseline characteristics 
two groups unknown
- Some patients also
receiving liposuction
which can be a 
confounding factor







- Side distribution not
disclosed
- Seroma not defined nor
method of diagnosis
Duscher - No difference in wound 
healing
- No difference in operating
time
- No difference in drainage
volume





- All operations by one
surgeon and two
residents
















CE = conventional electrosurgery, PPB = PEAK PlasmaBlade™, ITA = Internal thoracic artery, FU
= Follow-up
Ruidiaz et al. (2011) published a paper mainly focussing on comparing cutaneous wound
healing, inflammatory response and thermal injury depth after skin incisions with a scalpel,
conventional electrosurgery and the PEAK PlasmaBlade™ in 20 women undergoing an 
abdominoplasty. In the methods it is stated the data were collected as part of a randomised
controlled trial of 20 adult female subjects undergoing abdominoplasty with either the PBB™ 
or scalpel and conventional electrosurgery. Mean operating time between the two different
machines for the abdominoplasty was not significant (1h 39 min vs 1h 35 min p=0.47). There
is limited information on the outcome of this RCT, with only mentioned in the results “the
clinical course of healing and time to drain removal was comparable between the two groups”.
It was not clarified which settings were used for either the PEAK PlasmaBlade™ or the
conventional diathermy, neither was reported what the drain removal protocol was. It is
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unknown why the results of this PEAK PlasmaBlade vs. traditional Electrosurgery in
abdominoplasty (PRECISE) study were never published.
Dogan et al. (2013) published a prospective study including 46 consecutive patients
undergoing modified radical mastectomy, randomly allocated to either have their operation
performed with the PEAK PlasmaBlade™ (n=24) or conventional electrocautery (n=22).
Electrocautery was used in both cut and coagulation modes between 20 to 30 Volt and the
PPB was used in both cut and coagulation modes between settings 6 to 8. Drains were used
and removed when draining 50mL or less over 24 hours. A statistically significant difference
between drain output (707 vs 1,093mL, p=0.025) and drainage duration (5.5 vs 7.9 days,
p=0.020) in mastectomies favouring the use of the PEAK PlasmaBlade™ over conventional
electrocautery. Operation duration, intra-operative blood loss, time to start arm exercises and
complications such as seroma, haematoma, infection and mastectomy skin flap necrosis didn’t
not differ significantly.
This prospective study without randomisation or blinding only included a small number of
patients in each group. The authors describe the use of the plasmakinetic cautery device on
the numeric settings between 6 to 8 in both coagulation and cutting mode which corresponds
to a power between 20 - 50 Watt. This wide range is potentially higher than the 20 - 30 Watt
(the paper mentioned Volt, but this is most likely an error) used for the electrocautery, this
makes us question if the difference in drainage amount and duration is solely based on the
two different machines. Possibly, variations in the amount of lymphatic leak after axillary 
dissection in the respectively 27.2% and 29% of the patients in each group, could have had
an influence on the amount and duration of drainage. No comment was made regarding the 
number of different operating surgeons. The published lower median total drainage volume in
the plasma cautery group does not mean less seroma fluid was produced as the initial blood
loss in the immediate post-operative period can contribute significantly to the total drainage
volume. As a definition of seroma, the paper used “clinically diagnosed fluid collection under
skin flap or axilla requiring multiple aspirations”. This means any fluid collection not requiring
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or only requiring one drainage would not be regarded as a seroma, which results in an under
estimation of this complication.
Chiappa et al. (2018) published a single-institution observational study including sixty patients
undergoing breast cancer surgery (40% mastectomy and 60% quadrantectomy). Twenty
patients who had their operation performed with the PEAK PlasmaBlade™ were matched to
40 conventional diathermy cases, based on age, BMI, co-morbidities and procedure type.
They did not find a significant difference in mean drainage duration (PPB 14.31 ± 5.23 vs
10.93 ± 5.17 in control group, p=0.06), nor in the daily amount of drainage (PPB 60.15 ± 28.23
vs 56.78 ± 34.53 in the control group, p=0.761). Also, surgical duration, intra-operative blood
loss and length of hospital stay were equal. Seroma incidence between the two groups did
significantly differ in favour of the PlasmaBlade™ group (PPB 10% vs 37.5% in the control
group, p=0.034). Other complications such as haematoma, infection and skin flap necrosis did
not differ significantly.
This study only involved a small patient population of 20 operated with the PPB. The paper
did not disclose the used power settings for either of the machines and if they were
standardised, neither was commented on the number of different surgeons performing the
procedure and their experience level. A significant difference in seroma incidence was
diagnosed, but method of diagnosis (clinical or USS), size, time of detection and requirement
for intervention were not reported. The flaws in study design make it impossible to correlate
significant or non-significant finding to the use of either of the two machines as they could very
well be caused by other confounding factors. For the statistical analysis normal distribution of
the data was not analysed.
Zientara et al. (2018) published a prospective experimental study comparing the PEAK
PlasmaBlade™ to conventional electrosurgery for the harvest of skeletonised internal thoracic
artery (ITA). The study included twenty subjects undergoing coronary artery bypass grafting
with both internal thoracic arteries. In each patient one artery was prepared with the PEAK 
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PlasmaBlade™ and the other with a conventional electrosurgery device. All procedures were
performed by a single surgeon. PEAK PlasmaBlade™ settings were coagulation-5 (equal to 
35 Watt) and cut-1 and for the conventional electrosurgery device the coagulation setting was
20 Watt. Machine side for harvest was randomly allocated before the start of the procedure
and resulted in a balanced distribution of 10 right and 10 left ITAs harvested by each device,
resulting in a total of 40 grafts. Time to complete the harvest was recorded individually for
each machine. At the epigastric bifurcation a 5 cm arterial sample was taken for histological
analysis of endothelial damage (scored as percentage of circumference damage 0 = 0%, 1 =
1 – 25%, 2 = 26 – 50%, 3 = 51 -75% and 4 = over 75%), integrity of vessel wall and adventitial
haemorrhage by a single pathologist. Patency of the bypass graft was evaluated at 6 months
by cardiac computed tomography.  
Histological analysis showed a statistically significant reduction in endothelial damage in
samples harvested with the PPB (83% vs. 60% samples with a score of “0-1”, p=0.04). There
was a trend towards better wall integrity, but this was not statistically significant. The was no
difference in the presence of adventitial haemorrhage. Harvest time with the PPB was
significantly longer for the PPB (26.3 min vs. 21.2 min, p=0.001). It was mentioned the
surrounding tissue bed after harvest with the PPB required additional coagulation by the
conventional electrosurgery device and resulted in a modification of the preparation technique,
clipping both proximal and distal ends of side branches. It was unclear if this modification was
introduced for both conventional diathermy and PPB group and at which stage during the
study the modification was initiated. On CT scan all fifteen ITAs prepared with conventional
diathermy were patent, one of the ITAs harvested with the PBB was occluded.
The main flaw of the study is the difference of preparation technique which was introduced
while conducting the trial. If vessel clips were used more often in the PPB group due to
problems with haemostasis, this could be a major confounding factor and the reason for the
significant difference in endothelial damage. Another limitation of the study is the use of the





            
            
          
             
           
       
           
              
              
               
         
              
           
             
        
 
            
          
           
             
           
             
               
             
            
              
Sowa et al. (2018) published a retrospective study including 44 patients undergoing LD breast
reconstruction surgery. Patients in the PPB group had a significantly lower total drain
discharge (883.8 vs 624.4, p=0.0358) and required a significantly shorter hospital admission
(14.1 vs 11.7 days, p=0.011). There was no difference between operating time, intra-operative
blood loss or drain requirement between the two groups. The incidence of seromas was 
significantly higher in the electrocautery groups (47.8% vs 19%, p=0.043).
This retrospective study used medical notes to obtain information of the two small patient
groups. There was no comment on missing data, used settings of the PPB and conventional
monopolar or the number of different operating surgeons, which makes it difficult to comment
on the results. A seroma was defined as a persistent fluid collection for more than 4 weeks.
According to this definition fluid collections requiring multiple puncture drainages but resolving
within 4 weeks would not be considered a seroma, resulting in an under estimation of this 
complication. This definition of seroma has never been encountered in any other publication
and raises the suspicion it was introduced to create a significant difference in seroma
occurrence between the two groups.
Kypta et al. (2018) published a retrospective cohort study including 762 patients from two
centres who underwent an electrosurgical generator replacement of an implantable cardiac
device with either scissor, scalpel and electrosurgery or the PEAK PlasmaBlade™. Due to the
low thermal stability of the material covering the leads the use of electrocautery can cause
severe damage resulting in their malfunction. Propensity score matching was applied to create
two groups with similar age and gender, resulting in 508 patients in the conventional group
and 254 in the PPB group. The procedure was performed by one of three experienced
operators. The PPB group showed a significantly lower incidence of lead damage (5.3 vs
0.4%, p<0.001) and both operating time (47.9 vs 34.1 minutes p<0.001) and hospital stay (3.2
vs 2.4 days, p<0.001) were significantly shorter as well. A cost analysis based on the cost of
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consumables, duration of operating time and the cost due to complications was performed
and showed a potential over-all per patient saving of €81 when the PPB was used.
Study limitations were the retrospective character and possible time trend bias as the
conventional strategy was stopped after implementation of the PEAK PlasmaBlade™. The
reviewed period of 13 years will also have had an effect on surgeon experience, which could
contribute to the difference in incidence of lead damage and operating time. The significant
difference in hospital stay might not only be explained by the difference in operating machine
but also by changes to local hospital health policies between 2003 and 2015.
Schlosshauer et al. (2019) published a retrospective study including 24 patients undergoing
upper arm or medial thigh lifts. Each patient served as their own control with random allocation
of the PEAK PlasmaBlade™ to one side and the monopolar electrosurgery to the other. The
electrosurgery device was used at cut setting: auto; dry cut: effect 4, max. 180 Watt; forced
coag: Effect 2, max. 80 Watt. The PEAK PlasmaBlade™ cut setting was used between 5 – 6 
and coagulation at 7. Twenty specimens were histologically evaluated for acute thermal injury
depth by a single pathologist blinded to which machine was used. The total drain output on
the PEAK PlasmaBlade™ side was significantly lower compared to the conventional monopolar
side (61.1 vs 95.1 mL, p=0.04). No difference in day one drain output, time till drain removal
or complications such as seromas, haematoma and wound healing problems was observed.
No difference in thermal injury depth was found in the ten microscopy specimens from the two
different machines. This retrospective study only included a small patient population. Each
patient was consent before undergoing the procedure, therefore the presentation of this study
as retrospective seems incorrect. Five patients underwent simultaneous liposuction (with
unknown infiltration technique), which has been published to increase post-operative drainage
(Salgarello et al., 2012). The used settings for the monopolar were very high, with a maximum
coagulation setting of 80 Watt and cut of 180 Watt. The PEAK PlasmaBlade™ settings were
significantly lower with cut 5-6 (20 Watt) and coagulation 7 (35 Watt). Surprisingly, analysis of
20 specimens did not show a significant difference in thermal damage depth between the two
groups. In the results three major complications requiring reoperation were reported for the
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PPB group, but Table 2 only displays two major complications. It seems unlikely the two
haematomas in the PEAK PlasmaBlade™ group were included into the total drain and day 1 
drain volume as this would have significantly increased both values. Only the total operating
time was reported, it would have been more valuable to measure time for each side separately.
No comment was made on the number of different surgeons performing the procedure and
their experience level with either of the machines, neither was reported if the side distribution
of each machine was equal as surgeons’ hand dominance usually makes one side easier to
perform. No definition of seroma or method of diagnosis (clinical or USS) was given, neither
was the length of follow-up mentioned. Two of the “Key messages” outlined are untrue as the
PPB did not show as statistically significant difference in tissue damage neither did it result in
a statistically significant reduction in postoperative seromas. This paper quotes results of the
PEAK PlasmaBlade vs. traditional electrosurgery in abdominoplasty (PRECISE) study as
showing a markedly diminished serous drainage (31% less drainage p=0.02) and less
morbidity in the PPB group despite this never being published.
Duscher et al. (2019) published a randomised open label study comparing four different
surgical devices for abdominoplasty dissection in 57 patients. All procedures were performed
by one senior surgeon and two residents. Used settings for the electrocautery (n=14) were 60
Watt – cut blend, 40 Watt – coagulate spray; for the Ultracision Harmonic scalpel (n=14) stage
5; for the PEAK PlasmaBlade™ (n=12) setting 3; and the Argon Plasma Coagulation (APC,
n=17) at 80 Watt with a Plasma surgery Flow of 2.0 L/min. Blood loss was evaluated by
weighing gauzes. Abdominal drains were inserted and removed when producing 30 mL or
less over 24 hours. Compression garments were used for 8 weeks post-operatively. Patients
were seen in the out-patient clinic weekly for the first two weeks, followed by a 3-month and
1-year appointment. Clinical suspicion of seroma was verified with USS and drained if painful.
There was no significant difference in operating time between the four operating machines,
neither did the total drainage differ significantly. The Ultracision method resulted in a
significant increase in blood loss (100.2 mL, p< 0.01), compared to the other methods. No
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significant differences in complications such as seroma, haematoma and wound healing
problems were experienced. A cost analysis was performed based on personal costs, surgical
device costs and surgical time. Ultracision and the PEAK PlasmaBlade™ were associated with
higher costs compared to the APC and electrocautery, without showing any clinical benefit.
The open label character of the study could be a cause of bias in this small group randomised
trial. Five patients were excluded from the study because they had not attended all the follow-
up appointments. This decision will have led to exclusion bias and an intention-to-treat
analysis would have been more valuable. It was not disclosed if there were any significant
differences in the baseline characteristics of the groups, as only the average age, BMI and
pre-operative weight loss were mention for the whole group. Neither were the exact value
given for the total drainage amount for each group.
The Canadian agency for drugs and technologies in health (CADTH) publish a rapid response
report in August 2019 where they attempted to review clinical effectiveness and cost-
effectiveness of the pulsed electron avalanche knife (PEAK) PlasmaBladeä versus traditional
electrocautery for surgery (Peprah & Spry, 2019). From a total of 49 citations identified in their
literature research, eight articles (Table 1.6.3 - three RCTs and five retrospective cohort
studies) were included into the review.
Table 1.6. 3 Papers included in clinical effectiveness and cost-effectiveness of the PEAK












































   
    
    
   
   











        
      
  
   
    
    
    
   











      
   
  
  






   
 
 
      
   
  
  
   
   










   
  
   
   










     
















   
  
             
              
      
 
            
             
             
                 
             
Tan et al. Single-centre 58 tonsillectomy PPB vs - Post-OP pain
2019 prospective patients monopolar EC - Complications
Singapore double-blinded 
RCT
2013 - 2014 - Pain-killer tablets
- Days till normal diet
- Days till normal
activity













PPB vs EC - Thermal and mechanical




- Incidence of post-
operative infection
- Healing time
Kypta et al., Retrospective 762 patients PPB vs EC - Time procedure
2018 cohort study undergoing - Hospital stay








Sowa et al., Retrospective 44 LD breast PPB vs EC - Time procedure











Lane et al., Retrospective 1780 PPB, monopolar - Post-OP bleeding






EC and coblation - Hospital admissions
- ED visits
Kypta et al., Retrospective 611 patients PPB vs. EC - Time procedure








Thottam et Retrospective 1280 paediatric PPB, monopolar - Time procedure






PPB = PEAK PlasmaBladeä, EC = Electrocautery, UHS = Ultracision Harmonic Scalpel, APC =
Argon Plasma Coagulation, RF = Radiofrequency, RCT = Randomised Controlled Trial, LD =
Latissimus dorsi, ED = Emergency Department
Unfortunately, all papers reviewed were of low quality with design flaws introducing a high
chance of bias. The data suggest operating with the PEAK PlamsaBladeä resulted in
significantly shorter wound healing time (Duscher et al., 2019), shorter post-OP hospital stay
(Kypta et al., 2018; Kypta et al., 2015; Sowa et al., 2018), earlier pain free swallowing (Tan et
al., 2019), shorter drain requirement (Sowa et al., 2018), higher patient satisfaction (Tan et
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al., 2019), less damage to device leads (Kypta et al., 2018; Kypta et al., 2015) and less incision
site thermal damage (Marangi et al., 2018) compared to conventional electrocautery. No
significant differences were observed regarding post-op bleeding (Lane, Dworkin-Valenti,
Chiodo, & Haupert, 2016), post-op haematomas (Kypta et al., 2018; Kypta et al., 2015) and 
inflammatory response (Marangi et al., 2018). Inconsistent evidence was found regarding
length of procedure (Kypta et al., 2018; Kypta et al., 2015; Thottam et al., 2015), drainage
volume (Duscher et al., 2019; Sowa et al., 2018), post-op seroma (Duscher et al., 2019; Sowa
et al., 2018) and post-op infection rates (Kypta et al., 2018; Kypta et al., 2015; Marangi et al.,
2018) with some finding significant results in favour of the PEAK PlamsaBladeä and others 
with no differences between the PPB and conventional electrocautery. Reported inconsistent
results between some of the studies could be due to the variety of surgical procedures at
different anatomical sites. The conclusion was: “there is insufficient evidence to conclude on
the clinical effectiveness of the PEAK PlasmaBladeä compared with electrocautery for
surgery”, neither was there relevant evidence regarding the cost-effectiveness of PPB for
surgery identified (Peprah & Spry, 2019). 
Conclusion
At the beginning of this randomised controlled trial only the papers by Ruidiaz et al. (2011)
and Dogan et al. (2013) were published. Over the recent years more studies have been
published comparing the PEAK PlasmaBladeä to conventional diathermy. Unfortunately, as
concluded by the Canadian agency for drugs and technologies in health, papers reviewed
were of low quality with design flaws introducing a high chance of bias. Commonest flaws or
weaknesses were: small sample sizes without power calculation; poor study design; wide
range of or non-disclosed energy settings of electrosurgical machines; non-disclosed or high
number of different operating surgeons; different definitions of seroma; only clinical
assessment of seroma collections; unclear follow-up protocol.
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A well-designed, sufficiently powered study comparing the PEAK PlasmaBladeä to
conventional diathermy for tissue dissection was therefore required to supply a higher level of
evidence regarding differences in clinical outcomes between both machines. The conducted
double blinded randomised controlled trial has aimed to meet all these criteria and will be




               
          
             
            
         
           
          
 
           
         
              
            
        
 
             
            
       
           
             
 
          
            
             
           
          
            
          
1.7 Hypothesis
Breast cancer is one of the commonest forms of cancer in the UK with around 62,000 newly
diagnosed cases every year. Of this group 25-30% will have to undergo a mastectomy leading
to significant asymmetry. In 2002, the National Institute for Health and Clinical Excellence
(NICE) recommended that “reconstruction should be available [to all women with breast
cancer] at the initial surgical operation.” Autologous reconstruction usually provides the best
cosmetic and durable result but requires additional scars to the donor area and a longer
operating time, hospital stay and recovery compared to implant-based reconstruction.
The initial response to trauma, such as surgery is largely coordinated by endogenous soluble
mediators referred to as inflammatory cytokines. They are produced by systemic immune cells 
and other cell types at the site of injury. A higher degree of tissue injury results in production
of higher levels of pro-inflammatory cytokines, which can be measured in wound fluid. Levels
of most cytokines are highest 24 hours after the injury. 
Seroma is one of the most common donor site complications after DIEP or MS-TRAM breast
reconstruction. Due to the uncertain pathophysiology there is no consensus on how to reduce
its occurrence. Avoidance of electrosurgery in abdominoplasties has shown promising results
in reducing seroma formation but cannot be transferred directly to the DIEP/MS-TRAM
abdominal donor sites and should therefore be further explored for this patient group.
Electrosurgery uses an electrical current to cut through tissue. This device has increased the
surgical possibilities due to ability to cut and simultaneously coagulate blood vessels. One of 
the downsides of electrosurgery is the collateral thermal damage to the surrounding tissue.
Over recent years new technologies have been introduced trying to reduce this. One of these
devices is the PEAK PlasmaBlade™ which can operate on a lower temperature due to very 
brief pulses of radiofrequency energy. Different experimental studies in both animal and
human models comparing the PEAK PlasmaBlade™ and other surgical dissection devices for
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incisions have shown a reduction in width of zone of thermal injury, reduction in wound
inflammation, increased wound strength and reduced scaring in favour of the PEAK
PlasmaBlade™ and comparable to scalpel incisions. A prospective clinical study published by 
Dogan et al. in 2013, including 46 consecutive breast cancer patients receiving a modified
radical mastectomy either with the conventional diathermy (n=22) or the PEAK PlasmaBlade™ 
(n=24), showed a statistically significant reduction in wound fluid production (p=0.025), leading
to earlier drain removal (p=0.020) in the PEAK PlasmaBlade™ group.
The flap raise in abdominal based autologous breast reconstruction (DIEP/ MS-TRAM) with
the aid of electrosurgery, results in a large wound surface. Comparable to oncological breast
surgery (mastectomy), prolonged drain requirements for high wound fluid production and
seromas are often experienced in the post-operative course. To evaluate the effects of the
PEAK PlasmaBlade™ for abdominal dissection in autologous breast reconstruction on wound 
fluid production and complications such a seroma, this double blinded randomised controlled
clinical trial was conducted.
This is the first large double blinded randomised controlled clinical trial comparing the PEAK
PlasmaBlade™ to the conventional diathermy in DIEP/ MS-TRAM flap harvest. This study
differs from previous studies as it includes a large population of breast reconstruction patients
(n=108) which is sufficiently powered to identify a one-day difference in drain requirement,
based on data from a previously conducted pilot study. This study also included the collection
and testing of drain fluid samples to enable comparison of inflammatory cytokine profiles
between the two groups. Complications were recorded and to reliably identify seroma
collections an abdominal ultrasound was performed at the 2- and 6-week follow-up
appointments.
I hypothesised that the use of the PEAK PlasmaBlade™ for the DIEP/ MS-TRAM flap harvest
would result in 1) a reduced abdominal drains time requirement; 2) a lower total drainage from
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the abdominal drains; 3) lower levels of inflammatory cytokines in the drain fluid and 4) less
seroma and smaller seromas development in the follow-up period.
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1.8 Study aim and objectives
The aim of the study was to evaluate if there is a difference in outcomes after the use of the
PEAK PlasmaBlade™ for the raise of the DIEP/ MS-TRAM flaps, compared to the conventional
diathermy. 
• The primary outcome value compared between the two groups was:
o Number of days the abdominal drains were required
• Secondary outcome values compared between the two groups were:
o Peri-operative data (Operating time, flap weight, clips, perforators, fluid)
o Inflammatory markers in drain fluid (day 0,1 and 2)
o Pain scores (0 to 10) and morphine use (mg)
o Mobility (number of steps)
o Abdominal wound assessment (AIRE score)
o Total abdominal drain fluid output (mL)
o Complications (flap problems, haematoma, seroma, abdominal wound healing
problems)
Objectives
• Recruit a minimum of 106 breast reconstruction patients onto the trial
• Randomise the patients to either have the abdominal flap raise done with the
conventional diathermy or PEAK PlasmaBlade™.
• Blinded collection of primary and secondary outcome values to allow objective
comparison between the two groups through statistical analysis.
• Uni- and multivariable regression analysis to identify predictors and possible
confounders for drain requirement, seroma presence and complications.
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CHAPTER 2: MATERIAL AND METHODS
2.1 Study design
This clinical study was designed and conducted as a double blinded randomised controlled
trial, as for comparison of two different operating machines in a group of patients this will result
in the highest level of evidence, while excluding common causes of bias. Both patients and
me, the research fellow were blinded to which machine was used in theatre. The surgeons
were not blinded, but not involved in collection of any data. The blinding was broken after the
last patient had completed her follow-up. Patients were informed via a letter about the type of
operating machine (conventional diathermy or PEAK PlasmaBlade™) that was used for their
abdominal flap harvest. The study was conducted between November 2016 and May 2018 in
a single centre, St. Andrew’s Centre for Plastic Surgery and Burns in Broomfield Hospital, in
Chelmsford United Kingdom. The DIEP and MS-TRAM breast reconstruction patient
population was selected for this trial because of the high number of cases performed on a
yearly basis in the unit. Secondly, this procedure creates a large wound surface and can
therefore serve as a good model to compare the effects of two different operating machines.
Due to the mentioned large number of abdominal based breast reconstructions, even a small
reduction in hospital stay and/or complications could have a significant influence on costs and
bed availability for the department, making this a valuable population to study. Patients of two
different consultants in plastic surgery were included into the study, Mr Venkat Ramakrishnan
(VR) and Mr Matthew Griffiths (MG).
No changes were made to the study protocol after trial commencement.
2.2 Patient recruitment
Patients scheduled for a unilateral DIEP breast reconstruction, meeting the in-/exclusion
criteria (Table 2.1), were informed about the study by the normal care team during their first
clinic appointment. If the patient agreed, the research fellow would give further details, answer
any questions and supply the patient with the information leaflet. On the day before surgery
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the patient would be approached again and if willing to participate in the trial an informed
consent would be obtained.
To eliminate factors that could delay wound healing, patients that were active smokers,
patients suffering from diabetes, patients suffering from ischaemic heart disease, immuno-
suppressed patients and/ or patients using steroid medication were excluded. To reduce the
risk of post-operative bleeding patients with clotting disorders were excluded from the study.
Exclusion based on BMI, age, immune-suppression, active smoking or pregnancy was not
required for this study. The most common reason patients could not be recruited onto the trial
was the need for a bi-pedicled DIEP/MS-TRAM breast reconstruction.
Table 2. 1 In-/exclusion criteria
Inclusion Criteria Exclusion criteria
Adult (18-80 years) able to consent Children (<18yrs)
Adults older than 80 years
Unilateral immediate or delayed DIEP/ MS-
TRAM breast reconstruction
Bilateral or bi-pedicled DIEP/ MS-TRAM breast
reconstructions









The Anglia Ruskin Clinical Trial Unit (ARCTU) at Anglia Ruskin University (ARU) organised
access to the randomisation service of the Trans European Network for Clinical Trials Service
(TENALEA). This is an internet-based randomisation system that can be accessed 24 hours
a day. Enrolled patients underwent a 1:1 block randomisation. The system stores the pre-
determined sequence of randomisation. After consent was obtained by the research fellow
randomisation was carried out by the normal care team, either the day before or the morning
of surgery. The patient was either allocated to the ‘Group A - diathermy’ or ‘Group B - PEAK
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PlasmaBlade™. The results of the randomisation were sent via a confirmation email to senior
author (MG) and his secretary and selected members of ARCTU. The research fellow,
responsible for the post-operative data collection and the patients were blinded to the
randomisation and surgical machine used. The blinding was broken after the last patient had
completed the 6-week follow-up period.
2.4 Surgical procedure
All patients underwent a standard DIEP or MS-TRAM breast reconstruction procedure (Figure
30). On induction, every patient received prophylactic intravenous antibiotics and 1 gram of
tranexamic acid. A scalpel was used to make the skin incision to the depth of the dermis. The
raising of the flap was subsequently done either using the PEAK Plasma Blade™ or
conventional diathermy. The standardised maximum settings for the diathermy were cutting
40 Watt, coagulation 40 Watt and for the PEAK PlasmaBlade™ cutting 7 (35 Watt), coagulation
7 (35 Watt) (Appendix 1 – PEAK PlasmaBlade™ settings). If the bipolar was used for
haemostasis it was not used above 15 Watt.
During the operation data recorded as part of the normal protocol were the flap raise time
(min), number of clips used to seal off small blood vessels, the total weight of the flap, the
number of blood vessels supplying the flap (perforators raised) and the amount of fluid given
during the surgery (mL Hartmann’s solution and/ or Volpex®). An Ultrapro mesh (Ethicon
monocryl/proline composite) was placed underneath the abdominal fascia before it was closed
with a 1 Stratafix™ suture. Before the abdominal closure two 15 French Blake drains were
inserted and secured to the skin with a 2.0 Silk suture and connected to a low vacuum wound
drainage system (85 kPa/neg 100mmHg). For the closure of the deep abdominal layer/
Scarpa’s fascia 2.0 Vicryl® was used and for skin closure a subcutaneous 3.0 Stratafix™. The
abdominal scar was sealed with Prineo™ tape and Dermabond® and finally covered with blue






































     
      
         
      
         
     
          
  
      
   
    
 
        
       
 
        
   
right sided DIEP breast reconstruction flap
Figure 31 Steps of a delayed free
autologous deep inferior epigastric
perforator breast reconstruction flap.
a. Pre-operative markings for a delayed
b. Raise of DIEP flap, containing skin and fat
off the abdominal wall using electrosurgery 
c. Raised DIEP flap with attached vessels, which was 
dissected out from between the rectus abdominis 
muscle. The fascial defect will be closed with a mesh
and sutures
d. Closure of the abdominal donor site with
dissolvable sutures and skin glue after insertion of
two abdominal drains
e. Creation of the chest wall skin pocket
























     
         
 
          
     
    
     
      
 
       
   
vessels
f. Microsurgical connecting of flap vessels to chest wall
g. Insertion of flap into the skin pocket and h. Post-operatively an abdominal binder is 
closure with sutures and skin glue applied. The flow in the anastomosed blood
vessels can be checked with a handheld
Doppler
i. Result after a delayed right sided
DIEP breast reconstruction Drawings by Miss Julia Ruston
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2.5 Post-operative DIEP/ MS-TRAM protocol
Post-operative patients were monitored in a high dependency unit (HDU) setting. Depending
on clinical circumstances, each patient would follow the same standard departmental free flap
protocol (Table 2.2). 
Table 2. 2 DIEP/ MS-TRAM protocol
Day -1 • Pre-operative bloods and group and save
(Pre- • Clerking
operative) • Drug chart
• Clexane 40 mg subcutaneous (sc) into inner thigh and thromboembolism-
deterrent (TED) stockings for deep venous thrombosis (DVT) prevention
Day 0 • First 4 hours 30 minutes flap observations, after that 1 hourly
• Cardiovascular observations 1 hourly
• Sips of water, oxygen via nasal spec’s, Bair Hugger (warmer), urine
catheter
• Monitor urine and drain output
• Clexane 40 mg sc, TED stockings and flowtrons for DVT prevention
Day 1 • One hourly flap and cardiovascular observations
• Review by team in the morning, if all well can eat and drink
• Sit out in the chair with bra on
• Haemoglobin level check
• Physiotherapist input: encouraging deep breathing exercises and leg
movement
• Clexane 40mg sc, TED stockings and flowtrons for DVT prevention
Day 2 • Two hourly flap and cardiovascular observations
• Start mobilising, if able to walk to toilet removal of urine catheter
• Clexane 40mg sc and TED stockings for DVT prevention
Day 3 • Three hourly flap and cardiovascular observations
• Assisted shower
• Start removal of drains if 30mL or less in 24 hours and mobilising
• Mobilisation
• Clexane 40mg sc and TED stockings for DVT prevention
Day 4 till • Four hourly flap and cardiovascular observations
discharge • Independent shower
• Removal of drains if 30 mL or less in 24 hours
• Mobilisation
• Clexane 40 mg sc and TED stockings for DVT prevention
Discharge
with drain
• In case a patient was discharged with a drain they would call the ward
every morning informing us about the drain out-put (ml/24h). Drains were
removed in the hospital if draining 30 mL or less over 24 hours.
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During the post-operative inpatient period, the research fellow would see the patients every 
day, twice a day to collect the data (Figure 32).
Figure 32: Flow-chart patient follow-up
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2.6.1 Drain fluid samples
On the day of surgery and on post-operative days one and two, 3 mLs of drain fluid was
obtained from one of the abdominal drain tubes using a three-way tap and a 10 to 100 mL
syringe. Only 125 µL of drain fluid was required for the analysis, but because such small
amounts are difficult to measure it was decided to use 1.5 mL Eppendorf tubes which were
available from Broomfield hospital laboratory. The sample was transferred into two 1.5 mL
Eppendorf tubes, one being the back-up sample. All tubes were stored in a -80°C freezer in
the laboratory of Broomfield hospital. The samples were sent to Myriad RBM, Inc. a clinical
laboratory improvement amendments (CLIA) certified biomarker testing laboratory located in
Austin, Texas (United States). CytokineMAP A analysis (appendix 2 – M&M of analysis) was 
performed on the samples providing a quantitative measurement of key cytokines (Table 2.3) 
involved in inflammation, immune response and wound healing. The Cytokine MAP-A was
deemed the most suitable of the offered packages as it includes most important inflammatory 
markers. Individual testing of a select number would have resulted in higher costs. After
analysis only the cytokines bold in Table 2.3 were of measurable height and therefore included
in the statistical analysis.






Interleukin-3 Macrophage Inflammatory Protein-1 alpha
Interleukin-4 Macrophage Inflammatory Protein-1 beta
Interleukin-5 Monocyte Chemotactic Protein 1
Interleukin-6 Tumour Necrosis Factor alpha
Interleukin-7 Tumour Necrosis Factor beta
*Cytokines in bold were included in the statistical analysis for this study
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After half of all the samples were collected in November 2017, the first batch was transported
by World Courier on dry ice (-80°C) to Myriad RBM, Inc. in Austin, Texas. During the first
analysis one of the samples was insufficient. We were able to send the back-up sample with
the second batch in April 2018, resulting in the analysis of all 324 drain samples. The Myriad
clinical laboratory guarantees highly reproducible results by the use of automated systems
and processes in a tightly controlled environment. The cytokine analysis results were emailed
in an excel file. For each cytokine, the least detectable dose (LDD) was given, this value was
determined as the mean +3 standard deviation of 20 blank readings. Results below the LDD
are expected to be more variable compared to results above. The lower limit of quantitation
(LLOQ) represents the lowest concentration of cytokine that can be reliable detected (meeting
the laboratory’s requirements for accuracy). When reviewing Table 2.4 there is a clear
difference between the LDD and LLOQ between the 2017 and 2018 measurements for most
cytokines. The laboratory has confirmed these differences are not caused by the calibration
of the machines used for the analysis.
Table 2. 4 Cytokine Least Detectable Dose (LDD) and Lower Limit of Qualification (LLOQ)
levels in 2017 and 2018 analysis
Cytokine LDD2017 LLOQ2017 LDD2018 LLOQ2018
Interleukin-4 (pg/mL) 50 26 36 45
Interleukin-6 (pg/mL) 3.4 2.9 2.3 4.1
Interleukin-7 (pg/mL) 25 30 41 28
Interleukin -8 (pg/mL) 8.2 7.9 3.8 3.2
Interleukin-10 (pg/mL) 3.2 7.1 2.9 5.5
Interleukin-18 (pg/mL) 48 56 37 30
Macrophage Inflammatory
Protein-1 alpha (pg/mL)
50 37 48 34
Macrophage inflammatory
Prottein-1 beta (pg/mL)
62 44 34 41
Monocyte Chemotactic Protein
1 (pg/mL)
134 112 138 135
Tumour Necrosis Factor alpha
(pg/mL)
16 20 27 62
LDD: Least Detectable Dose; LLOQ: Lower Limit of Qualification
pg/mL = pictogram/ millilitre; ng/mL = nanogram/millilitre
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2.6.2 Abdominal drain output
While the patients were admitted to the hospital the abdominal drain output was measured
twice a day, morning and evening. The total amount of fluid (mL) in the bottle was noted down,
also the weight of the drain bottles was measured and subtracted from the weight of the empty
bottle. Drains were removed when draining 30 mL or less in 24 hours. In some cases, drains
fell out accidentally or were removed earlier for clinical reasons. In case of prolonged high
drain output, patients were occasionally discharged home with one abdominal drain. If this
was the case patients were asked to call into the hospital every morning after reviewing the
total amount of drain fluid in the bottle. If the drain fluid production had reached 30 mL or less
in 24 hours the patient would return to the hospital where the drain was removed.
2.6.3 Pain and morphine consumption
Twice a day, patients were asked to score their pain or discomfort using the numerical rating
scale (NRS) with 0 being no pain at all and 10 the worse pain imaginable. Every patient was
given daily paracetamol and ibuprofen for pain control. For breakthrough pain patients could
request 5 to 10 mg of liquid morphine (Oramorph). Its use was discouraged as it often causes
sickness, drowsiness and constipation. Daily total morphine (Oramorph in mg) consumption
was extracted from the drug chart.
2.6.4 Abdominal wound assessment
Once daily the abdominal wound was assessed using the Acute Inflammatory Response
Evaluation (AIRE) score (Richter et al., 2012). This evaluates the wound on the following
aspects: erythema (redness), oedema (swelling), pain and local temperature. Scoring them 0
to 3 (Table 2.5) resulting in a total score between 0 to 12.
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Table 2. 5 Acute inflammatory response evaluation (AIRE) (Richter et al., 2012)
Score Erythema Oedema Pain Local temperature
0 Non-observed Non-observed None No change
















either side of wound
Pitting of the skin
around the incision
with mild pressure









Continuous pain Radiating heat
around wound site
2.6.5 Mobility
Patients started mobilising from the second post-operative day, to reduce their risk of
developing a deep venous thrombosis (DVT) or pulmonary embolism (PE). They were
provided with a pedometer (Willful Fitness Activity Tracker Watch) to give an estimation of
daily mobility (number of steps).
2.6.6 Complications
Any complications during the inpatient period such as bleeding, infection, flap problems and
problems in abdominal wound healing were registered.
2.7 Out-patient follow-up
Following their discharge patients were seen in our outpatient department after two and six
weeks. The timing of these appointments was chosen to be in concordance with the regular
follow-up appointments, avoiding extra appointments for the study participants. The week two
was a nurse led clinic appointment and week six was a consultant led clinic appointment. At
both follow-up appointments, data on complications and abdominal AIRE scores were
recorded. An abdominal ultrasound was performed by the research fellow using the V-
Universal™ Stand portable ultrasound machine produced by SonoSite, Inc.
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With the patient flat on an examination table with the head slightly raised the nine regions of
the abdomen (Figure 33) were systematically examined for fluid collections (seromas).
Figure 33 Nine regions of abdomen
If a seroma was identified the dimensions were measured (length, width and maximum height
in cm) and recorded. To estimate the volume of the identified fluid collections half of the
volume of an ellipsoid was used (Figure 34).
5 � ���
6 
Figure 34 Formula to calculate the volume of an ellipsoid
Almost all seromas were treated conservatively and only drained (Figure 35) if they were
causing discomfort for the patient.
Figure 35 Drainage of abdominal seroma collection through needle aspiration (Vidal, Berner, & Will,
2017)
After completion of the 6-week follow-up period patients were discharged from the study. No
changes to trial outcomes were made after trial commencement.
99
  
    
              
          
              
  
              
           
               
               
          
	 	  
              
            
           
              
             
 




            
 
        
           
            
      
 
_ _ 
2.8 Statistics and analysis
Using data from the in our unit conducted pilot study comparing the PEAK PlasmaBlade™ to
conventional diathermy in 40 DIEP patients (Chow, Oni, Ramakrishnan, & Griffiths, 2019), 
looking at total drain output (mL) and amount of days drains were required a power calculation
was performed.
For the pilot study using the independent sample t-test, the mean number of days the drain
was required in the diathermy group was 5.55 days with a standard deviation of 1.00 and 6.70 
days with a standard deviation of 2.36 in the PEAK PlasmaBlade™ group.
In order to detect a significant difference in abdominal drainage duration based on a 5%
significance level to give a power of 80% using Lehr’s formula2:
16 16 
= (������������ ����������)_ 0.30 
The standard difference was calculated by
b
a with � being the smallest difference in mean
which is clinically important and � the assumed equal standard deviation of the observations
in each of the two groups. The smallest difference in mean to be clinically important was set
on 1 day, as a 1-day reduction in drain requirement would lead to earlier discharge, reducing
costs on hospital stay. This would also increase turn-over resulting in the ability to treat more
patients.
The pooled standard deviation was used for the �, using the formula:
= i
(��j + ��_ = i 
1_ + 2.36_
� = ��effghM = 1.812 2 
This results in a minimal sample size of 53 patients for each group (106 overall).
To determine if collected continuous data was normally distributed the Shapiro-Wilk test was
performed. If normally distributed the independent samples t-test was used to establish if there
was a statistically significant difference between the two groups. If the data was not normally
distributed the Mann-Whitney U Test was used.
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To calculate statistical significance for categorical data the Pearson Chi-Square Test for
numbers over 5 was used. If the count was equal to or less than 5 the Fisher’s Exact Test was
used. Categorical data were: consultant (VR/MG), procedure (DIEP/MS-TRAM), adjuvant
therapy (radiotherapy/ neo-adjuvant chemotherapy/ hormone therapy) and complications.
For the primary outcome value three analysis were conducted because drains were incorrectly
removed in 19 occasions (accidental or due to clinical reasons). First the incorrectly removed
day of drain removal was kept into the analysis, secondly the patients with an incorrect drain
removal were excluded from the analysis and thirdly multiple imputation was applied where
incorrect drain removal days were replaced.
Linear regression (Cox proportional hazard model) was used to identify significant
determinants for the time to drain removal. Variables that had a significant p-value in the
univariate analysis were included in a multivariable analysis. Significant determinants could
indicate confounding factors for which would be corrected.
Logistic regression was used to identify determinants for complications and the presence of
seroma at the 2- and 6-week abdominal ultrasound scan. Variables that had a significant p-
value in the univariate analysis were included in multivariable analysis, if none of the
determinates were significant p values <0.10 were included in the multivariable analysis.
Significant determinants could indicate confounding factors for which would be corrected.
A value below or equal to 0.05 (2-tailed) was considered to be statistically significant.
Blinding made it impossible to perform an interim analysis.
2.9 Ethics
Patients were given the option to participate in this study, it was emphasised participation was
voluntary, and refusal would not affect their care in any way. Patients participating in this
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randomised controlled trial were given the regular post-operative care, only the harvest of the
abdominal free flap was either done with conventional diathermy or the PEAK PlasmaBlade™. 
No extra invasive tests were required. The drain fluid was collected from the abdominal drain
tube and non-invasive ultrasound was used to detect any abdominal seroma formation.
Patients could choose to leave the study at any time without a required reason, which was not
experienced.
Before commencing the study, the research fellow and both Plastic surgeons Mr Griffiths and
Mr Ramakrishnan completed the “Good Clinical Practice (GCP)”: eLearning module, which
gives a practical guide to ethical and scientific quality standards in clinical research.
Organisation that evaluated the study protocol and rewarded ethical approval:
• The East of England - Cambridge Central Research Ethics Committee (REC
reference: 16/EE/0005, Protocol number: 137680 and IRAS project ID: 192471). 
Approval was acquired on the 11th February 2016.
• The Research and Development (R&D) department of Mid Essex Hospital Services
NHS Trust (MEHT). Approval was acquired on the 19th August 2016.
• The Faculty of Medical Science Research Ethics Panel (FREP) of the Anglia Ruskin
University (ARU) ethical application (FREP number: 16/17 086). Approval was
acquired on the 24th February 2017.
During the study course the Cambridge Ethics Committee which is part of the Health Research
Authority, was contacted in February 2017 to inform if it would be allowed to collect data for
the study if there were additional hospital visits by patients for clinical reasons. This 
amendment was deemed non-substantial and it was therefore not necessary to make formal




          
              
            
              
































The study received monetary support from Medtronic. The first part (£56,652) was given at
the start of the study and the second part (£37,229) after delivery of the final study results.
The PEAK Plasma generator and blades were provided free of charge by Medtronic. The
funder was not involved in the study design, in the collection, analysis and interpretation of





     
           
           
               
              
         
             




           
        
            
          
          
        
          
     
 
                                             
         
     
     
      
     
     
      
     
     
     
     
        
CHAPTER 3: RESULTS
3.1 Baseline characteristics of the study population
During the 19-month recruitment period (between November 2016 and May 2018), 119
patients were recruited. Two patients were accidentally randomised twice because of a glitch
in the computer system, resulting in a total number of 121 randomisations. For these two
patients the result of the first randomisation was used and the second one deleted by the
operator. Eleven patients were excluded from the study following clinically necessary pre- or
peri-operative diversion from the protocol not caused by the surgical instrument used (Table
3.1). Resulting in a final study population of 108 patients.
Table 3. 1 Reasons for exclusion from study
Study number Group Day of exclusion Reason for exclusion
1010030 CD 0 Repair of abdominal hernia with mesh
1010057 CD 0 Bi-pedicled DIEP
1010080 CD 0 Bi-pedicled DIEP
1010081 CD 0 Different operating consultant
1010083 PPB 0 Bi-pedicled DIEP
1010104 CD 0 Bi-pedicled DIEP
1010105 CD 0 Different operating consultant
1010106 PPB 0 Operation cancelled
1010107 PPB 0 Bi-pedicled DIEP
1010117 CD 0 Bi-pedicled DIEP
1010119 PPB 0 SIEA flap performed
PPB = PEAK PlasmaBlade™; CD= Conventional diathermy
Fifty-two patients were randomised to the conventional diathermy and 56 to the PEAK
PlasmaBlade™ group. The baseline characteristics of the two groups are shown in table 3.2.
Age, height, weight and BMI were comparable between the two different groups. The patients 
were evenly distributed between the two operating consultants and two procedures (DIEP and
MS-TRAM), axillary sampling or clearance and procedures on the ipsilateral side. The
requirement for (neo-) adjuvant cancer treatment (radiotherapy, neo-adjuvant chemotherapy





   
              
 
         
 
                                                                 
                                                                                                          
        
        
        
        
     
 
 
   
 
 
   
     
    
  
 
   
    
 
 
   
     
      
     
                                        
                                                    
  
 
                                                                                               
                                                                                     
   




   
   
 
   
 
     
   
 
   
 
   
   
 
   
 
            
     
            
Table 3. 2 Patient baseline characteristics for the two study groups
Characteristic Conventional PEAK PlasmaBlade™ p-
diathermy (n=52) (n=56) value
Age (yr.) † 52.5 (45.0 – 62.8) 52 (44.0 – 60.0) 0.44
Height (cm) † 161 (154.3 – 168.6) 163 (158.0 – 169.0) 0.32
Weight (kg) * 76.8 ± 12.1 75.0 ± 13.5 0.44
Body mass index† 28.6 (26.0 – 32.6) 27.7 (24.7 – 31.38) 0.14
Consultant (MG/VR) 17/35 16/40 0.68∂
Procedure (DIEP/MS-
TRAM)
50/2 52/4 0.68∆ 
Timing
(immediate/delayed)
39/13 43/13 0.83∂ 
Axillary clearance 21.2% 32.1% 0.20∂ 
SLNB 11.5% 10.7% 0.90∂ 
Procedure ipsilateral
breast
34.6% 28.6% 0.50∂ 
Pre-op radiotherapy 28.8% 28.6% 1.00∂ 
Neo-adjuvant
chemotherapy
21.2% 25% 0.66∂ 
Hormone Therapy 28.8% 26.8% 0.83∂ 
* Mean ± SD; Independent samples t-test
† Median (IQR); Mann-Whitney U test
∂ Pearson Chi-Square test SLNB = sentinel lymph node biopsy
∆ Fisher’s Exact test SD = Standard Deviation; IQR = Interquartile Range
3.2 Peri-operative data
Table 3.3 shows the data collected during the operation with either of the two different
operating machines.



























Amount of IV fluid given (L) † 2.0 (1.8 – 2.5) 2.0 (2.0 – 2.5) 0.41
†Median (IQR); Mann-Whitney U test
IV = Intravenous; min = minutes; mg = milligram; L = litre
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There was no statistically significant difference in time (min) to raise the abdominal flap
(p=0.80) using either of the two different machines. The number of perforators taken to
supplying the abdominal flap did not statistically significantly differ (p=0.47) between the two 
groups. The number of vessel clips used during the procedure to clamp arteries and veins did
not differ significantly (p=0.63). The flap weight (gram) of the removed abdominal flap did
significantly differ (p=0.03) between the two groups, being higher in the conventional
diathermy group. The amount of intravenous fluid (L) given during the operation (Hartmann’s
solution and Volpex®) did not show a statistically significant difference (p=0.41).
3.3 Inflammatory cytokines
Drain fluid samples collected on day 0,1 and 2 were analysed to determine if there were
significant differences between levels of inflammatory cytokines produced after operating with
either of the two operating machines. Levels of the inflammatory cytokines’ TNF-alpha, IL-4,
IL-6, IL-8, IL-10, IL-18, MIP-1 alpha, MIP-1 beta and MCP-1 at the three different days can be
found in table 3.4.
Table 3. 4 Inflammatory Cytokines in drain fluid on day 0,1 and 2
Conventional PEAK
diathermy PlasmaBlade™ 
Cytokine (n=52) (n=56) p-value
Day 0 TNF-alpha† 62.0 (20.0 – 62.0) 62.0 (20.0 – 62.0) 0.41

















MIP-1 alpha† 83.5 (57.3 – 139.5) 77.5 (55.8 – 125.8) 0.50
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Day 1 TNF-alpha† 62.0 (22.0 – 62.0) 62.0 (22.0 – 62.0) 0.91





















MIP-1 alpha† 84.0 (58.0 – 151.5) 68.5 (50.0 – 103.3) 0.054










Day 2 TNF-alpha† 62.0 (29.0 – 62.0) 62.0 (25.3 – 62.0) 0.48





















MIP-1 alpha† 116.0 (80.0 – 181.8) 97.5 (79.0 – 155.0) 0.19










† Median (IQR); Mann-Whitney U test
None of the inflammatory cytokines differed significantly between the two groups on any of
the three days. The levels of inflammatory cytokines MIP-1 beta on day 0 (p=0.07), MIP-1 
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alpha on day 1 (p=0.054) and IL-18 on day 2 (p=0.07) showed a tendancy towards lower levels
in the PEAK PlasmaBlade™, almost reaching statistical significance.
3.4 Abdominal drains
Table 3.5 presents the median drain fluid volume (mL) and weight (mg) of the drain fluid for
each group, the number of patients who went home with a drain and the primary outcome
“number of days drains were required”.















Discharge home with drain (%) 19% 29% 0.26∂







† Mann-Whitney U test; Median (IQR), ∂ Pearson Chi-Square test
There was no statistically significant difference (p=0.68) between the total volume drained in
the conventional diathermy group (342.5 mL) and the PEAK PlasmaBlade™ group (355.0 mL). 
Also, the weight of the drain fluid was equal between the two groups therefore not showing
any statistically significant differences (p=0.75). Patients in both groups went home with the
drain equally often, not reaching statistical significance (19.2% vs 28.6%, p=0.26). In the
PEAK PlasmaBlade™ group the drains were required for 5 days compared to the 6 days in the
conventional diathermy group, this did not reach statistical significance (p=0.48). In diagram
1.1 are two histograms showing the distribution of the amount of days the drains were required




             
       
 
    
            
             
            
                
     
 
               
    
 
 
         
 
                                                                                            
                                                                                                   
                                                                                                     
    
       
   
     
   
 
   
 
     
Diagram 1. 1 Histograms for the amount of days the drains were required. On the left for the diathermy 
(n=52) and on the right for the PEAK PlasmaBlade™ (n=56)
3.4.1 Exclusion of incorrectly removed drain values
In the normal diathermy group ten patient’s drains accidentally came out or were removed for
clinical reasons while draining over 30mL in 24 hours, in the PEAK PlasmaBlade™ group this
was the case in nine patients. An analysis of the patient groups excluding these patients (drain
removed draining >30 mL/ 24 hours) was performed. The results can be found in Table 3.6.
Diagram 1.2 shows the adjusted histograms.
Table 3. 6 Patients with abdominal drains removed according to protocol (<30mL/24h)
Conventional PEAK
diathermy   PlasmaBlade™ p-value
(n=42) (n=47)
Cases excluded based on too
early drain removal (>30 mL/ 24h)
10 9





† Mann-Whitney U test; Median (IQR)
The median number of days the drains were required in both groups was the same as in the




               
             
 
 
            
               
           
 
       
 
                                                               
                                                                                                    
        
        
        
         
     
  
 
   
 
 
   
     
    
 
 
   
     
 
 
   
     
Diagram 1. 2 Histograms for the amount of days the drains were required after excluding too early drain
removal (>30mL/24h). On the left for the diathermy (n=42) and on the right for the PEAK PlasmaBlade™ 
(n=47)
Table 3.7 shows the baseline characteristics for the cohort of 89 patients (after exclusion of
patients that had their drain removed too early >30 mL/ 24 hours). Like in the total study
population, the difference in flap weight (p=0.006) is the only significant variable.
Table 3. 7 Characteristics patients excluding drain removed >30mL/24h
Characteristic Conventional PEAK PlasmaBlade™ 
diathermy (n=42) (n=47) p-value
Age (yr.) † 53.5 (44.8 – 63.0) 52.0 (44.0 – 62.0) 0.26
Height (cm) * 161.3 ± 8.1 162.7 ± 6.6 0.29
Weight (kg) * 76.3 ± 11.7 74.1 ± 13.1 0.41
Body mass index* 29.4 ± 4.3 27.9 ± 4.4 0.11
Consultant (MG/VR) 10/32 12/35 1.00∂
Procedure
(DIEP/MS-TRAM)
40/2 43/4 0.68∆ 
Timing
(immediate/delayed)
34/8 37/10 1.00∂ 
Axillary clearance 21.4% 36.2% 0.16∂ 
SLNB 11.9% 10.6% 1.00∆ 
Procedure ipsilateral
breast
38.1% 29.8% 0.50∂ 
Pre-op radiotherapy 31.0% 23.4% 0.48∂ 
Neo-adjuvant
chemotherapy
21.4% 25.5% 0.80∂ 




      
           
         
             
            
               
            
     
 
  
            
             
 
            








       
          
 
   







   
 
   
 
   
 
 
   
 
   
 
       
 
  
     
      
     
    

























Flap weight (mg) * 979.1 ± 355.8 781.7 ± 305.7 0.006
Amount of IV fluid 
given (L) † 
2.5 (2.0 – 2.5) 2.0 (2.0 – 2.5) 0.96
* Mean ± SD; Independent samples t-test
† Median (IQR); Mann-Whitney U test
∂ Pearson Chi-Square test
∆ Fisher’s Exact test
3.4.2 Multiple imputation for missing data
Multiple imputation was performed for the incorrectly removed drains, considering them as
missing data. Five imputations were performed. The independent samples t-test was used to
identify a difference between the means of the pooled imputation drain data, which resulted in
a non-significant p-value of 0.41, compared to the original data with missing values p=0.28.
The Mann-Witney U test cannot be performed for the pooled data, but only for each separate
imputation model resulting in p=0.53, p=0.17, p=0.32, p=0.12, p=0.21, compared to the
original data with missing values p=0.17.
3.4.3 Kaplan-Meier curve
A Kaplan-Meier curve was created (Diagram 1.3). All patients were included, but the 19
patients who had their drains remove too early (draining more than 30 ml/ 24hours) were
censored.
There was no statistically significant difference between the two groups using the Log Rank





















              
     
 
    
              
          
  
 
       
 
                                                                                                                
                                                                                                    
       
          
         
       
            
            
             
       
            
            
         
Diagram 1. 3 Kaplan-Meier curve for the amount of days the drains were required. Censored patients
were shown with a cross.
3.5 Pain score and morphine use
Table 3.8 shows pain scores (0 – 10) and morphine (mg) use during the first seven days of
admission. The number of patients decreases over the subsequent days due to discharge
from the hospital.





Day 0 Number of patients 52 55
Pain† 2 (1.0 – 4.8) 4 (1.0 – 6.0) 0.02
Morphine (mg) † 0 (0) 0 (0.0 – 5.0) 0.60
Day 1 Number of patients 50 56
Pain morning† 3.0 (2.0 – 4.8) 2.0 (1.0 – 5.0) 0.62
Pain afternoon† 2.5 (1.0 – 4.3) 2.0 (1.0 – 5.0) 0.63
Morphine (mg) † 5.0 (0 – 10) 0.0 (0 – 18.8) 0.77
Day 2 Number of patients 51 56
Pain morning† 2.0 (1.0 – 4.0) 2.0 (1.0 – 4.0) 0.52
Pain afternoon† 1.0 (1.0 – 3.0) 2.0 (1.0 – 3.0) 0.77
Morphine (mg) † 0 (0 – 10.0) 0 (0 – 5.0) 0.19
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Day 3 Number of patients 50 54
Pain morning† 1.0 (1.0 – 3.0) 2.0 (1.0 – 4.0) 0.31
Pain afternoon† 1.0 (1.0 – 3.0) 1.0 (0 – 2.0) 0.11
Morphine (mg) † 0 (0) 0 (0) 0.78
Day 4 Number of patients 50 54
Pain morning† 1.0 (1.0 – 3.0) 1.0 (0 – 2.0) 0.16
Pain afternoon† 1.0 (1.0 – 2.3) 1.0 (0 – 2.0) 0.77
Morphine (mg) † 0 (0) 0 (0) 0.14
Day 5 Number of patients 44 43
Pain morning† 1.0 (1.0 – 2.0) 1.0 (0 – 2.5) 0.58
Pain afternoon† 1.0 (1.0 – 1.0) 1.0 (0 – 2.0) 0.88
Morphine (mg) † 0 (0 – 10.0) 0 (0) 0.16
Day 6 Number of patients 30 30
Pain morning† 1.0 (0.3 – 1.8) 1.0 (0.8 – 2.3) 0.68
Pain afternoon† 1.0 (0 – 2.0) 1.0 (0 – 2.0) 0.63
Morphine (mg) † 0 (0) 0 (0) 0.42
Day 7 Number of patients 12 14
Pain morning† 1.0 (0 – 2.0) 1.0 (0 – 2.0) 0.80
Pain afternoon† 1.0 (0 – 1.3) 1.0 (0 – 3.5) 0.82
Morphine (mg) † 0 (0) 0 (0) 0.72
†Median (IQR); Mann-Whitney U test
The only statistically significant result was the median pain score post-operatively, in recovery
(day 0). The PEAK PlasmaBlade™ group had a statistically significant (p=0.02) higher median
pain score of 4 (IQR 1.0 – 6.0), compared to the normal diathermy group with a pain score of
2 (IQR 1.0 – 5.0).
3.6 Abdominal wound assessment (AIRE score)
From day 1 the abdominal wound was inspected and scored on a daily basis using the Acute
Inflammatory Response Evaluation (AIRE) score, scoring between 0 and 12. As the AIRE
scores were very low throughout the study population Table 3.9 shows the percentage of
patients having an AIRE score ≥ 1 for day 1 till day 7.
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Table 3. 9 Daily admission abdominal wound assessment (AIRE score)
Conventional PEAK
Diathermy PlasmaBlade™ p-value
Day 1 Total number of patients 52 56
Patients with AIRE score ≥1 1.9% 5.4% 0.62† 
Day 2 Total number of patients 52 56
Patients with AIRE score ≥1 7.7% 8.9% 0.88† 
Day 3 Total number of patients 52 56
Patients with AIRE score ≥1 9.6% 3.6% 0.22† 
Day 4 Total number of patients 51 54
Patients with AIRE score ≥1 11.8% 3.7% 0.09† 
Day 5 Total number of patients 45 43
Patients with AIRE score ≥1 15.6% 4.7% 0.13† 
Day 6 Total number of patients 31 30
Patients with AIRE score ≥1 19.4% 6.7% 0.20† 
Day 7 Total number of patients 13 14
Patients with AIRE score ≥1 38.5% 14.3% 0.33† 
†Mann-Whitney U test; AIRE: Acute Inflammatory Response Evaluation
There were no statistically significant differences between the low total AIRE scores
throughout the admission comparing the two different groups, neither was there a difference 
between the individual aspects of the score (erythema, oedema, pain, temperature).
Table 3.10 shows the percentage of patients with an AIRE score ≥1 at their 2- and 6- week 
follow-up appointments.





Week 2 Total number of patients 52 55
Patients with AIRE score ≥1 21.2% 20% 0.96† 
Week 6 Total number of patients 50 55
Patients with AIRE score ≥1 6.0% 9.0% 0.58† 
†Mann-Whitney U Test ; AIRE: Acute Inflammatory Response Evaluation
During the follow-up appointments, the total AIRE scores were low, not showing any
statistically significant differences between the two groups. Neither was there a difference




                 
 
 
   
                                                                                                                  
                                                                                                      





    
     
 
     
 
    
    
 
    
 
    
    
 
    
 
    
    
 
    
 
    
     
 
    
 
    
    
 
    
 
          
 
         
       
 
      
        
           
             
         
     
       
 
3.7 Mobility
Table 3.11 shows the median number of steps from days 1 till day 7 of the admission for the
two different groups.










Steps day 2† n=39
92.0 (15.0 – 317.0)
n=47
150.0 (26.0 – 293.0)
0.38
Steps day 3† n=43
389.0 (126.0 – 626.0)
n=47
400.0 (222.0 – 648.0)
0.99
Steps day 4† n=46
717.0 (298.3 – 1173.5)
n=48
618.5 (287.8 – 1004.8)
0.84
Steps day 5† n=35
663.0 (262.0 – 1370.0)
n=39
805.0 (309.0 – 1632.0)
0.50
Steps day 6† n=22
635.0 (277.3 – 1019.0)
n=24
809.5 (354.3 – 1459.5)
0.17
Steps day 7† n=9
707.0 (342.5 – 1719.5)
n=10
609.0 (218.0 – 1545.0)
0.60
†Median (IQR); Mann-Whitney U Test, n= total number of patients in group
There was no statistically significant difference in activity (number of steps a day) comparing
the different days between the two different groups.
3.8 Seroma on abdominal ultrasound scan
During their clinic follow-up appointments at 2- and 6 weeks post-operative an abdominal ultra-
sound was performed to evaluate the abdomen for fluid collections (seromas). In eleven
patients, the abdominal drain was still in situ at the 2-week appointment and subsequently
removed. Two patients were unable to attend the 2-week follow-up appointment, three
patients were unable to attend the 6-week follow-up appointment.
Table 3.12 and 3.13 displays the results of the ultrasounds.
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Drain still in situ 7.8% 12.7% 1.0∆ 
Presence of seroma 70.6% 54.5% 0.09∂ 










†Median (IQR); Mann-Whitney U Test; ∂ Pearson Chi-Square test; ∆ Fisher’s Exact test








Presence of seroma 26.0% 23.2% 0.78∂ 










†Median (IQR); Mann-Whitney U Test; ∂ Pearson Chi-Square test; ∆ Fisher’s Exact test
There was a trend towards fewer seromas at the 2-week follow-up appointment (70.6% vs
54.5%, p=0.09), but this did not reach statistical significance. At the 2-week follow-up
appointment the total seroma size (cm3) was significantly smaller in the PEAK PlasmaBlade™ 
group compared to the normal diathermy group (62.8cm3 vs 45.6cm3, p=0.04). At the 6-week 
follow-up appointment there were no statistically significant differences in presence and size
of seromas between the two groups.
3.9 Complications





                                                                                                                    
                                                                                                              
                                                                                                     
      
      








    
  
 
     
  
 
     
     
   
 
    
          
 
 
             
           
         
             
 
 
   
        
 
       
              
             
           
             










Free flap problem Theatre 6 3 0.31∆ 









Theatre 1 1 1.00∆ 
Abdominal wound
infection
Oral antibiotics 0 2 0.50∆ 
Partial abdominal
wound breakdown
Wound dressings 4 5 1.00∆ 
Total amount of
complications
15 13 0.58∂ 
∆ Fisher’s Exact test ; ∂ Pearson Chi-Square test
There was a total of 28 complications in our study population, with 15 complications in the
normal diathermy and 13 complications in the PEAK PlasmaBlade™ group. The complications
were evenly distributed between the two groups, not showing any statistically significant
differences for any of the individual complications, nor for the total amount of complications
(p=0.58). 
3.10 Regression analysis
To look at predictors and to identify possible confounders, regression analysis was performed.
3.10.1 Analysis of days drains were required (Cox proportional hazards model)
Comparing the machine used, the hazards ratio for the number of days drains were required
was 1.16 (95% confidence interval 0.76 - 1.76; table 3.15), which did not reach statistical
significance (p=0.50). Other factors such as age, BMI, flap weight, consultant, procedure and
adjuvant therapies were analysed for their association with time to drain removal. BMI and
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flap weight were statistically significantly inversely associated with time to drain removal; other
variables were not significantly associated with the time of drain removal (Table 3.15).
Table 3. 15 Univariable Cox regression analysis for drain requirement
Hazard Ratio Confidence interval p-value
Machine
(Ref group: diathermy)
1.16 0.76 – 1.76 0.50◊ 
Age
(per 5 years increment)
0.94 0.86 – 1.03 0.21◊ 
BMI
(per 5kg/m2 increment)
0.78 0.62 – 0.99 0.04◊ 
Flap weight
(per 100g increment)
0.94 0.89 – 0.99 0.03◊ 
Consultant
(Ref group: VR)
0.86 0.53 – 1.40 0.55◊ 
Procedure
(Ref group: DIEP)
1.69 0.73 – 3.90 0.22◊ 
Radiotherapy
(Ref group: no radiotherapy)
0.99 0.62 – 1.58 0.97◊ 
Neo-adjuvant chemotherapy
(Ref group: no chemotherapy)
1.03 0.63 – 1.68 0.92◊ 
Hormonal therapy
(Ref group: no hormonal therapy)
0.98 0.63 – 1.56 0.95◊ 
◊ Cox Model
Three multivariable analyses were conducted. In the first analysis, machine use was adjusted
for the significant value BMI. In the second analysis, machine use was adjusted for the other
significant variable, flap weight. In the third multivariable analysis, machine use was adjusted
for both BMI and flap weight (Table 3.16).
Table 3. 16 Multivariable Cox regression analysis





p = 0.50◊ 
1.06*
(0.69 – 1.62)†
p = 0.79◊ 
1.08*
(0.70 – 1.66) † 
p = 0.72◊ 
*Hazard Ratio (HR); †95.0% Confidence Interval (CI); ◊p-value Cox model
Multivariable 1: only adjusted for BMI (p=0.04)
Multivariable 2: only adjusted for flap weight (p=0.03)
Multivariable 3: adjusted for BMI and flap weight
After correction for significant predictors associated with drain removal, the type of machine




        
              
           
             
          
              
           
  
 
           
 
                                                                                           
 
 
   
    
 
   
    
 
  
    
 
   
    
 
   
    
 
   
     
 
    
    
  
    
    
  
     
    







3.10.2 Logistic regression for seroma presence on 2- and 6-week ultrasound
A logistic regression was performed for the presence of seroma on ultrasound at 2- and 6-
week follow-up appointments, to review the influence of different parameters. The odds ratio
of 0.5 (95% confidence interval 0.22 – 1.12) for the machine’s association with seroma
incidence at the 2-week ultrasound almost reached statistical significance (p=0.09) (Table
3.17). At the 6-week ultrasound the odds ratio of 0.79 (95% confidence interval 0.32 – 1.95)
for the machine’s association with seroma incidence did not reach statistical significance
(p=0.62) (Table 3.18).
Table 3. 17 Univariable logistic regression for seroma presence on ultrasound at 2 weeks
Odds Ratio Confidence interval p-value
Machine
(Ref group: diathermy)
0.50 0.22 – 1.12 0.09◊
Age
(per 5-year increment)
1.22 0.999 – 1.50 0.051◊ 
BMI
(per 5kg/m2 increment)
1.26 0.80 – 1.99 0.32◊ 
Flap weight
(per 100g increment)
1.09 0.97 – 1.22 0.16◊ 
Consultant
(Ref group: VR)
0.44 0.19 – 1.04 0.06◊ 
Procedure
(Ref group: DIEP)
1.70 0.33 – 8.9 0.53◊ 
Radiotherapy
(Ref group: no radiotherapy)
1.15 0.48 – 2.74 0.76◊ 
Neo-adjuvant chemotherapy
(Ref group: no chemotherapy)
0.88 0.35 – 2.21 0.79◊ 
Hormone therapy
(Ref group: no hormonal therapy)
0.72 0.30 – 1.71 0.46◊ 
◊ Logistic regression model
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Table 3. 18 Univariable logistic regression for seroma presence on ultrasound at 6 weeks
Odds Ratio Confidence interval p-value
Machine
(Ref group: diathermy)
0.79 0.32 – 1.95 0.62◊
Age
(per 5-year increment)
1.41 1.11 – 1.79 0.005◊ 
BMI
(per 5kg/m2 increment)
1.17 0.72 – 1.90 0.52◊ 
Flap weight
(per 100g increment)
1.07 0.95 – 1.21 0.24◊ 
Consultant
(Ref group: VR)
0.24 0.07 – 0.87 0.03◊ 
Procedure
(Ref group: DIEP)
3.5 0.66 – 18.57 0.14◊ 
Radiotherapy
(Ref group: no radiotherapy)
0.74 0.26 – 2.07 0.56◊ 
Neo-adjuvant chemotherapy
(Ref group: no chemotherapy)
0.80 0.27 – 2.43 0.70◊ 
Hormone therapy
(Ref group: no hormonal therapy)
1.03 0.38 – 2.79 0.96◊ 
◊ Logistic regression model
Univariable logistic regression for the 2-week seroma presence did not show any significant
parameters, therefore age and consultant both with a p value <0.10 were used in the
multivariable logistic regression (Table 3.19).
Univariable logistic regression for the 6-week seroma presence did show a significant odds
ratio for age (p=0.005) and consultant (p=0.03). Both values were used in the multivariable
logistic regression (Table 3.20).
Table 3. 19 Multivariable logistic regression for seroma presence on USS at 2 weeks





p = 0.13◊ 
0.47*
(0.21 – 1.07)†
p = 0.07◊ 
0.49*
(0.21 – 1.13)†
p = 0.09◊ 
*Odds Ratio (OR); †95.0% Confidence Interval (CI); ◊Logistic regression model
Multivariable 1: only adjusted for age (p=0.051)
Multivariable 2: only adjusted for consultant (p=0.06)




             
              
            
    
 
    
           
           
   
 
           
 
                                                                                
  
   
 
   
  
 
   
  
 
   
  
      
      
      
        
      
                                               
                                                                                          
    
   
    
   
    
    
   
  
    
   
   
    
   
   
    
   
   
    
 
    
    
  
    
    
  
     
    
   
Table 3. 20 Multivariable logistic regression for seroma presence on USS at 6 weeks





p = 0.79◊ 
0.76*
(0.30 – 1.91)†
p = 0.56◊ 
0.86*
(0.33 – 2.26)†
p = 0.76◊ 
*Odds Ratio (OR); †95.0% Confidence Interval (CI); ◊Logistic regression model
Multivariable 1: only adjusted for age (p=0.005)
Multivariable 2: only adjusted for consultant (p=0.03)
Multivariable 3: adjusted for both age and consultant
After multivariable logistic regression adjusting for age and consultant, the type of machine
used was not significantly associated with the presence of a seroma collection at the 2-week
ultrasound (Table 3.19). The same was shown in the multivariable logistic regression for the
6-week ultrasound (Table 3.20).
3.10.3 Logistic regression for complications
A logistic regression was performed for all the experienced complications. The number of
complications experienced by each patient ranged from 0 to 3. Results from univariable
analysis are displayed in Table 3.21.
Table 3. 21 Univariable logistic regression for complications
Odds Ratio Confidence interval p-value
Machine
(Ref group: diathermy)
0.73 0.29 – 1.87 0.52◊ 
Age
(per 5 years increment)
1.10 0.88 – 1.37 0.42◊ 
BMI
(per 5kg/m2 increment)
1.74 1.01 – 2.98 0.045◊ 
Flap weight
(per 100g increment)
1.11 0.98 – 1.26 0.09◊ 
Consultant
(Ref group: VR)
0.56 0.21 – 1.46 0.24◊ 
Procedure
(Ref group: DIEP)
1.85 0.33 – 10.37 0.48◊ 
Radiotherapy
(Ref group: no radiotherapy)
0.84 0.31 – 2.30 0.73◊ 
Neo-adjuvant chemotherapy
(Ref group: no chemotherapy)
2.24 0.61 – 8.29 0.23◊ 
Hormonal therapy
(Ref group: no hormonal therapy)
0.84 0.31 – 2.31 0.74◊ 
◊ Logistic regression model
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A higher BMI was associated with a higher number of complications, reaching statistical
significance (p=0.045). Other values (age, flap weight, procedure and neo-adjuvant
chemotherapy) had an odds ratio above 1, but did not reached statistical significance.
Two multivariable analyses were conducted. The first analysis adjusted for BMI only, as this
was the only statistically significant predictor for complications in the univariate analysis. The
second analysis adjusted for all variables with a p-value smaller than 0.10 (BMI and flap
weight, Table 3.22).
Table 3. 22 Multivariable logistic regression for complications





p = 0.70◊ 
0.86*
(0.33 – 2.26)†
p = 0.77◊ 
*Odds Ratio (OR); †95.0% Confidence Interval (CI); ◊p-value ordered logistic regression model
Multivariable 1: only adjusted for BMI
Multivariable 2: adjusted for BMI and flap weight (all p<0.2)
After correction for predictors for complications, the type of machine used was not significantly




            
            
            
  
 
    
           
          
         
                
                 
  
             
                 
               
               
             
          
            
       
 
                 
             
         
              
           
CHAPTER 4: DISCUSSION
In this final discussion chapter of the thesis a comprehensive discussion on the different
aspects of the research will be given. This has enabled me to critically evaluate the work I
have done and draw evidence-based conclusions from my own findings and those published
by others.
4.1 The primary outcome value
This study has been unable to reject the null hypothesis, as there was no statistically
significant difference for the drain requirement between patients operated with the PEAK
PlasmaBlade™ compared to the conventional diathermy. The conventional diathermy group
required the drains for a median of 6.0 days with an interquartile range of 5.0 – 8.8 days
compared to a median of 5.0 with an interquartile range of 5.0 – 8.5 days in the PEAK
PlasmaBlade™ group.
In 19 patients the last drain was removed too early (draining >30mL/24 hours). Exclusion of
this cohort did not result in a statistically significant difference in the amount of days the drains
were required between the two groups. With a median of 6.0 days with an interquartile range
of 5.0 – 9.0 days in the conventional diathermy group compared to a median of 5.0 days with
an interquartile range of 4.0 – 8.0 days in the PEAK PlasmaBlade™ group. Exclusion of these
cases reduced the sample size significantly. To try and overcome this imputation was applied.
After imputation, in which incorrect drain removal days were replaced by expected days of
drain requirement, no statistically significant difference was found.
Analysis of each of these three data sets had its own problem. The first option in which all
data are included, wrongfully removed drain data will skew the actual result. When looking at
the wrongful drain removed group more specifically it shows for the conventional diathermy 
group n=10, median=4.5 IQR 3.75 – 6.25 compared to the PPB group n=9, median=5.0 IQR
3 – 6.5. Those values are fairly similar, not showing any statistically significant difference using
123
  
            
               
            
            
            
              
             
        
 
             
            
               
             
              
           
      
 
        
             
           
 
           
             
             
             
                 
        
             
the Mann-Whitney U test p=0.26. When comparing the data, the median values stay the same
for both machine groups (PPB median 5.0 IQR 5.0 – 8.5 vs median 5.0 IQR 4.0 – 8.0 and CD 
median 6.0 IQR 5.0 – 8.8 vs median 6.0 IQR 5.0 – 9.0).
Excluding the incorrectly removed drain data as mentioned before results in a significant loss
of data, resulting in the study being insufficiently powered. The problem with the imputation
technique on a high percentage (17.6%) of a relatively small dataset is that it is an artificial
way to increase your power and is usually not performed on the outcome of interest. Neither
of the three techniques resulted in a statistically significant difference.
The Kaplan-Meier survival curve most likely makes optimal use of the existing data by
including the patients whose drain was removed too early as censored data.
Looking at the Kaplan-Meier curve (diagram 1.3), the line of drain removal for the PEAK
PlasmaBlade™ group lies below the conventional diathermy group at all time, but this did not
reach statistical significance using the Log Rank test, p=0.42. On the contrary to the situation
in which the curves would have crossed, this might suggest that the non-significant finding
could have been a power issue.
Cox linear regression did identify BMI and flap weight as parameters significantly inversely
associated with the time to drain removal but a multivariable analysis including those factors
with machine used, did not result in a statistically significant hazard ratio.
A possible explanation for the inability to find a significant difference between the two groups
can be the used power settings and mode for the PEAK PlasmaBlade™. When comparing the
experimental studies in chapter 1.5.5.1 to the clinical studies in chapter 1.6, it reveals the
PEAK PlasmaBlade™ was used at much lower energy settings (3) and only in the cut mode in
the experimental studies compared to both cut (1 to 7) and coagulation mode (3 to 8) in the
clinical studies. The largest difference in operating temperature between the two different
machines, resulting in thermal collateral damage is when used in the cut mode on low power
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levels. For the raise of the abdominal flap “cut” was used to dissect and “coagulation” for
haemostasis, resulting in a combination of both the cut and coagulation mode. It is impossible,
for either of the two machines to exactly quantify how often it was used in either of the two
different settings. The use of both modes might be a factor contributing to a smaller difference
than expected. For this study the settings cut 7 (35 Watt) and coagulation 7 (35 Watt) were
used. Possibly these settings were too high and therefore did not result in a significant
difference. It would be valuable to evaluate the PPB in a similar model but at lower power
settings.
Other studies producing similar results were Ruidiaz et al. (2011) who didn’t find a difference
in time to drain removal time in 20 abdominoplasties; Chiappa et al. (2018) who did not find a
significant difference in drainage duration in 60 breast cancer patients; Sowa et al. (2018) who
didn’t find a difference in drain requirement in 44 LD patients and Schlosshauer et al. (2019)
who didn’t find a difference in drainage duration in upper arm or medial thigh lifts. The paper
published by Dogan et al. (2013) was the only one that did find a reduced drain requirement
after the use of the PPB compared to conventional electrosurgery in 46 mastectomy patients.
The difference in surgical area and tissue characteristics (skin in breast surgery and
subcutaneous fat in abdominal surgery) could be a possible reason for the different effects of
the PEAK PlasmaBlade™ on drain requirement between Dogan’s breast study (2013) and our
abdominal study. The permittivity of skin (�skin=1832.8) is much higher compared to
subcutaneous fat (�fat=27.22), therefore skin polarises much easier making it less resistive to
an electric flux, reducing the height of heat conversion at similar power settings. Electric 
conductivity for skin (�skin=0.22) is also much larger than that of fat (�fat=0.025), making skin
more capable of dispersing heat (Jimenez-Lozano et al., 2012).  
The difference between the two breast studies (Chiappa 2018 and Dogan 2013) could be due
to power settings which cannot be confirmed as Chiappa did not disclose theirs. The study
population of Chiappa at al. also included quadrantectomies which result in lower wound
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drainage as the wounds are much smaller and the created cavity can be closed off with
sutures, therefore usually not requiring a drain.
4.2 The secondary outcome values
4.2.1 Peri-operative data
Time to raise flap
The operative time for the PEAK PlasmaBladeä (120 min IQR 93.5 – 154.5), did not differ
significantly from the conventional diathermy (129 min IQR 90 – 159.3). This shows the use
of the new technology of the PEAK PlasmaBlade™ only requires a short learning curve and is
as effective for dissection and haemostasis as the conventional diathermy. This is important
as theatre time is expensive with an average cost of approximately £1200 per hour (Fletcher,
Edwards, Tolchard, Baker, & Berstock, 2017). The senior plastic surgeons (VR and MG)
performing the flap raises had the subjective perception the PEAK PlasmaBlade™ was slower/
less effective in performing haemostasis in the coagulation mode, but this was proven only
subjective by the equal objective flap raise times, number of vessel clips used and post-
operative haematomas recorded.
Similar results have been published in other papers comparing the operating time between
the conventional diathermy and PEAK PlasmaBlade™: Duscher et al. (2019) did not find a
statistical significant difference in operating time for abdominoplasties, Sowa et al. (2018) not
in LD breast reconstruction operations, Dogan et al (2013) not for mastectomies and Chiappa
et al. (2018) not for breast cancer surgery (mastectomy and lumpectomy). The PEAK
PlasmaBlade™ has been shown to significantly reduce operating time in replacement of
implantable devices such as cardiac pacemakers/ defibrillators and neuromodulation implants
(Kypta et al., 2018; Kypta et al., 2015; Ughratdar et al., 2018) as the lower operating
temperature makes it acceptable to touch the device leads without causing damage, making
removal of the old generator out of the fibrotic tissue easier, quicker and safer. Zientara et al.
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(2018) report a significantly longer operating time (5.1 minutes longer, p=0.01) in the PEAK 
PlasmaBlade™ group for internal thoracic artery harvest for cardiac by-pass surgery. This
could be explained by the low settings at which the PEAK PlasmaBlade™ was used, namely
cut mode 1 and coagulation mode 5. Due to the reduced haemostatic ability of the PPB on
those low settings a modification to the preparation technique was introduced, namely clipping
of the distal end of side branches. Duscher at al. (2019) was the only other clinical study using
the PPB on a low setting 3 (not specified if this was cut or coagulation) but this did not result
in an increased operating time as mentioned earlier.
Flap weight
Despite randomisation, the flap weight was significantly (p=0.03) higher in the conventional
diathermy group 958.5 gram (IQR 759 – 1239) compared to the PPB group 833.0 gram (IQR
575.0 – 1031.0). Therefore flap weight is a confounding factor in this study for which should
be corrected to prevent false associations. Univariate Cox regression analysis was used to
identified flap weight as a significant (p=0.03) covariant with a hazard ratio of 0.94 per 100
gram increment. Multivariable Cox regression was performed to correct for the signififcant flap
weight on the primary outcome value. After correction with the multivariable Cox regression
the effect of the different machines on the primary outcome value (days drain requirement)
remained insignificant.
4.2.2 Inflammatory cytokines
Ozdogan et al. (2008) and Yilmaz et al. (2011) showed a significant difference in levels of
TNF-alpha and IL-6 in 24-hour post mastectomy drain fluid, between knife and electrosurgical
dissection. These were the only two studies published comparing cytokine levels after scalpel
and electrosurgery. As mentioned in the introduction the reported fluid collection within 24
hours post-operatively was the major flaw in the second paper.
This RCT was unable to find a significant difference in inflammatory cytokines on day 0,1 and
2 between the two groups. There were some observed tendencies for MIP-1 beta on day 0
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(p=0.07), MIP-1 alpha on day 1 (p=0.054) and IL-18 on day 2 (p=0.07) towards statistically 
significant lower values in the PEAK PlasmaBlade™ group. Clinical significance of these values 
is unclear and further research on the effects of electrosurgery on inflammatory cytokines is 
required. As the power of this study was not calculated for the levels of inflammatory cytokines,
the inability to reach statistical significance could be due to a too small study population. A 
possible explanation for the failure to show a significant difference in key inflammatory
markers between the two different machines could be because both use electricity, which
causes collateral thermal injury. This finding also supports the hypothesis that if the PEAK
PlasmaBlade™ is used in both the “cut” and “coagulation” mode at higher settings, its’
operating temperature rises, resulting in more collateral tissue damage comparable to the
conventional diathermy.
When reviewing Table 2.4 there is a clear difference between the LDD and LLOQ between
the 2017 and 2018 measurements for most cytokines. The laboratory has confirmed these
differences are not caused by the calibration of the machines used for the analysis. In
hindsight analysis of all the samples at the end of the study would have been more preferable.
The reason for the first analysis half way through the study was to identify any possible
problems with the sample collection, storage or transport on dry ice to the United States, giving
us the opportunity to make adjustments, would it have been required, at least ensuring correct
sample testing for half of the included patients.
4.2.3 Pain scores
The numerical rating scale (NRS) from 0 to 10 was a useful tool to assess pain intensity during
the inpatient stay. It’s easy use, feasibility and good compliance have been proven in previous
studies (Haefeli & Elfering, 2006). Other scores such as visual analogue scale (VAS) or
graphic rating scale (GRS) were deemed less useful as scoring is more time consuming, more




           
             
               
               
               
           
        
            
             
           
    
              
            
           
          
        
            
            
        
           
             
             
                
          
            
        
             
            
In the immediate post-operative period in recovery pain was significantly higher in the PEAK
PlasmaBlade™ group. A possible explanation for the significantly higher pain in the PPB group
could be correlated to the significantly lower flap weight in this group. In patient with a smaller
amount of abdominal fat a larger abdominal flap including more tissue would have to be
harvested to acquire a sufficient volume to reconstruct the breast. This would result in a tighter
more painful abdominal closure. Another factor most likely having influence on pain 
immediately post-operatively is the axillary lymph node clearance, which is removal of all
lymph nodes from the armpit. Axillary lymph node clearance was performed in 32,1% of the
PEAK PlasmaBlade™ group and 21.2% in the conventional diathermy group, but this did not
reach statistical significance. Possibly the difference in pain score is based on interpatient
variability as pain remains a subjective matter.
Spektor et al. (2016) publishes a paper in 2016 comparing pain and analgesia requirement in
a prospective, non-randomised, non-blinded cohort study including 100 patients aged 3 to 12
years undergoing a tonsillectomy performed with the PEAK PlasmaBlade™ or bipolar
radiofrequency ablation (coblation). Parents or legal guardians had to quantify pain in the first
14-days post-operative using a validated 11-point proxy-evaluated paediatric pain scale
(Children’s and Infants’ Postoperative Pain Scale, CHIPPS) over the phone. A mean pain
difference of 3 points was considered clinically relevant. The requirement for any doses of
narcotic or non-narcotic medication were also registered. Pain scores were significantly lower
in the PEAK PlasmaBlade™ group between post-operative days 7 to 9, but this did not reach
the clinically significant difference of 3. There was no significant difference in the amount of
analgesic medication required between the two groups. Drawbacks of the study were the
young age of the patients, requiring a proxy to rate the pain, the pain assessment over the
phone and the non-blinded/ non-randomised character of the study.
More recently Tan et al. (2019) published their study comparing the PEAK PlasmaBlade™ to
monopolar electrocautery for tonsillectomy in a prospective double-blinded randomised
controlled trial in 58 adults. They found that patients in the PEAK PlasmaBlade™ groups were
able to pain-free swallowing in a shorter period of time compared to the electrocautery group
129
  
            
              
            
           
                
         
             
           
            
   
 
  
            
        
            
     
 
      
         
          
        
               
        
                
                
             
                 
(13.28 vs 15.76 days p=0.035). There was no difference in the daily visual analogue score for
pain nor in the number of analgesia tablets taken. Patients who underwent their tonsillectomy
with the PEAK PlasmaBlade™ had a higher satisfaction score compared to those who
underwent the procedure with the monopolar electrocautery (8.92 vs 8.24 out of 10, p=0.046).
This study has been unable to show a reduction in pain after use of the PEAK PlasmaBlade™ 
possibly as other factors such axillar node clearance, inter-rib dissection for vessel
preparation, drains and tension on abdominal closure are more significant in the amount of
pain experienced, compared to the abdominal wound surface created. The significant
difference on day 0 in pain scores will most likely be caused by other confounding factors and
not the difference in machine used.
4.2.4 Mobility
Mobility was equal between the two groups during the in-patient period not showing any
statistical significance. This variable was measured not because a difference was expected 
but to make sure both groups were mobilising equally because immobility has been linked to
a reduced drain out-put (Beer & Wallner, 2010).
4.2.5 Abdominal wound assessment (AIRE scores)
Both during the in-patient and out-patient period the AIRE scores (total and individual aspects)
have not shown a statistically significant difference in local inflammatory reaction of scars 
between the PEAK PlasmaBlade™ and conventional diathermy group. During admission (day
1 to day 7) total AIRE scores were low in both groups, which was expected as the inflammatory
reaction of wound healing requires time to develop.
At the 2-week appointment most patient had an AIRE score of 0 (78.7%, n=85), the rest had
score of 1 (13.9%, n=15) and 2 (3.7%, n=4). The highest AIRE scores acquired were 5 (0.9%,
n=1) and 6 (1.9%, n=2). At the 6-week appointment most patients had an AIRE score of 0
(89.8%, n=97), the rest had scores of 1 (2.8%, n=3), 2 (2.8%, n=3) and 4 (0.9%, n=1). The
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highest score acquired by one patient (0.9%) was 9. As skin incisions were made with a
scalpel in both groups, a difference in this AIRE score was not expected.
Richter et al. (2012) introduced the AIRE score for local inflammatory reactions of scars to
compare two different methods of skin closure. They did show some significant differences of
individual aspects of the score but were unable to show significant differences for the total
AIRE scores at 24 hours, 7 days, between 12 to 25 days, 90 days, 6 months and 12 months.
The AIRE scoring system has only been used in the publication by Richter et al. (2012). The
paper does not comment on validity, reproducibility, sensitivity and inter-rater reliability of their
scoring system. In our study the abdominal wounds were scored by one person, the research
fellow, therefore only influenced by intra-rater reliability.
A great variety of scar-measuring devices and assessment scales have been published over
the years, rating both objective and subjective aspects of scars. Validation processes have
demonstrated acceptable consistency and reliability, but due to evaluation of only a few
aspects they have limited sensitivity. This results in the ability to only detect large differences 
between scars. Most studies on classifications and scar evaluation focus on burn scars,
making them less applicable to (early) surgical scars (Fearmonti, Bond, Erdmann, & Levinson,
2010). 
4.2.6 Total abdominal drain fluid output
This study has been unable to show a statistically significant reduction in the total drain output
after performing the abdominal flap raise with the PEAK PlasmaBlade™. The influence of
electrosurgery on abdominal seromas in the literature is contradictory and mainly focussed on
(cosmetic) abdominoplasties. Even though there are a lot of similarities between the cosmetic
abdominoplasty and DIEP/MS-TRAM donor site there are usually differences in placement of
scar, amount of intramuscular dissection, operating time, BMI and dissection technique
(Salgarello et al., 2012). An RCT performed by Mash et al. (2015) comparing scalpel and
handheld electrocautery dissection in abdominoplasties in 102 patients did not show a
difference in seroma rates. Rousseau et al. (2011) published in 2011 a longer drainage period,
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higher drain volumes and more seroma collections after an abdominoplasty (n=551) with
diathermo-coagulation compared to scalpel dissection. In 2015 similar results were reported
by Valença-Filipe et al. (2015) in 119 abdominoplasties. All studies suffered from design flaws 
introducing a high chance of bias.
In clinical studies comparing the PPB to electrosurgery Chiappa et al. (2018) in 60 breast
cancer patients and Duscher et al. (2019) in 57 abdominoplasty patients also did not find a
significant difference in total abdominal drain output. In contrast to Dogan et al. (2013) in 46
mastectomy patients, Sowa et al. (2018) in 44 LD patients and Schlosshauer et al. (2019) in
24 upper arm and medial thigh lifts, who did find a significant reduction in total drainage after
the use of the PPB.
Abdominal drain fluid contains both blood and wound fluid and usually changes from
serosanguinous initially to serous after a few days. A reduction in total drain fluid can therefore
also be caused by a reduction in immediate post-operative bleeding. Schlosshauer et al.
(2019) were the only group that tried to control for this by also reporting the drain output for
the 1st post-operative day. A possible explanation for the difference found in total drainage in
the paper from Schlosshauer et al. were the extremely high settings used for the conventional
diathermy (Coagulation max. 80 Watt and cut max. 180 Watt). Sowa et al. did not disclose
their power settings, therefore this could also be an explanation for their significant difference.
4.2.7 Complications
Haematoma and wound healing problems
Abdominal haematomas were experienced twice in the conventional diathermy 
groupcompared to none in the PEAK PlasmaBlade™ group. This did not reach statistical 
significance. These results support the conclusion that the PEAK PlasmaBlade™ is as effective
in haemostasis as the conventional diathermy.
Minor wound healing problems occurred in about 1% of cases, which all resolved with wound
dressing. No significant differences were seen in wound healing.
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Univariate logistic regression for complications showed a statistically significant association
with a higher BMI. Correction with multivariable logistic regression, the type of machine was
not significantly associated with a higher number of complications.
Due to the low number of experienced complications in both groups we have been unable to
show statistically significant differences. These findings are comparable to papers published
by Dogan et al. (2013), Chiappa et al. (2018), Kypta et al. (2018) and Duscher et al. (2019), 
who were also unable to show statistically significant differences in complications in their
clinical studies comparing the PPB to the conventional diathermy.
Post-operative seroma collections
Only two patients required surgery for abdominal wound breakdown caused by excessive
seroma production and four required a single needle aspiration for a large seroma causing
discomfort. These complications were equal between the two groups and did not reach
statistical significance.
At the two-week follow-up appointment there was a tendancy towards more seromas in the
conventional diathermy group, almost reaching statistically significance (p=0.09). Seroma
collections were statistical significantly smaller (p=0.04) in the PEAK PlasmaBlade™ group.
Five patients developed a new seroma collection between the 2- and 6-week appointment,
two of them had the abdominal drain only removed at the 2-week follow-up appointment. In
most patients (n=42, 64%), the one or multiple seroma collections at 2 weeks had
spontaneously reabsorbed at the 6-week appointment.
These findings are similar to Di Martino et al. (2015) who evaluated the beginning and
progression of seroma formation following abdominoplasty in a prospective trial by performing
abdominal ultrasounds at 7-day intervals in 21 female patients. They concluded the highest
incidence of seroma formation was between day 11 (38.1%) and 18 (33.3%) post-operatively,
which fell significantly to 19% on day 32.
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The tendancy towards less abdominal seromas after the use of the PEAK PlasmaBlade™ at
the 2-week follow-up appointment might have resulted in a significant difference if a larger
patient population would have been included as this study was not powered for seroma
occurrence. 
The follow-up for this study was only 6 weeks, but patients were seen as part of their regular
follow-up at 6 months and 1 year post-operatively. In this time one patient presented 3 months 
post-op with a chronic seroma, not requiring any further intervention. Potentially more patients
will have developed subclinical small chronic seromas with pseudo-cyst formation without
causing any discomfort or influencing cosmetic outcome possibly due to a high BMI of 28.
Further studies with long-term follow-up using abdominal ultrasound could give more clarity
on this subject, though clinical relevance is questionable. The low incidence (0.3%) for surgical
intervention for late seromas in TRAM and DIEP flaps patients has also published by
Nahabedian (2007).
As drainage of every seroma collection is unnecessarily invasive and increases the risk of
infection, in this study only large seromas causing discomfort to the patient were drained via
needle aspiration. Therefore, an alternative method to estimate the volume of an identified
seroma collection had to be used. With the use of the ultrasound machine the dimensions
(length, width and maximum height in cm) of each seroma collection were measured. Since
the shape of an abdominal seroma collection most approximates the shape of half an ellipsoid
its formula was used to estimate the volume. This method most likely underestimates the
actual volume of a seroma collection, but because ultrasound was performed by a single
person using the same technique for every individual measurement, outcomes were
considered comparable.
Logistic regression did identify age and consultant as statistically significant parameters for
the presence of seroma at 6 weeks. Correction for those in a multivariable logistic regression
for seroma presence at 6 weeks, did not result in a significant odds ratio for the machine used.
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The definition for seroma greatly varied between the different clinical papers, making it difficult
to compare results. Seromas were usually only identified clinically which also leads to under
diagnosis of this complication.
4.3 Experienced difficulties
The Post Graduate Medical Institute Clinical Trials Unit (PGMICTU) at the Anglia Ruskin
University set-up an online electronic database (MACRO database) for the data collection. A
print-out of the Case Report Forms (CRFs) was used to collect the data during the study
period. Those results were added onto the database during the course and after completion
of the study. After finalising the data entry onto the database, it was exported into SPSS .sav
files. The data had to be broken down in different files as it was too large to process. The
separate .sav files had to be adjusted considerably to allow data analysis with SPSS. Due to
the necessity for adjustments which were very time-consuming, the usefulness of the MACRO
database is questionable. 
4.4 Limitations of the study
The power calculation for this randomised controlled trial was based on the data acquired from
a pilot study performed in our department (Chow et al., 2019). This pilot study only included
40 MS-TRAM/DIEP breast reconstruction patients, resulting in 20 patients in the normal
diathermy and 20 patients in the PEAK PlasmaBlade™ group. The mean amount of days the
abdominal drains were required was calculated using the two-sample t-test. Because the
power calculation was only based on a small patient population, the results could be skewed,
leading to a number of patients required which is too low to show a statistically significant
result.
For this study patients undergoing both the DIEP and MS-TRAM procedure were included,
which could be a confounding factor. The number of included MS-TRAM flaps was low and
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not significantly different between the two groups. If an MS-TRAM was clinically required
only a small amount of muscle would be sacrificed, making it very comparable to the DIEP.
Regression did show type of procedure was a confounding factor, but this never reached
statistical significance.
Due to the high costs of the drain sample testing it was not possible to include patients
requiring diversion from the study protocol. Therefore, a per-protocol analysis was performed
for this trial, which could result in bias. The main reason for patient exclusion from follow-up
was conversion into a bi-pedicled DIEP flap in seven cases, which was one of the exclusion
criteria. A conversion from a uni-pedicled into a bi-pedicled DIEP flap is required if the
abdominal fat tissue does not receive sufficient blood supply from one blood vessel. This can
be difficult to judge pre-operatively and was unexpectedly required in seven patients. One
patient had a large abdominal hernia, requiring repair with a mesh by the general surgeons,
one surgery was cancelled, and two patients were operated by a different surgeon. All the
reasons for post-randomisation exclusion were unrelated to the type of operating machine
used.
Due to 1:1 randomisation of the two groups in blocks of 6, and exclusion of 11 patients after
randomisation, the two groups were unequal when the predetermined number of 106
inclusions was reached. It was therefore decided to include a further two patients in the hope
the power-calculated minimal sample size of 53 would be met. Unfortunately, this number was
not reached resulting in the final numbers of 56 patients in the PEAK PlasmaBlade™ group
and 52 in the conventional diathermy group.
To be able to include enough patients in an acceptable time period it was required to include
patients from two senior plastic surgeons (VR and MG). Operating techniques of both 
surgeons are very similar. The standardised operation protocol reduced inter-operator
variation further. Both surgeons’ patients were equally divided over the two groups.
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Regression analysis did show a consultant was a significant predictor for seromas at 6 weeks,
therefore making it a likely confounder, for which was corrected in the multivariable regression.
The single centre character of the study could make the results less transferable to other units
and is something that must be kept in mind.
The used settings for the diathermy of cut 40 Watt and coagulation 40 Watt were chosen as
these are levels normally used for a standard DIEP flap raise. The PEAK PlasmaBlade™ 
settings of cut 7 (35 Watt) and coagulation 7 (35 Watt) were discussed with the production
company Medtronic and deemed the most suitable for this type of operation. For both
machines, the cut mode was used for cutting and coagulation for haemostasis. Unfortunately,
it is impossible to exactly quantify the use of the different electrosurgical modes 
(cut/coagulation). Possibly the used machine settings for the PPB were too high to result in
significantly less collateral thermal injury
4.5 Strengths of study
The randomised controlled character of this study is a strength, which will reduce selection
bias (Groenwold, 2013). The randomisation was mostly successful but did result in a
significantly higher resected flap weight in the conventional diathermy group. Prolonged drain
requirement and increased seroma formation have been linked to a higher flap weight and is 
therefore a confounding factor (P. Andrades & Prado, 2007). Cox regression analysis of our
data did identify flap weight as significantly inversely associated with drain requirement and
therefore correcting was applied. Linear regression did not identify flap weight as a significant 
variable for the presence of seroma at the 2- and 6-week ultrasound, consequently it was not
required to correct for this.
The double blinded character of the study is another strength as it reduces the chance of
experimenter bias. I personally would never consider falsifying results but are able to imagine
why researches could be tempted to do so. Despite the fact negative findings are valuable
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and make an important contribution to new knowledge, they can be more difficult to publish
and are not as satisfying as finding something significant. By blinding the patients, information
bias was reduced because knowing the “new” machine was used could influence a patient as
they think they should feel better having received the new treatment option. Values that could
have been affected are the pain score, morphine use and mobility as patients would have had
an influence on these three (Groenwold, 2013).
Most patients completed the 6-week follow-up, with only three patients in the conventional
diathermy and one patient in the PEAK PlasmaBlade™ group not attending this final
appointment. The completion of the study by 96.3% of the participants will reduce the chance
of selection bias (Groenwold, 2013).
4.6 Contribution to new knowledge
This study had a well-designed study research protocol explicitly outlining data collection and
analysis with a standardised operating protocol, standardised diathermy and PEAK
PlasmaBlade™ settings, clear outcome values and a set follow-up period for each patient. All
data was collected by one person (myself, the research fellow). No adjustments were made
to the study protocol after commencement of the study. All these factors help to reduce bias 
and result in a higher level of evidence compared to studies previously published on the
subject (Smith & Noble, 2014).
Abdominal seroma collections can be identified clinically but abdominal ultrasound is the
method of choice as it is more sensitive resulting in a higher accuracy of fluid collection
identification (Marcello Di Martino et al., 2010; M. Di Martino et al., 2015). Using the ultrasound
machine to identify seromas in DIEP and MS-TRAM breast reconstruction patients has given
more information about the natural evolution of seromas in this cohort, which can be a valuable
baseline for future comparisons.
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This level 1 evidence study shows the PEAK PlasmaBlade™ at settings cut-7 and coagulation-
7, does not have a significant benefit over the conventional diathermy for abdominal free flap
harvest, as it does not reduce drain requirement or total output and does not result in a
reduction in complications. These results can also be considered for other procedures 
resulting in large (donor site) wounds such as latissimus dorsi breast reconstruction, cosmetic
abdominoplasties and abdominal wall reconstructions.
4.7 Conclusion
Experimental studies on the use of the PEAK PlasmaBlade™ have showed very promising
results, with regards to wound healing profiles and reduction in collateral thermal injury.
Though clinical studies so far have mostly been unable to reveal significant improvement in
post-operative recovery and a reduction in complications, possibly due small numbers and
bias following poor design.
The conducted large double blinded randomised controlled trial including 108 abdominal free-
flap breast reconstruction patients has been unable to show a statistically significant difference
in drain requirement, total drainage or complications between patients operated with the
conventional diathermy and the PEAK PlasmaBlade™ using the cut 7 and coagulation 7
settings. Inflammatory marker levels were similar between the two study groups, suggesting
comparable inflammatory responses. Immediately post-operative pain scores (day 0) were
significantly higher in the PEAK PlasmaBlade™ group, but most likely due to factors other than
the used operating machine. The flap weight was significantly higher in the conventional
diathermy group, which could have been a confounding factor, but logistic regression did not
identify flap weight as a significant parameter for seroma presence at the 2- and 6-week
abdominal ultrasound. There was a trend towards less seromas at the 2-week follow-up 
appointment, which were significantly smaller in the PEAK PlasmaBlade™ group. These
differences had disappeared at the 6-week follow-up appointment, making the 2-week findings
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of questionable clinical significance. Despite the high incidence of seromas on abdominal
ultrasound after abdominal based autologous breast reconstruction, intervention was rarely
required in either of the two groups.
In the future, further high-quality clinical trials should to be conducted for example on lower
coagulation and cut settings, to give more information regarding the potential benefits of
different electrosurgical devices on improving recovery time and reducing complications, all
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Appendix 2: Materials and Methods cytokine analysis Myriad.
Materials and Methods
All samples were stored at less than -70°C until tested. Samples were thawed at room temperature,
vortexed, spun at 3700 x g for 5 min for clarification and transferred to a master microtiter plate. Using
automated pipetting, an aliquot of each sample was added to individual microsphere multiplexes of
the selected Multi Analyte Profile (MAP) and blocker. This mixture was thoroughly mixed and
incubated at room temperature for 1 hour. Multiplexed cocktails of biotinylated reporter antibodies
were added robotically and after thorough mixing, incubated for an additional hour at room
temperature. Multiplexes were labelled using an excess of streptavidin-phycoerythrin solution,
thoroughly mixed and incubated for 1 hour at room temperature. The volume of each multiplexed
reaction was reduced by vacuum filtration and washed 3 times. After the final wash, the volume was
increased by addition of buffer for analysis using a Luminex instrument and the resulting data
interpreted using proprietary software developed by Myriad RBM. For each multiplex, both calibrators
and controls were included on each microtiter plate. Eight-point calibrators to form a standard curve
were run in the first and last column of each plate and controls at 3 concentration levels were run in
duplicate. Standard curve, control, and sample QC were performed to ensure proper assay
performance. Study sample values for each of the analytes were determined using 4 and 5 parameter
logistics, weighted and non-weighted curve fitting algorithms included in the data analysis package.
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Appendix 3: First prize poster presentation Anglia Ruskin University Cambridge -11th
Annual research study conference July 2017.
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